Atezolizumab plus Bevacizumab in Unresectable Hepat

New England Journal of Medicine
382, 1894-1905
DOI: 10.1056/nejmoa1915745

Citation Report

#	Article	IF	Citations
1	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers, 2020, 12, 2859.	1.7	92
2	Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist, 2020, 25, e1921-e1929.	1.9	5
3	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188451.	3.3	36
5	Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032.	5.2	46
6	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2020, 19, 153303382094748.	0.8	3
7	Targeting STAT3 in Cancer Immunotherapy. Molecular Cancer, 2020, 19, 145.	7.9	423
8	Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers, 2020, 12, 2729.	1.7	12
9	Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer, 2020, 20, 936.	1.1	17
10	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	1.7	12
11	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. Drug Metabolism and Disposition, 2020, 48, 1257-1263.	1.7	16
12	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Frontiers in Oncology, 2020, 10, 563249.	1.3	18
13	Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and Its Role in Multidisciplinary Therapy. Cancers, 2020, 12, 2955.	1.7	4
14	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2020, 12, 2961.	1.7	8
15	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers, 2020, 12, 3025.	1.7	55
16	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 583-595.	4.2	71
17	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines, 2020, 8, 616.	2.1	47
18	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, e204930.	3.4	124
19	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 719-737.	1.0	29

#	Article	IF	Citations
20	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines, 2020, 8, 578.	2.1	16
21	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. International Journal of Molecular Sciences, 2020, 21, 7378.	1.8	62
22	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Reports, 2020, 2, 100170.	2.6	86
23	Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 117-131.	1.8	15
24	Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441.	3.3	52
25	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2021, 19, 1520-1530.	2.4	23
26	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. Liver International, 2020, 40, 2476-2488.	1.9	6
27	Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 2020, 80, 1203-1210.	4.9	21
28	Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1048-1053.	0.5	2
29	A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 367-377.	4.2	22
30	Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651.	1.9	15
31	A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 530-533.	0.7	3
32	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. Pharmaceuticals, 2020, 13, 389.	1.7	36
33	Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Frontiers in Oncology, 2020, 10, 600233.	1.3	10
34	The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. International Journal of Molecular Sciences, 2020, 21, 8689.	1.8	38
35	Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. , 2020, 8, e000932.		16
36	Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 11725-11740.	1.0	25
37	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87

#	Article	IF	Citations
38	Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers, 2020, 12, 3405.	1.7	10
39	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	0.7	1
40	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers, 2020, 12, 3529.	1.7	60
41	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	1.3	5
43	Hepatocellular carcinoma: old friends and new tricks. Experimental and Molecular Medicine, 2020, 52, 1898-1907.	3.2	154
44	Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries . Cancer Management and Research, 2020, Volume 12, 12239-12248.	0.9	4
45	Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient . OncoTargets and Therapy, 2020, Volume 13, 12477-12487.	1.0	9
46	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
47	Increasing alternatives in systemic treatment for hepatocellular carcinoma: Will algorithms be understandable?. Liver International, 2020, 40, 1829-1831.	1.9	0
48	Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 289-299.	1.8	25
49	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 580241.	1.3	31
50	Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection. International Journal of Biological Sciences, 2020, 16, 3210-3220.	2.6	22
51	In situ tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor. Theranostics, 2020, 10, 11998-12010.	4.6	19
52	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	0.8	350
53	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397.	1.7	17
54	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 2020, 14, 947-957.	1.9	46
55	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107135.	1.7	17
56	Telomeres and Telomerase in the Development of Liver Cancer. Cancers, 2020, 12, 2048.	1.7	30

#	Article	IF	Citations
57	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Journal of Clinical Medicine, 2020, 9, 2533.	1.0	15
58	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2020, 9, 452-463.	0.7	267
59	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 383, 693-695.	13.9	16
60	Effectiveness and Safety of Nivolumab in Childâ€“Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers, 2020, 12, 1968.	1.7	40
61	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 5631-5637.	3.2	31
62	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5232.	1.8	7
63	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers, 2020, 12, 2045.	1.7	12
64	An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1189.	1.3	6
65	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers, 2020, 12, 2132.	1.7	18
66	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2020, 38, 2960-2970.	0.8	723
67	Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncology, 2020, 16, 2587-2589.	1.1	42
68	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines, 2020, 8, 447.	2.1	19
69	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Reports, 2020, 2, 100167.	2.6	51
70	Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 146.	7.1	320
71	Letter: sequential or combinated systemic treatment for unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 52, 915-916.	1.9	1
72	Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. Journal of Clinical Medicine, 2020, 9, 3368.	1.0	2
73	Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma. JCO Clinical Cancer Informatics, 2020, 4, 1002-1013.	1.0	29
74	PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Frontiers in Immunology, 2020, 11, 589997.	2.2	45

#	Article	IF	Citations
75	Novel Therapies for Hepatocellular Carcinoma. Cancers, 2020, 12, 3049.	1.7	2
76	Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score. Journal of Vascular and Interventional Radiology, 2020, 31, 2028-2032.	0.2	7
77	Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. OncoImmunology, 2020, 9, 1824863.	2.1	22
78	New advances in the diagnosis and management of hepatocellular carcinoma. BMJ, The, 2020, 371, m3544.	3.0	210
79	Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Frontiers in Oncology, 2020, 10, 570958.	1.3	8
80	Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma. International Journal of Radiation Biology, 2020, 96, 1541-1549.	1.0	4
81	Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. Cancers, 2020, 12, 3145.	1.7	42
82	Ramucirumab in Combination with Pembrolizumab in Treatment-NaÃ¯ve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers, 2020, 12, 2985.	1.7	21
83	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâˆ1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048.	1.7	37
84	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 6302.	1.8	16
85	Realâ€world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e249-e261.	0.7	18
86	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
87	Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?. Journal of Hepatology, 2020, 73, 1588-1590.	1.8	1
88	Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors. Cancer Prevention Research, 2020, 13, 897-900.	0.7	3
89	Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncology, The, 2020, 21, e412.	5.1	23
90	Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma. Immuno-Oncology Technology, 2020, 7, 1.	0.2	2
91	Gd-EOB-DTPA-MRI Could Predict WNT/Î²-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 479-490.	4.2	42
92	Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 133-142.	1.8	29

#	Article	IF	Citations
94	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495.	1.7	12
95	Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinomaâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 917-918.	1.9	0
96	Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells, 2020, 9, 2027.	1.8	88
97	Shifting paradigms in the systemic management of hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2020, 5, 883-885.	3.7	1
98	Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21598-21608.	3.3	46
99	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a highâ€volume liver surgery center in East Asia. Journal of Surgical Oncology, 2020, 122, 1587-1594.	0.8	16
100	Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094877.	1.4	45
101	HSP70â€"eIF4G Interaction Promotes Protein Synthesis and Cell Proliferation in Hepatocellular Carcinoma. Cancers, 2020, 12, 2262.	1.7	7
102	Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 2682.	1.0	4
103	Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. American Journal of Gastroenterology, 2020, 115, 1960-1969.	0.2	11
104	Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies. Hepatobiliary Surgery and Nutrition, 2020, 9, 809-811.	0.7	9
105	Human Hepatocellular Carcinoma (HCC). Cancers, 2020, 12, 3739.	1.7	5
106	Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study . OncoTargets and Therapy, 2020, Volume 13, 12683-12693.	1.0	26
107	Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2020, 8, 596679.	1.8	84
108	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers, 2020, 12, 3830.	1.7	47
109	Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. Pharmaceutics, 2020, 12, 1243.	2.0	26
110	Current Locoregional Therapies and Treatment Strategies in Hepatocellular Carcinoma. Current Oncology, 2020, 27, 144-151.	0.9	12
111	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. Current Oncology, 2020, 27, 152-164.	0.9	14

#	Article	IF	Citations
112	Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers, 2020, 12, 3826.	1.7	11
113	Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Research, 2020, 4, 191-198.	0.5	8
114	Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research, 2020, 4, 180-190.	0.5	6
116	Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Seminars in Interventional Radiology, 2020, 37, 441-447.	0.3	7
117	Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. Gastroenterology Report, 2021, 9, 443-450.	0.6	3
118	A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated Î±Î² Tâ€cell immunotherapy in advanced breast cancer. Breast Journal, 2020, 26, 2420-2423.	0.4	0
119	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097535.	1.4	18
120	Recent updates on Sintilimab in solid tumor immunotherapy. Biomarker Research, 2020, 8, 69.	2.8	26
121	The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Frontiers in Oncology, 2020, 10, 594125.	1.3	23
122	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers, 2020, 12, 3173.	1.7	36
123	The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells, 2020, 9, 2382.	1.8	22
124	TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 575776.	1.1	15
125	Atezolizumab plus bevacizumab versus sorafenib as firstâ€line treatment for unresectable hepatocellular carcinoma: a costâ€effectiveness analysis. Cancer Communications, 2020, 40, 743-745.	3.7	29
126	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877.	2.2	133
127	Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut, 2021, 70, 1746-1757.	6.1	60
128	Management of patients with intermediate stage hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097084.	1.4	25
129	Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 8165.	1.8	147
130	A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Current Hepatology Reports, 2020, 19, 478-485.	0.4	4

#	Article	IF	Citations
131	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 48-49, 101709.	1.0	2
133	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 629-639.	4.2	20
134	Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. Journal of Vascular and Interventional Radiology, 2020, 31, 1740-1744.e9.	0.2	5
135	Atezolizumab plus Bevacizumab â€" A Landmark in Liver Cancer. New England Journal of Medicine, 2020, 382, 1953-1955.	13.9	44
136	Combination set to transform HCC therapy. Nature Reviews Clinical Oncology, 2020, 17, 389-389.	12.5	10
137	Antiâ€"PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infectionâ€"Related Advanced Hepatocellular Carcinoma: A Literature Review. Frontiers in Immunology, 2020, 11, 1037.	2.2	55
138	Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody. Annals of Surgical Oncology, 2020, 27, 4070-4072.	0.7	1
139	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3003-3012.	1.2	18
140	Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology International, 2020, 14, 765-775.	1.9	37
141	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536.	1.1	50
142	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells, 2020, 9, 1370.	1.8	256
143	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology and Hepatology, 2020, 5, 765-775.	3.7	33
144	Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093518.	1.4	6
145	Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 126.	3.5	290
146	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	4.3	35
147	Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 4398.	1.8	26
148	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 4414.	1.8	87
149	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Annals of Hepatology, 2020, 19, 546-569.	0.6	11

#	Article	IF	Citations
150	A combination therapy to keep hepatocellular carcinoma in check. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 452-452.	8.2	1
151	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668.	1.7	54
152	Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188391.	3.3	96
153	Immunotherapy combinations for the treatment of patients with solid tumors. Future Oncology, 2020, 16, 1715-1736.	1.1	6
154	Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology, 2021, 73, 150-157.	3.6	70
155	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	3.6	235
156	Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 2021, 73, 137-149.	3.6	69
157	Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatology Research, 2021, 51, 5-18.	1.8	29
158	Hepatocellular carcinoma, novel therapies on the horizon. Chinese Clinical Oncology, 2021, 10, 12-12.	0.4	12
159	Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus. Digestive Diseases and Sciences, 2021, 66, 1797-1801.	1.1	0
160	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1836-1841.	3.2	102
161	Extracellular vesicleâ€associated organotropic metastasis. Cell Proliferation, 2021, 54, e12948.	2.4	36
162	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 17-29.	3.7	307
163	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. Journal of Thoracic Oncology, 2021, 16, 299-309.	0.5	72
164	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359.	1.8	122
165	Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Investigational New Drugs, 2021, 39, 260-268.	1.2	19
166	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut, 2021, 70, 204-214.	6.1	150
167	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021, 73, 27-37.	3.6	23

#	Article	IF	Citations
168	Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunology, Immunotherapy, 2021, 70, 391-404.	2.0	25
169	Targeting Tumorâ€Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology, 2021, 73, 821-832.	3.6	25
170	Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology, 2021, 73, 104-114.	3.6	54
171	Palliative care in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 618-628.	1.4	29
172	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. Journal of the Formosan Medical Association, 2021, 120, 1-4.	0.8	8
173	Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 1008-1015.	1.0	10
174	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833.	2.9	6
175	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clinical Cancer Research, 2021, 27, 1003-1011.	3.2	334
176	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. JAMA Oncology, 2021, 7, 113.	3.4	213
177	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151.	2.6	77
178	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	3.2	27
179	Ribociclib enhances infigratinibâ€induced cancer cell differentiation and delays resistance in FGFRâ€driven hepatocellular carcinoma. Liver International, 2021, 41, 608-620.	1.9	11
180	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. International Journal of Clinical Oncology, 2021, 26, 598-605.	1.0	6
181	Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis. Medical Hypotheses, 2021, 146, 110399.	0.8	5
182	Systemic treatment of HCC in special populations. Journal of Hepatology, 2021, 74, 931-943.	1.8	72
183	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecularâ€targeted agent sequential therapy: A propensity scoreâ€matched analysis. Hepatology Research, 2021, 51, 472-481.	1.8	23
184	Immunosuppressive Drugâ€Resistant Armored Tâ€Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. Hepatology, 2021, 74, 200-213.	3.6	29
185	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715.	1.8	60

#	Article	IF	Citations
186	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research, 2021, 27, 1267-1277.	3.2	21
187	Tumor Necrosis in Hepatocellular Carcinomaâ€"Unfairly Overlooked?. Annals of Surgical Oncology, 2021, 28, 600-601.	0.7	8
188	Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?. International Journal of Radiation Biology, 2021, 97, 111-119.	1.0	6
189	Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 62-75.	1.4	7
190	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	2.0	30
191	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
192	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607.	1.9	13
193	Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort. Liver International, 2021, 41, 851-862.	1.9	8
194	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 1048-1057.	3.2	129
195	Signaling pathways in hepatocellular carcinoma. Advances in Cancer Research, 2021, 149, 63-101.	1.9	56
196	Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874.	2.0	20
197	The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cellular and Molecular Immunology, 2021, 18, 279-293.	4.8	102
198	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2021, 120, 1051-1060.	0.8	72
199	Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 739-762.	2.3	29
200	Milestones in the treatment of hepatocellular carcinoma: A systematic review.. Critical Reviews in Oncology/Hematology, 2021, 157, 103179.	2.0	14
201	Combination of Immunotherapy and Antiangiogenic Therapy in Cancerâ€"a Rational Approach. Journal of Thoracic Oncology, 2021, 16, 178-182.	0.5	8
202	ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1150-1161.	3.2	42
203	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2021, 20, 389-397.	1.9	7

#	Article	IF	Citations
204	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, 26, e1036-e1049.	1.9	30
205	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Medical Journal of Australia, 2021, 214, 475-483.	0.8	36
206	Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1518-1528.	1.4	2
207	Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. International Immunopharmacology, 2021, 91, 107281.	1.7	32
208	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Japanese Journal of Clinical Oncology, 2021, 51, 321-332.	0.6	22
209	Systemic therapy of advanced hepatocellular carcinoma. Future Oncology, 2021, 17, 1237-1251.	1.1	31
210	Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. Clinical Imaging, 2021, 70, 33-45.	0.8	18
211	Hyperprogression in hepatocellular carcinoma: Illusion or reality?. Journal of Hepatology, 2021, 74, 269-271.	1.8	9
212	A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Review of Anticancer Therapy, 2021, 21, 341-349.	1.1	6
213	Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 217-233.	1.4	37
214	Functional long non-coding RNAs in hepatocellular carcinoma. Cancer Letters, 2021, 500, 281-291.	3.2	32
215	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 123-136.	3.0	28
216	Recurrence of hepatocellular carcinoma following liver transplantation. Expert Review of Gastroenterology and Hepatology, 2021, 15, 91-102.	1.4	21
217	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
218	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clinical Cancer Research, 2021, 27, 665-679.	3.2	69
219	Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunology, Immunotherapy, 2021, 70, 1929-1937.	2.0	19
220	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	1.7	30
221	Subsequent Ultrasound Vascular Targeting Therapy of Hepatocellular Carcinoma Improves the Treatment Efficacy. Biology, 2021, 10, 79.	1.3	8

#	Article	IF	Citations
222	A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1151-1152.	2.3	0
223	Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review. Hepatobiliary Surgery and Nutrition, 2022, 11, 709-717.	0.7	5
224	Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2021, 10, 85-93.	4.2	22
225	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 2021, 13, 160.	1.7	38
226	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications, 2021, 27, 100328.	0.7	70
227	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer, 2021, 10, 360-369.	4.2	25
228	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology, 2021, 99, 641-651.	0.9	9
229	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer, 2021, 10, 107-114.	4.2	66
230	HepatozellulÃres Karzinom. , 2021, , 447-454.		0
231	Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	10
232	Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer, 2021, 10, 167-180.	4.2	17
233	Immunotherapy for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 185-194.		0
234	Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. Seminars in Liver Disease, 2021, 41, 001-008.	1.8	14
235	Liver metastases inhibit immunotherapy efficacy. Nature Medicine, 2021, 27, 25-27.	15.2	20
236	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110109.	1.4	15
237	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq1 1 0.784314	1.8	3
238	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Annals of Surgical Oncology, 2021, 28, 1499-1510.	0.7	3
239	Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 1-9.	4.2	13

#	Article	IF	Citations
240	Analysis of bevacizumab treatments and metastatic sites of lung cancer. Cancer Treatment and Research Communications, 2021, 26, 100290.	0.7	5
241	Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1095-1117.	2.3	21
242	Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. Liver Cancer, 2021, 10, 289-295.	4.2	6
243	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. Oncology, 2021, 99, 507-517.	0.9	38
244	Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes. Journal of Immunology, 2021, 206, 1204-1214.	0.4	12
245	Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nature Communications, 2021, 12, 227.	5.8	76
246	Systemic therapy of liver cancer. Advances in Cancer Research, 2021, 149, 257-294.	1.9	44
247	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	1.4	74
248	NDRG2 inhibition facilitates angiogenesis of hepatocellular carcinoma. Open Medicine (Poland), 2021, 16, 742-748.	0.6	2
249	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. Oncology, 2021, 99, 327-335.	0.9	5
250	Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Applied Health Economics and Health Policy, 2021, 19, 605-618.	1.0	14
251	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311.	1.4	19
252	Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. Aging, 2021, 13, 3969-3993.	1.4	7
253	Quantitative Approaches to Therapeutic Decision Making in Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, OP.20.00846.	1.4	0
254	Immunotherapy in hepatocellular cancer. Advances in Cancer Research, 2021, 149, 295-320.	1.9	0
255	Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 574778.	1.3	4
256	Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)â€"Multi-Omic and Singulomic Approaches. Seminars in Liver Disease, 2021, 41, 009-018.	1.8	13
257	Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Frontiers in Immunology, 2020, 11, 613946.	2.2	40

#	Article	IF	Citations
258	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. Current Oncology, 2021, 28, 661-670.	0.9	3
259	Namodenoson in Advanced Hepatocellular Carcinoma and Childâ€“Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers, 2021, 13, 187.	1.7	25
260	The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treatment and Research Communications, 2021, 27, 100360.	0.7	4
261	Immunotherapy and Interventional Radiology (IR): Time to Change the Paradigmâ€”Keynote Lecture PAIRS 2021. The Arab Journal of Interventional Radiology, 2021, 5, 001-002.	0.1	0
262	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers, 2021, 13, 426.	1.7	4
263	Antiâ€“PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	2.3	15
264	Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics, 2021, 11, 5365-5386.	4.6	324
265	Insights on Hepatocellular Carcinoma in Saudi Arabia. , 2021, , 247-257.		2
266	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110027.	1.4	91
267	Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatology International, 2021, 15, 137-145.	1.9	12
268	The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. Journal of Hematology and Oncology, 2021, 14, 13.	6.9	49
269	Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. Journal of Surgical Oncology, 2021, 123, 963-969.	0.8	6
270	ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399.	1.4	7
271	Pursuing efficacious systemic therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 95-96.	8.2	9
272	Definitive Radiotherapy for Locally Advanced Hepatocellular Carcinoma. , 2021, , 191-207.		0
273	Perspectives of Radiotherapy in Immuno-oncology Era. , 2021, , 325-337.		0
274	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
275	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 2694-2701.	1.2	8

#	Article	IF	Citations
276	Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics, 2021, 11, 5759-5777.	4.6	19
277	Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de lâ€™immunologie des Cancers Digestifs (Gastriques et HÃ©patocellulaires). Oncologie, 2021, 23, 47-59.	0.2	5
278	Organoids for the Study of Liver Cancer. Seminars in Liver Disease, 2021, 41, 019-027.	1.8	8
279	Immune microenvironment in primary and metastatic liver cancers. Hepatology Research, 2021, 51, 3-4.	1.8	0
280	Immunotherapy in cholangiocarcinoma. Current Opinion in Gastroenterology, 2021, 37, 105-111.	1.0	10
281	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian Journal of Hepato-gastroenterology, 2021, 11, 32-40.	0.1	10
282	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	4.2	31
283	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. , 2021, 5, 304-322.		2
284	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Scientific Reports, 2021, 11, 1614.	1.6	17
285	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. Oncology, 2021, 99, 491-498.	0.9	1
286	Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. , 2021, , 123-141.		0
287	Development and External Validation of a Novel Immune Checkpointâ€“Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 620765.	1.6	12
288	Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook. Chinese Clinical Oncology, 2021, 10, 7-7.	0.4	9
289	A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. Journal of Translational Medicine, 2021, 19, 5.	1.8	66
290	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. OncoImmunology, 2021, 10, 1878599.	2.1	11
291	Interferon-Î³/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC). Oncotarget, 2021, 12, 2316-2317.	0.8	4
292	A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues. Lab on A Chip, 2021, 21, 2142-2152.	3.1	32
293	The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Cancers, 2021, 13, 238.	1.7	14

#	Article	IF	Citations
294	Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2624-2634.	3.3	10
295	Immunotherapy in colorectal cancer. Advances in Cancer Research, 2021, 151, 137-196.	1.9	18
296	Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110423.	1.4	1
297	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion on Investigational Drugs, 2021, 30, 377-388.	1.9	5
298	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins, 2021, 13, 149.	1.5	6
299	Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine. International Journal of Molecular Sciences, 2021, 22, 1631.	1.8	23
300	Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Scientific Reports, 2021, 11, 3731.	1.6	7
301	Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers, 2021, 13, 730.	1.7	35
302	Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 1794.	1.8	27
303	The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma. Applied Sciences (Switzerland), 2021, 11, 2023.	1.3	4
305	The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. Targeted Oncology, 2021, 16, 153-163.	1.7	5
306	Randomized Trials for Esophageal, Liver, Pancreas, and Rectal Cancers. International Journal of Radiation Oncology Biology Physics, 2021, 109, 305-311.	0.4	0
308	Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. ESMO Open, 2021, 6, 100020.	2.0	19
309	Clinical outcomes and influencing factors of PDâ€'1/PDâ€'L1 in hepatocellular carcinoma (Review). Oncology Letters, 2021, 21, 279.	0.8	36
310	Lethal lipotoxicity for liver cancer therapy. Nature Cancer, 2021, 2, 138-140.	5.7	0
311	Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies. Journal of the Chinese Medical Association, 2021, 84, 121-122.	0.6	2
312	Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2021, 20, 23-33.	0.4	10
313	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e210037.	2.8	81

#	Article	IF	Citations
314	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
315	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2471-2481.	1.2	6
316	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers, 2021, 13, 584.	1.7	6
317	Targeting Angiogenesis for Advanced Hepatocellular Carcinoma. Internal Medicine, 2021, 60, 321-322.	0.3	1
318	Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging. International Journal of Molecular Sciences, 2021, 22, 2238.	1.8	13
319	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	1.2	20
320	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
321	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2021, 13, 931.	1.7	26
322	Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Reports, 2021, 34, 108765.	2.9	25
323	Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia. Internal Medicine Journal, 2021, 51, 181-188.	0.5	5
324	Distinct functions of transforming growth factor-Î² signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Cell Death and Disease, 2021, 12, 200.	2.7	16
325	Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis. Amino Acids, 2021, 53, 1807-1815.	1.2	12
326	LXRÎ± activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer, 2021, 2, 201-217.	5.7	27
327	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. Journal of Clinical Medicine, 2021, 10, 629.	1.0	1
328	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers, 2021, 13, 651.	1.7	7
329	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. Targeted Oncology, 2021, 16, 249-254.	1.7	18
330	Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?. JCO Oncology Practice, 2021, 17, 164-166.	1.4	3
331	Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Applied Sciences (Switzerland), 2021, 11, 1882.	1.3	2

#	Article	IF	Citations
332	Atezolizumab and bevacizumab combination compared with sorafenib as the firstâ€line systemic treatment for patients with unresectable hepatocellular carcinoma: A costâ€effectiveness analysis in China and the United states. Liver International, 2021, 41, 1097-1104.	1.9	43
333	Cellular heterogeneity and plasticity in liver cancer. Seminars in Cancer Biology, 2022, 82, 134-149.	4.3	58
334	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191
335	Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. Journal of Experimental and Clinical Cancer Research, 2021, 40, 73.	3.5	24
336	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers, 2021, 13, 646.	1.7	19
337	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Molecular Cancer, 2021, 20, 27.	7.9	54
338	Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Frontiers in Oncology, 2021, 11, 667555.	1.3	14
339	Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions, 2021, 05, 277-282.	0.3	0
340	Managing Immune checkpoint inhibitor induced hepatitis in a patient with concurrent hepatitis C. Current Problems in Cancer Case Reports, 2021, 3, 100066.	0.1	0
341	A new perspective on the immune escape mechanism in HCC: onco-foetal reprogramming. British Journal of Cancer, 2021, 124, 1897-1899.	2.9	7
342	Results of a Doseâ€Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 2021, 10, 1142-1155.	0.8	8
343	Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Digestive Medicine Research, 0, 4, 15-15.	0.2	1
344	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. Liver International, 2021, 41, 1105-1116.	1.9	10
345	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	1.2	4
346	A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	43
347	Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 71-83.	1.8	4
348	Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clinical Journal of Gastroenterology, 2021, 14, 699-713.	0.4	38
349	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652172.	2.2	21

#	Article	IF	Citations
350	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 2021, 10, 320-329.	4.2	108
351	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 343-350.	1.9	75
352	Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. European Journal of Cancer, 2021, 146, 48-55.	1.3	11
353	Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 654020.	1.3	6
354	Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 1607.	1.7	19
355	Immunotherapy in Advanced Biliary Tract Cancers. Cancers, 2021, 13, 1569.	1.7	19
356	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 919-927.	1.4	14
357	Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. , 2021, 9, e002191.		38
358	MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cellular Immunology, 2021, 361, 104295.	1.4	28
359	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 145-154.	1.8	12
360	Angiodiversity and organotypic functions of sinusoidal endothelial cells. Angiogenesis, 2021, 24, 289-310.	3.7	48
361	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101590.	0.7	17
362	Palliating Symptoms in Patients With Hepatocellular Carcinoma Involving the Inferior Vena Cava With External Beam Radiation Therapy. Cureus, 2021, 13, e14107.	0.2	1
363	Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. Frontiers in Molecular Biosciences, 2021, 8, 602227.	1.6	3
364	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. , 2021, 9, e002391.		3
365	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS ONE, 2021, 16, e0247728.	1.1	3
366	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers, 2021, 13, 1188.	1.7	27
367	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Frontiers in Immunology, 2021, 12, 655697.	2.2	126

#	Article	IF	Citations
368	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Research, 2021, 9, 19.	2.8	43
369	Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Frontiers in Immunology, 2021, 12, 616837.	2.2	72
370	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	1.7	18
371	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	3.4	14
372	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
373	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellularâ€cholangiocarcinoma. Liver International, 2021, 41, 1398-1408.	1.9	22
374	Sequential Treatment of Sorafenibâ€“Regorafenib Versus Sorafenibâ€“Physicianâ€™s Choice: A Propensity Score-Matched Analysis. Targeted Oncology, 2021, 16, 401-410.	1.7	5
375	Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncology, 2021, 17, 755-757.	1.1	60
376	High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1857-1867.	1.3	9
378	Paradigm-Shifting Research in Gastroenterology, Hepatology, and Nutrition: A Top 20 List of Articles Published in 2020. Gastroenterology, 2021, 160, 979-981.	0.6	0
379	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drugâ€eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatology Research, 2021, 51, 482-489.	1.8	6
380	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). Current Treatment Options in Gastroenterology, 2021, 19, 351-368.	0.3	6
381	Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 77, 145-147.	0.2	0
382	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Frontiers in Oncology, 2021, 11, 589680.	1.3	23
383	CD8+ T Cell Responses during HCV Infection and HCC. Journal of Clinical Medicine, 2021, 10, 991.	1.0	22
384	Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. , 2021, 9, e001657.		63
385	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. International Journal of Cancer, 2021, 149, 546-560.	2.3	18
386	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3665-3671.	1.2	12

#	Article	IF	Citations
387	Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652007.	2.2	7
388	Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry. Journal of Liver Cancer, 2021, 21, 58-70.	0.3	18
389	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	7.7	197
390	Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. Case Reports in Oncology, 2021, 14, 224-231.	0.3	2
391	Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1343-1354.	0.9	5
392	Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. Journal of Medical Case Reports, 2021, 15, 132.	0.4	7
393	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
394	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology and Hepatology, 2021, 15, 589-598.	1.4	17
395	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiotherapy and Oncology, 2021, 156, 120-126.	0.3	19
396	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. Journal of Gastroenterology, 2021, 56, 456-469.	2.3	11
397	First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 1061-1067.	0.7	29
398	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS Journal, 2021, 23, 39.	2.2	356
399	Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 257 Td (	1.3	12
400	Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 2021, 13, 1115.	1.7	36
401	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. Hepatology International, 2021, 15, 287-289.	1.9	2
402	How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals, 2021, 14, 233.	1.7	9
403	Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2020-002807.	0.8	2
404	Beyond immune checkpoint blockade: emerging immunological strategies. Nature Reviews Drug Discovery, 2021, 20, 899-919.	21.5	208

#	Article	IF	Citations
405	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 177-191.	1.8	9
406	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 170-185.	1.8	1
407	Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. International Journal of Molecular Sciences, 2021, 22, 2669.	1.8	22
408	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021, 10, 521.	1.8	13
409	Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Supportive Care in Cancer, 2021, 29, 5417-5423.	1.0	15
410	The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 653037.	1.3	7
412	Developments in Hepatocellular Cancer Treatment. Journal of the Advanced Practitioner in Oncology, 2021, 12, 310-314.	0.2	1
413	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e214846.	2.8	42
414	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 190-199.	2.9	26
415	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs, 2021, 35, 429-444.	2.2	15
416	The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Medical Oncology, 2021, 38, 60.	1.2	26
417	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences, 2021, 8, 635243.	1.6	22
418	Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib. Anticancer Research, 2021, 41, 2025-2032.	0.5	6
419	Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers. Cancers, 2021, 13, 2121.	1.7	14
420	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2021, 549, 171-178.	1.0	13
421	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	1.2	13
422	Too Good to be True?. Journal of Thoracic Oncology, 2021, 16, 507-508.	0.5	2
423	Congenital heart disease-associated liver disease: a narrative review. Cardiovascular Diagnosis and Therapy, 2021, 11, 577-590.	0.7	4

#	Article	IF	Citations
424	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers, 2021, 13, 1729.	1.7	14
425	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 473-484.	4.2	28
426	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 2164.	1.7	14
427	Anti-angiogenic agents â€" overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nature Reviews Clinical Oncology, 2021, 18, 527-540.	12.5	162
428	Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 371-385.	1.0	16
429	Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World Journal of Gastrointestinal Oncology, 2021, 13, 197-215.	0.8	13
430	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
431	Advances in Targeting Cutaneous Melanoma. Cancers, 2021, 13, 2090.	1.7	19
432	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. Hepatobiliary Surgery and Nutrition, 2021, 10, 180-192.	0.7	47
433	Depleting Tumor Cells Expressing Immune Checkpoint Ligandsâ€"A New Approach to Combat Cancer. Cells, 2021, 10, 872.	1.8	2
434	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. Journal of Nuclear Medicine, 2021, 62, 1692-1701.	2.8	9
435	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer, 2021, 10, 249-259.	4.2	49
436	Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer, 2021, 10, 296-308.	4.2	63
437	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clinical and Molecular Hepatology, 2021, 27, 236-245.	4.5	38
438	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3123-3133.	1.2	3
439	Frontiers of therapy for hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3648-3659.	1.0	16
440	MR-Guided Radiotherapy for Liver Malignancies. Frontiers in Oncology, 2021, 11, 616027.	1.3	43
441	Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Letters, 2021, 502, 84-96.	3.2	80

#	Article	IF	Citations
442	Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543.	8.2	609
443	Î²-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers, 2021, 13, 1830.	1.7	16
444	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Frontiers in Immunology, 2021, 12, 643310.	2.2	27
445	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer, 2021, 10, 407-418.	4.2	17
446	Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Medicine, 2021, 10, 3059-3067.	1.3	19
447	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1217-1224.	0.5	8
448	Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma. Aging, 2021, 13, 13822-13845.	1.4	8
449	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers, 2021, 13, 1962.	1.7	40
450	NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239.	1.8	33
451	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology, 2021, 12, 642958.	2.2	12
452	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184.	0.8	54
453	The Next Decade of Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 838-857.	7.7	363
454	Therapies for hepatocellularÂcarcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdominal Radiology, 2021, 46, 3540-3548.	1.0	3
455	Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Annals of Translational Medicine, 2021, 9, 652-652.	0.7	22
456	Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Cancers, 2021, 13, 1768.	1.7	10
457	Challenges for Measuring Cost-effectiveness of Immunotherapy in Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e215476.	2.8	4
458	Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 1715.	1.0	12
459	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29

#	Article	IF	Citations
460	Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells. Journal of Biochemistry, 2021, 170, 307-315.	0.9	3
461	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Current Opinion in Oncology, 2021, 33, 386-394.	1.1	13
462	Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. Translational Oncology, 2021, 14, 101034.	1.7	20
463	Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology (Dordrecht), 2021, 44, 715-737.	2.1	109
464	Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective. Hepatobiliary Surgery and Nutrition, 2021, 10, 241-245.	0.7	11
465	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist, 2021, 26, e1216-e1225.	1.9	26
466	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kongâ€"A Territory-Wide Cohort Study. Cancers, 2021, 13, 2002.	1.7	8
467	Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 493-495.	0.6	4
468	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers, 2021, 13, 1949.	1.7	31
469	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer, 2021, 21, 376.	1.1	7
470	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. British Journal of Cancer, 2021, 125, 240-246.	2.9	8
471	Resistance mechanisms to checkpoint inhibitors. Current Opinion in Immunology, 2021, 69, 47-55.	2.4	19
472	Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439.	1.1	17
473	Macâ€2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 498-507.	1.4	3
474	Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy, 2021, 38, 2759-2778.	1.3	11
475	Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers, 2021, 13, 2454.	1.7	16
476	Amplification of DDR2 mediates sorafenib resistance through NFâ€ºB/câ€Rel signaling in hepatocellular carcinoma. Cell Biology International, 2021, 45, 1906-1916.	1.4	8
477	Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. Genomics, 2021, 113, 1057-1069.	1.3	4

#	Article	IF	Citations
478	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer, 2021, 10, 240-248.	4.2	39
479	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	1.7	6
480	Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Design, Development and Therapy, 2021, Volume 15, 1873-1882.	2.0	20
481	Hyperthermia and Tumor Immunity. Cancers, 2021, 13, 2507.	1.7	24
483	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers, 2021, 13, 2621.	1.7	15
484	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172.	3.5	104
485	Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asiaâ€“Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers, 2021, 13, 2626.	1.7	9
486	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers, 2021, 13, 2708.	1.7	19
487	Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells, 2021, 10, 1332.	1.8	24
488	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers, 2021, 13, 2247.	1.7	8
489	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208.	2.9	22
490	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 369-385.	1.8	12
491	DLL1 orchestrates CD8⁺T cells to induce long-term vascular normalization and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	32
492	Control of Tumor Progression by Angiocrine Factors. Cancers, 2021, 13, 2610.	1.7	19
493	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 2021, 9, 532.	2.1	65
494	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	2.3	6
495	Combined hepatocellularâ€cholangiocarcinoma â€“ More questions than answers. Liver International, 2021, 41, 1186-1188.	1.9	2
496	Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004â€“2014. Cancer Medicine, 2021, 10, 4397-4404.	1.3	1

#	Article	IF	Citations
497	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. International Immunopharmacology, 2021, 94, 107467.	1.7	18
499	CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. Cancers, 2021, 13, 2288.	1.7	32
500	Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIOâ€SOR study. Liver International, 2021, 41, 2200-2211.	1.9	8
501	Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study. Cancer Management and Research, 2021, Volume 13, 4233-4240.	0.9	17
502	Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells. Oncology Letters, 2021, 22, 546.	0.8	9
503	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. Frontiers in Oncology, 2021, 11, 663612.	1.3	8
504	Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma. Journal of Biomedical Nanotechnology, 2021, 17, 771-792.	0.5	1
505	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	1.8	15
506	New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy. Journal of Clinical and Experimental Hepatology, 2021, 11, 284-287.	0.4	7
507	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
508	Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 387-401.	1.8	62
509	Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 652186.	1.1	22
510	Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Letters, 2021, 506, 95-106.	3.2	36
511	Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology, 2021, 73, 2591-2593.	3.6	13
512	Liver dysfunction of Atezolizumab + Bevacizumab â€a matter of life or deathâ˜. Liver International, 2021, 41, 1702-1703.	1.9	1
513	Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs. Anticancer Research, 2021, 41, 2569-2573.	0.5	2
514	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3625-3633.	1.0	5
515	Tâ€cell mediated responses against alphaâ€foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patientsâ€™ survival. Liver Cancer International, 2021, 2, 7-14.	0.2	0

#	Article	IF	Citations
516	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 403-419.	1.8	25
517	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
518	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801.	1.8	182
519	Systemic Therapy for Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 337-340.	1.0	5
520	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. Advances in Oncology, 2021, 1, 85-95.	0.1	0
521	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS ONE, 2021, 16, e0249426.	1.1	11
522	A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1233-1239.	0.4	8
523	Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 686621.	1.3	28
524	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers, 2021, 13, 2651.	1.7	18
525	Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 247-253.	0.5	4
526	Immunotherapy for GI Cancers. Advances in Oncology, 2021, 1, 283-295.	0.1	0
527	Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers, 2021, 13, 2700.	1.7	6
528	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	1.8	10
529	Therapeutic efficacy of lenvatinib as thirdâ€line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15
530	Decreased expression of ARID1A invasively downregulates the expression of ribosomal proteins in hepatocellular carcinoma. Biomarkers in Medicine, 2021, 15, 497-508.	0.6	1
531	The Immunotherapy Landscape in Adrenocortical Cancer. Cancers, 2021, 13, 2660.	1.7	8
532	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	2.2	26
533	Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Review of Anticancer Therapy, 2021, 21, 621-628.	1.1	11

#	Article	IF	Citations
534	Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 5-6.	0.2	1
535	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). Journal of Hepatology, 2021, 74, 1225-1233.	1.8	42
536	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina ClÃnica (English Edition), 2021, 156, 463.e1-463.e30.	0.1	16
537	Radiation Therapies for the Treatment of Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 341-346.	1.0	4
538	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1623-1634.	1.4	10
539	Gastrointestinal cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 342-348.	0.1	0
540	Current status of cancer immunotherapy with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 326-331.	0.1	1
541	Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World Journal of Gastroenterology, 2021, 27, 2415-2433.	1.4	16
542	Cellular based treatment modalities for unresectable hepatocellular carcinoma. World Journal of Clinical Oncology, 2021, 12, 290-308.	0.9	4
543	The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2021, 11, 10728.	1.6	3
544	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 507-512.	1.8	8
545	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. European Journal of Cancer, 2021, 149, 49-60.	1.3	1
546	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
547	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	4.2	307
548	The two facets of gp130 signalling in liver tumorigenesis. Seminars in Immunopathology, 2021, 43, 609-624.	2.8	7
550	Hepatocellular carcinoma: a clinical and pathological overview. Pathologica, 2021, 113, 203-217.	1.3	30
551	Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma. Medicine (United States), 2021, 100, e26471.	0.4	5
552	Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World Journal of Gastroenterology, 2021, 27, 3466-3482.	1.4	13

#	Article	IF	Citations
553	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer, 2021, 10, 500-509.	4.2	9
554	Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion. International Journal of General Medicine, 2021, Volume 14, 2259-2274.	0.8	3
555	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opinion on Investigational Drugs, 2021, 30, 827-835.	1.9	3
556	Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report. World Journal of Clinical Cases, 2021, 9, 4110-4115.	0.3	6
557	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight, 2021, 6, .	2.3	10
558	Exploring liver cancer biology through functional genetic screens. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 690-704.	8.2	31
559	Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. , 2021, 9, e002305.		59
560	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs and Aging, 2021, 38, 579-591.	1.3	5
561	Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden. JCO Precision Oncology, 2021, 5, 1040-1043.	1.5	2
562	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	0.7	2
563	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. Digestive Diseases, 2022, 40, 322-334.	0.8	3
564	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767.	1.9	5
565	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of Translational Medicine, 2021, 9, 1035-1035.	0.7	9
566	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. ESMO Open, 2021, 6, 100129.	2.0	6
567	Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs. Journal of Medicinal Chemistry, 2021, 64, 7879-7899.	2.9	35
568	Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers, 2021, 13, 2899.	1.7	58
569	Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discovery Today, 2021, 26, 1539-1546.	3.2	18
570	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Communications, 2021, 41, 830-850.	3.7	42

#	Article	IF	Citations
571	Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nature Communications, 2021, 12, 3684.	5.8	136
572	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644.	1.0	63
573	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokineticsÂand future treatment strategies. Future Oncology, 2021, 17, 2243-2256.	1.1	36
574	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	10
575	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. Journal of Experimental and Clinical Cancer Research, 2021, 40, 215.	3.5	23
576	The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. Advances in Therapy, 2021, 38, 3900-3910.	1.3	7
577	Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?. World Journal of Gastroenterology, 2021, 27, 3429-3439.	1.4	4
578	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 2662.	1.0	13
579	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Molecular Medicine, 2021, 13, e08253.	3.3	18
580	MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers, 2021, 13, 3026.	1.7	104
581	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. Clinical and Experimental Medicine, 2022, 22, 65-74.	1.9	41
582	Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry. Journal of Vascular and Interventional Radiology, 2021, 32, 845-852.	0.2	15
583	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	1.8	1
585	Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2955-2968.	1.2	6
586	Portal hypertension and hepatocellular carcinoma: Des liaisons dangereusesâ€¦. Liver International, 2021, 41, 1734-1743.	1.9	31
587	Role of endothelial cells in tumor microenvironment. Clinical and Translational Medicine, 2021, 11, e450.	1.7	32
588	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clinical Cancer Research, 2021, 27, 4848-4858.	3.2	39
589	Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Quality of Life Research, 2022, 31, 473-485.	1.5	10

#	Article	IF	Citations
590	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. Frontiers in Immunology, 2021, 12, 693609.	2.2	21
591	Expected outcomes and patientsâ€™ selection before chemoembolizationâ€”â€œSix-and-Twelve or Pre-TACE-Predictâ€•scores may help clinicians: Real-life French cohorts results. World Journal of Clinical Cases, 2021, 9, 4559-4572.	0.3	4
592	Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 8391-8409.	2.9	29
593	Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clinical Gastroenterology and Hepatology, 2022, 20, 898-907.	2.4	29
594	Characterization of response to atezolizumabÂ+Âbevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Medicine, 2021, 10, 5437-5447.	1.3	29
595	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. Medicine (United States), 2021, 100, e26377.	0.4	10
596	Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab. Internal Medicine, 2021, 60, 1847-1853.	0.3	14
597	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology, 2021, 74, 483-490.	3.6	48
598	Innovating TACE to Keep Up with the Rapidly Changing Field of Oncology. CardioVascular and Interventional Radiology, 2021, 44, 1681-1682.	0.9	0
599	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	0.6	43
600	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 2021, 13, 2786.	1.7	44
601	Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yesâ€Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology, 2021, 74, 248-263.	3.6	22
602	Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Digestive and Liver Disease, 2022, 54, 316-323.	0.4	4
603	Realâ€world evidence in hepatocellular carcinoma. Liver International, 2021, 41, 61-67.	1.9	6
604	Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver Cancer, 2021, 10, 485-499.	4.2	8
605	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 4746-4756.	3.2	22
606	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	0.6	91
607	Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. Scientific Reports, 2021, 11, 13021.	1.6	1

#	Article	IF	Citations
608	The TGF-Î² Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 2021, 13, 3248.	1.7	37
609	The therapeutic effect of IL-21 combined with IFN-Î³ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma. Journal of Advanced Research, 2021, 36, 89-99.	4.4	3
610	Immune changes linked to locoregional treatment of hepatocellular carcinoma. Histopathology, 2021, 79, 34-35.	1.6	0
612	Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metabolism, 2021, 33, 1221-1233.e11.	7.2	138
613	Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. Hepatology, 2021, 74, 2264-2276.	3.6	39
614	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 613-623.	1.8	9
615	Nuclear factor erythroid 2â€“related factor 2 and Î²â€Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology, 2021, 74, 741-759.	3.6	32
616	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276.	1.8	14
617	Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry. Liver Transplantation, 2021, 27, 928-929.	1.3	11
618	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Journal of the National Cancer Institute, 2021, 113, 1531-1541.	3.0	43
619	The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 689132.	2.2	55
620	ASO Author Reflections: Perspectives of Laparoscopic Hepatectomy with Venous Tumor Thrombectomy for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 8240-8241.	0.7	0
621	Prospects and Challenges for T Cell-Based Therapies of HCC. Cells, 2021, 10, 1651.	1.8	13
622	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs, 2022, 31, 371-378.	1.9	65
623	Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 692940.	1.8	55
624	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Annals of Oncology, 2021, 32, 801-805.	0.6	235
625	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). Journal of Clinical Oncology, 2021, 39, 1842-1855.	0.8	183
626	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1397-1408.	1.8	133

#	Article	IF	Citations
627	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cellâ€“Mediated Antitumor Immunity Through PDâ€L1. Hepatology Communications, 2022, 6, 178-193.	2.0	16
628	Targeted agents in older patients with gastrointestinal cancers â€“ An overview. Journal of Geriatric Oncology, 2021, 12, 1240-1252.	0.5	0
629	Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor. Liver International, 2021, 41, 2233-2234.	1.9	6
630	The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers, 2021, 13, 3740.	1.7	23
631	Spinal Cord Compression as Initial Presentation in Hepatocellular Carcinoma. Cureus, 2021, 13, e16238.	0.2	1
632	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncology Practice, 2022, 18, 35-41.	1.4	12
633	Patient preferences for advanced hepatocellular carcinomaÂtreatment: a multicountry stated preference study. Future Oncology, 2021, 17, 4275-4287.	1.1	12
634	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
635	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery, 2021, 11, 2738-2747.	7.7	37
636	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World Journal of Gastroenterology, 2021, 27, 4104-4142.	1.4	15
637	Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768.	0.3	9
638	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World Journal of Clinical Cases, 2021, 9, 5988-5998.	0.3	2
639	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. Clinical Science, 2021, 135, 1649-1668.	1.8	10
640	The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma. American Journal of Pathology, 2021, 191, 1180-1192.	1.9	11
641	EarlyÂdiarrhoea under sorafenib as a marker to consider the early migration to secondâ€line drugs. United European Gastroenterology Journal, 2021, 9, 655-661.	1.6	2
642	Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. Clinical Journal of Gastroenterology, 2021, 14, 1517-1524.	0.4	0
643	Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221.	3.4	43
644	Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation. Life Sciences, 2021, 277, 119521.	2.0	15

#	Article	IF	Citations
645	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 3666.	1.7	25
646	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
647	CX-072 (pacmilimab), a Probody^{Â®}PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
649	Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 077-086.	1.8	9
650	Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic. World Journal of Gastroenterology, 2021, 27, 3780-3789.	1.4	9
651	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	1.0	13
652	Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 673-683.	0.8	9
653	Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Science Translational Medicine, 2021, 13, .	5.8	54
654	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatology Research, 2021, 51, 979-989.	1.8	20
655	Systemic therapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology, 2021, 51, 1363-1371.	0.6	3
656	Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomarker Research, 2021, 9, 59.	2.8	32
657	How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers, 2021, 13, 3536.	1.7	4
659	Hepatocellular Carcinoma â€" Origins and Outcomes. New England Journal of Medicine, 2021, 385, 280-282.	13.9	60
660	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers, 2021, 13, 3633.	1.7	10
661	Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases. Tumori, 2021, 107, 030089162110333.	0.6	1
662	Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Current Oncology Reports, 2021, 23, 100.	1.8	26
663	BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death and Disease, 2021, 12, 736.	2.7	10
664	TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. Journal of Hepatology, 2021, 75, 120-131.	1.8	22

#	Article	IF	Citations
665	Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. JCO Oncology Practice, 2021, , OP.21.00451.	1.4	0
666	Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis. PLoS ONE, 2021, 16, e0254829.	1.1	1
667	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines, 2021, 9, 813.	1.4	11
668	Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. European Journal of Cancer, 2021, 152, 165-182.	1.3	60
669	Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers, 2021, 13, 3771.	1.7	7
670	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Review of Clinical Pharmacology, 2021, 14, 1353-1365.	1.3	6
671	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells, 2021, 10, 1698.	1.8	5
672	Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. International Journal of Molecular Sciences, 2021, 22, 7800.	1.8	26
673	The immunological and metabolic landscape in primary and metastatic liver cancer. Nature Reviews Cancer, 2021, 21, 541-557.	12.8	212
674	Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 511-520.	0.6	29
675	AÂpatient with liver cirrhosis and hepatic lesions. Memo - Magazine of European Medical Oncology, 2021, 14, 309-312.	0.3	0
676	Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and <scp>B</scp>ayesian analysis. Journal of Digestive Diseases, 2021, 22, 496-502.	0.7	12
677	Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 4453-4467.	1.4	8
678	The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1195-1210.	1.2	8
679	Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 498-508.	0.8	0
680	Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 640461.	1.3	1
681	Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. Cancers, 2021, 13, 3375.	1.7	11
682	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9

#	Article	IF	Citations
683	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	6
684	The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. International Journal of Molecular Sciences, 2021, 22, 8036.	1.8	11
685	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. International Immunopharmacology, 2021, 96, 107594.	1.7	11
686	Atezolizumab with bevacizumab, paclitaxelÂand carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy, 2021, 13, 799-806.	1.0	29
687	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	1.8	29
688	Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study. Anti-Cancer Drugs, 2021, 32, 1093-1098.	0.7	4
689	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nature Cancer, 2021, 2, 891-903.	5.7	147
690	Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653.	0.8	11
691	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells, 2021, 10, 1909.	1.8	6
692	Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. Lancet Oncology, The, 2021, 22, 896-898.	5.1	1
693	IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Advanced Science, 2021, 8, e2101230.	5.6	26
694	MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma. Cancer Investigation, 2021, 39, 756-768.	0.6	11
695	Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-12.	0.9	2
696	Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Case Reports in Oncology, 2021, 14, 1103-1110.	0.3	1
697	Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896.	1.3	23
698	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2â€“3 study. Lancet Oncology, The, 2021, 22, 977-990.	5.1	459
699	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	4
700	Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 851-860.	1.8	7

#	Article	IF	Citations
701	Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers, 2021, 13, 3797.	1.7	2
702	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer, 2021, 21, 775.	1.1	28
703	Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?. Expert Opinion on Investigational Drugs, 2021, , 1-3.	1.9	1
704	Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Frontiers in Genetics, 2021, 12, 691391.	1.1	14
705	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	1.8	17
706	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824.	1.3	7
707	Recent advances in gastrointestinal cancers. World Journal of Gastroenterology, 2021, 27, 4493-4503.	1.4	11
708	TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines, 2021, 9, 876.	1.4	41
709	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 991-1001.	5.1	179
711	Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	1.6	13
712	Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?. Gut and Liver, 2021, 15, 500-516.	1.4	36
713	Liver Inflammation and Hepatobiliary Cancers. Trends in Cancer, 2021, 7, 606-623.	3.8	46
714	EGFR activation limits the response of liver cancer to lenvatinib. Nature, 2021, 595, 730-734.	13.7	183
715	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
716	Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?. Human Pathology, 2021, 113, 39-46.	1.1	11
717	Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives. World Journal of Gastroenterology, 2021, 27, 5341-5350.	1.4	13
718	ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101784.	0.7	2
719	Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles. Digestive and Liver Disease, 2021, 53, 1059-1061.	0.4	0

#	Article	IF	Citations
720	Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. Journal of the Formosan Medical Association, 2021, , .	0.8	0
721	Immune Checkpoint Inhibitors in the Aged. Current Oncology Reports, 2021, 23, 115.	1.8	3
722	Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. Journal of Interventional Medicine, 2021, 4, 105-113.	0.2	7
724	Cancer and hepatic steatosis. ESMO Open, 2021, 6, 100185.	2.0	9
725	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers, 2021, 13, 4334.	1.7	20
726	The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096.	1.8	18
727	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897.	1.8	17
728	Treatment strategy for and malignant potential of hepatocellular carcinoma within the Milan criteria. Acta Hepatologica Japonica, 2021, 62, 439-447.	0.0	1
729	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1245-1251.	1.4	75
730	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open, 2021, 6, 100190.	2.0	12
731	Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2115-2125.	1.2	55
732	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2021, 10, 522-525.	0.7	9
733	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers, 2021, 13, 3958.	1.7	29
734	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 649-658.	3.7	58
735	Are we ready for patient-reported outcomes in hepatocellular carcinoma?. The Lancet Gastroenterology and Hepatology, 2021, 6, 602-603.	3.7	0
736	Cytotoxic effect of xyloglucan and oxovanadium (IV/V) xyloglucan complex in HepG2 cells. International Journal of Biological Macromolecules, 2021, 185, 40-48.	3.6	1
737	Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics, 2021, 11, 1394.	1.3	1
738	Treatment of Advanced Hepatocellular Carcinoma. , 0, , .		0

#	Article	IF	Citations
739	Using cell-free DNA for HCC surveillance and prognosis. JHEP Reports, 2021, 3, 100304.	2.6	27
740	TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27. BioMed Research International, 2021, 2021, 1-10.	0.9	7
741	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Clinical Drug Investigation, 2021, 41, 795-808.	1.1	4
742	Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports, 2021, 4, 25.	0.2	0
743	Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Experimental Hematology and Oncology, 2021, 10, 45.	2.0	19
744	Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	0
745	Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clinical and Translational Science, 2022, 15, 130-140.	1.5	27
746	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	2.3	20
747	The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion. Cancer Investigation, 2022, 40, 81-89.	0.6	3
748	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. Digestive and Liver Disease, 2021, 53, 1011-1019.	0.4	7
749	Upregulation of C/EBPÎ± Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	3.2	47
750	TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. Journal of Hepatology, 2022, 76, 123-134.	1.8	28
751	The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma. Anti-Cancer Drugs, 2022, 33, e781-e783.	0.7	2
752	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research, 2021, 9, 64.	2.8	13
753	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surgery and Nutrition, 2021, 10, 434-442.	0.7	28
754	Intrinsic activation of Î²-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Scientific Reports, 2021, 11, 16732.	1.6	10
755	ILâ€1Î²â€Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Upâ€Regulating Programmed Death Ligand 1 and Colonyâ€Stimulating Factor 1. Hepatology, 2021, 74, 3174-3193.	3.6	64
756	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells, 2021, 10, 2034.	1.8	20

#	Article	IF	Citations
757	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World Journal of Gastrointestinal Oncology, 2021, 13, 772-798.	0.8	11
758	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology, 2022, 10, 147-158.	0.7	21
759	Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine. European Journal of Surgical Oncology, 2021, 47, 2209-2210.	0.5	0
760	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Reports, 2021, 3, 100305.	2.6	83
761	Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2069-2077.	1.2	13
762	Liver transplantation in malignant disease. World Journal of Clinical Oncology, 2021, 12, 623-645.	0.9	7
763	Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 845-855.	0.8	10
764	SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 899-912.	1.8	8
765	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. Canadian Liver Journal, 2021, 4, 257-274.	0.3	4
766	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 615-628.	4.2	31
767	Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin Î²1 Signaling. Frontiers in Cell and Developmental Biology, 2021, 9, 678670.	1.8	7
768	Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Frontiers in Immunology, 2021, 12, 712351.	2.2	5
769	Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. Journal of Clinical Medicine, 2021, 10, 3932.	1.0	13
770	Targeting ER stress in the hepatic tumor microenvironment. FEBS Journal, 2022, 289, 7163-7176.	2.2	23
771	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	1.1	9
772	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. British Journal of Cancer, 2021, 125, 911-919.	2.9	3
773	Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Oncologist, 2021, 26, 854-864.	1.9	16
774	Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. Journal of the Neurological Sciences, 2021, 427, 117556.	0.3	4

#	Article	IF	Citations
775	Immune checkpoint inhibitor-related hepatotoxicity: A review. World Journal of Gastroenterology, 2021, 27, 5376-5391.	1.4	52
776	Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. Annals of Translational Medicine, 2021, 9, 1285-1285.	0.7	3
777	Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. American Journal of Surgery, 2022, 223, 945-950.	0.9	7
778	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer, 2021, , .	2.9	12
779	Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 963-973.	1.8	7
780	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Scientific Reports, 2021, 11, 16663.	1.6	30
781	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 9044.	1.8	7
782	Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060.	1.3	8
783	Transient deterioration of albuminâ€“bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation. Medicine (United States), 2021, 100, e26820.	0.4	2
784	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open, 2021, 5, 1085-1091.	0.7	5
785	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepatic Oncology, 2022, 9, HEP41.	4.2	2
786	Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology, 2021, 22, 87.	1.3	25
787	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, 2021, 13, .	5.8	44
788	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs, 2022, 31, 415-423.	1.9	78
789	Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?. Future Oncology, 2021, 17, 3579-3584.	1.1	2
790	Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics, 2021, 13, 1387.	2.0	18
791	A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1129-1145.	1.8	5
792	Progress of MRI Radiomics in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 698373.	1.3	24

#	Article	IF	Citations
793	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. Frontiers in Immunology, 2021, 12, 720748.	2.2	5
795	Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy. Molecular Cancer Therapeutics, 2021, 20, molcanther.MCT-21-0031-E.2021.	1.9	6
796	Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. British Journal of Cancer, 2021, 125, 1350-1355.	2.9	15
797	Medical therapy of HCC. Journal of Hepatology, 2022, 76, 208-210.	1.8	11
798	Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World Journal of Hepatology, 2021, 13, 1132-1142.	0.8	8
799	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668.	5.8	91
800	Lenvatinib versus Sorafenib as firstâ€line treatment in hepatocellular carcinoma: A multiâ€institutional matched caseâ€control study. Hepatology Research, 2021, 51, 1229-1241.	1.8	33
801	The Impact of Histologic Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 893-902.	0.7	9
802	Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyteâ€rich hepatocellular carcinoma. Clinical Case Reports (discontinued), 2021, 9, e04764.	0.2	2
803	Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report. Journal of Liver Cancer, 2021, 21, 177-180.	0.3	0
804	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 1007-1015.	1.9	2
805	Firstâ€line chemotherapy or in combination with programmed cell death proteinâ€1 antibody in patients with metastatic or recurrent biliary tract cancer. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	2
806	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma â€“ The Changing Tides. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1089-1115.	1.8	28
807	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 1132-1143.	0.8	2
808	Immune-related hepatitis in aÂpatient with hepatocellular carcinoma treated with nivolumab. Memo - Magazine of European Medical Oncology, 0, , 1.	0.3	2
809	An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. Journal of Hepatology, 2021, , .	1.8	3
811	The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 2021, , 107815522110450.	0.5	3
812	Treatment for Hepatocellular Carcinoma in South Asia. Journal of Clinical and Experimental Hepatology, 2021, 11, 641-645.	0.4	0

#	Article	IF	Citations
813	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
814	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). European Journal of Cancer, 2021, 154, 46-56.	1.3	10
815	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882.	1.7	15
816	Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data. Cancers, 2021, 13, 4638.	1.7	8
817	Liver cirrhosis. Lancet, The, 2021, 398, 1359-1376.	6.3	515
818	Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma. Frontiers in Oncology, 2021, 11, 750807.	1.3	4
819	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1195-1207.	1.8	19
820	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunology, Immunotherapy, 2022, 71, 1063-1074.	2.0	26
821	Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation. Medicine (United States), 2021, 100, e27082.	0.4	5
822	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
824	An Overview of the Genomic Characterization of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1077-1088.	1.8	8
825	Cancer as a Global Health Priority. JAMA - Journal of the American Medical Association, 2021, 326, 809.	3.8	19
826	Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1147-1158.	1.8	8
828	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology, 2021, 99, 756-765.	0.9	4
829	Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. Medicine (United States), 2021, 100, e27013.	0.4	4
830	Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. Cancers, 2021, 13, 4732.	1.7	12
831	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). Gastroenterology, 2021, 161, 879-898.	0.6	123
832	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. Liver Cancer, 2021, 10, 545-560.	4.2	22

#	Article	IF	Citations
833	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers, 2021, 13, 4719.	1.7	7
834	Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?. Oncology Reviews, 2021, 15, 564.	0.8	4
835	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. Cancers, 2021, 13, 4550.	1.7	6
836	Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 2022, 12, 558-580.	5.7	181
837	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Investigational New Drugs, 2022, 40, 392-402.	1.2	36
838	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	1.7	0
839	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
840	Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1035-1054.	1.8	17
841	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transplantation, 2021, 27, 1758-1766.	1.3	15
842	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	3
843	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103.	1.8	10
844	Sintilimab plus IBI305 for hepatocellular carcinoma. Lancet Oncology, The, 2021, 22, e386.	5.1	0
845	Hypoxia is a key regulator in liver cancer progression. Journal of Hepatology, 2021, 75, 736-737.	1.8	15
846	Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. Anticancer Research, 2021, 41, 4555-4562.	0.5	7
847	Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Lithuania), 2021, 57, 1000.	0.8	2
848	Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma. Molecular Therapy, 2022, 30, 632-643.	3.7	13
849	Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. Journal of Oncology, 2021, 2021, 1-7.	0.6	10
850	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. Journal of Hepatology, 2022, 76, 446-457.	1.8	121

#	Article	IF	Citations
851	Solitary skull metastasis mimicking a meningioma with dural tail sign as the initial presentation of hepatocellular carcinoma: A case report and a brief review. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2021, 25, 101255.	0.2	0
852	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. Frontiers in Oncology, 2021, 11, 736620.	1.3	19
853	Deep Learning-Based Prediction of Future Extrahepatic Metastasis and Macrovascular Invasion in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1065-1076.	1.8	5
854	The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers, 2021, 13, 4876.	1.7	27
855	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
856	Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Scoreâ€“Matched Analysis with Target Trial Emulation. Journal of Vascular and Interventional Radiology, 2021, 32, 1258-1266.e6.	0.2	7
857	Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in theÂUSA. Hepatic Oncology, 2021, 8, HEP37.	4.2	0
858	Paradigm shift in the treatment options of hepatocellular carcinoma. Liver International, 2022, 42, 2067-2079.	1.9	19
859	Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658.	1.5	5
860	Atezolizumab plus bevacizumab as a second-line treatment after lenvatinib failure. Acta Hepatologica Japonica, 2021, 62, 585-587.	0.0	2
861	Does immune checkpoint inhibitor exhibit limited efficacy against nonâ€viral hepatocellular carcinoma?: A review of clinical trials. Hepatology Research, 2022, 52, 67-74.	1.8	9
862	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. American Journal of Pathology, 2021, 191, 1651-1667.	1.9	12
863	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. Oncologist, 2021, 26, e2254-e2264.	1.9	12
864	Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1181-1193.	1.8	14
865	Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes. PLoS ONE, 2021, 16, e0257556.	1.1	3
866	Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. Seminars in Cancer Biology, 2021, 74, 24-44.	4.3	34
867	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology, 2021, 74, 2622-2632.	3.6	31
868	Immunomodulatory Effects of Lenvatinib Plus Antiâ€“Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 2021, 74, 2652-2669.	3.6	95

#	Article	IF	Citations
869	Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Annals of Translational Medicine, 2021, 9, 1412-1412.	0.7	5
870	Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 156.	6.9	202
871	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stageÂsmall-cell lung cancer: a single-center experience. Cancer Immunology, Immunotherapy, 2022, 71, 1093-1101.	2.0	23
872	The CD112R/CD112 axis: a breakthrough in cancer immunotherapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 285.	3.5	24
873	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Clinical and Translational Science, 2022, 15, 141-157.	1.5	13
874	Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. Journal of Clinical Oncology, 2021, 39, 3002-3011.	0.8	171
875	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
876	Allâ€cause hepatocellular carcinoma survival in the era of directâ€acting antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	5
877	The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 4523.	1.0	12
878	Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Frontiers in Immunology, 2021, 12, 733530.	2.2	23
879	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Translational Oncology, 2021, 14, 101153.	1.7	5
880	Sintilimab plus IBI305 for hepatocellular carcinoma â€“ Author's reply. Lancet Oncology, The, 2021, 22, e388.	5.1	0
881	Systemic Therapy in Hepatocellular Carcinoma. , 0, , .		0
883	Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. Cancer Immunology, Immunotherapy, 2022, 71, 889-903.	2.0	8
884	Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 4603.	1.7	10
885	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	0.8	5
886	Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 10271.	1.8	14
887	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology, 2021, 11, 635731.	1.3	26

#	Article	IF	Citations
888	Advances in immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Liver Cancer, 2021, 21, 139-145.	0.3	3
889	HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines, 2021, 9, 1345.	1.4	22
890	Current pharmacological treatment of hepatocellular carcinoma. Current Opinion in Pharmacology, 2021, 60, 141-148.	1.7	12
891	Deficiency of GFRÎ±1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy. Pharmacological Research, 2021, 172, 105815.	3.1	2
892	Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2021, 10, 737-740.	0.7	7
893	Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology, 2021, 75, 960-974.	1.8	217
894	Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 879-887.	1.8	12
895	Recent Advances in Hepatocellular Carcinoma Treatment. Clinical Gastroenterology and Hepatology, 2021, 19, 2020-2024.	2.4	26
896	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Reports, 2021, 3, 100347.	2.6	57
897	Invited Commentary: Key Role of Imaging in Management and Prognosis of Hepatocellular Carcinoma. Radiographics, 2021, 41, E171-E172.	1.4	0
898	Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology?. Journal of Hepatology, 2021, 75, 763-764.	1.8	1
899	The upward trend in the immunotherapy utilization for hepatobiliary cancers. Hepatobiliary Surgery and Nutrition, 2021, 10, 692-695.	0.7	8
900	Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib. Hepatology Research, 2021, 51, 1029-1030.	1.8	2
901	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. International Immunopharmacology, 2021, 100, 108128.	1.7	13
902	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	1.3	42
903	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. European Journal of Cancer, 2021, 157, 10-20.	1.3	4
904	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. European Journal of Medical Genetics, 2021, 64, 104313.	0.7	19
905	Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Translational Oncology, 2021, 14, 101201.	1.7	4

#	Article	IF	Citations
906	Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology, 2021, 100, 108135.	1.7	3
907	Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. Materials and Design, 2021, 209, 109958.	3.3	8
908	Robust Effect of Hepatic Arterial Infusion Chemotherapy, and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease: A Case Report. Internal Medicine, 2022, , .	0.3	2
909	Mechanisms of immune suppression in glioblastoma. , 2022, , 1-17.		0
910	Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 399-403.	4.2	21
911	Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. Expert Opinion on Drug Delivery, 2021, 18, 383-398.	2.4	25
912	Regional lymph node sampling in hepatoma resection: insight into prognosis. Hpb, 2021, 23, 1360-1370.	0.1	1
913	Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel. Internal Medicine, 2021, 60, 3273-3277.	0.3	2
914	Research Progress of PD-1 Inhibitor Combination. Pharmacy Information, 2021, 10, 112-120.	0.1	0
915	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 11-11.	0.4	8
916	A Phase II Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinomaâ€“ CA 209-678. SSRN Electronic Journal, 0, , .	0.4	0
917	Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma. 4open, 2021, 4, 3.	0.1	2
918	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 39-52.	1.0	9
919	Overview of Clinical HCC and Its Management. , 2021, , 111-126.		0
920	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0
921	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics, 2021, 11, 3489-3501.	4.6	35
922	Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
923	Early effect of 90Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. European Radiology, 2021, 31, 5791-5801.	2.3	6

#	Article	IF	Citations
924	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer, 2021, 10, 380-393.	4.2	51
926	Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan. JMA Journal, 2021, 4, 241-245.	0.6	2
927	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 2021, 13, 271.	1.7	39
930	Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma. Current Hepatology Reports, 2021, 20, 12-22.	0.4	12
931	Predicting HCC Response to Multikinase Inhibitors With InÂVivo Cirrhotic Mouse Model for Personalized Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1313-1325.	2.3	12
932	Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Research, 2021, 2021, .	0.6	14
933	Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. , 2021, , 277-283.		0
934	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. Cancers, 2021, 13, 213.	1.7	6
935	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals, 2021, 14, 43.	1.7	8
936	Checkpoint Inhibitors and Hepatotoxicity. Biomedicines, 2021, 9, 101.	1.4	17
937	Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean Journal of Radiology, 2021, 22, 1822-1833.	1.5	9
938	Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. SSRN Electronic Journal, 0, , .	0.4	1
939	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 293-313.	8.2	428
940	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110365.	1.4	24
941	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer, 2021, 10, 151-160.	4.2	20
942	Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1827-1829.	3.2	9
943	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
944	Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. Journal of Oncology, 2021, 2021, 1-20.	0.6	26

#	Article	IF	Citations
945	Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries. Liver Cancer, 2021, 10, 404-406.	4.2	4
946	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460.	4.2	5
947	A Realâ€World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGETâ€HCC. Hepatology Communications, 2021, 5, 538-547.	2.0	6
948	Asian perspective on NAFLD-associated HCC. Journal of Hepatology, 2022, 76, 726-734.	1.8	59
949	Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2021, 30, 333-341.	1.9	3
950	Immunotherapies in clinical development for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 351-363.	1.9	28
951	Emerging paradigms in metastasis research. Journal of Experimental Medicine, 2021, 218, .	4.2	16
953	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 19-27.	0.7	2
954	Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut, 2021, 70, 951-961.	6.1	93
955	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. Clinical Cancer Research, 2021, 27, 908-910.	3.2	11
956	Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer, 2020, 9, 640-662.	4.2	78
957	Hypoxia-inducible factors and innate immunity in liver cancer. Journal of Clinical Investigation, 2020, 130, 5052-5062.	3.9	85
958	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. Journal of Clinical Oncology, 2020, 38, 549-549.	0.8	4
959	Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Research, 2020, 2020, .	0.6	6
960	Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure. Annals of Translational Medicine, 2020, 8, 1700-1700.	0.7	6
961	Camrelizumabâ€”targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1614-1614.	0.7	2
962	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 403-412.	1.8	6
963	Hepatic Hippo signaling inhibits development of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2020, 26, 742-750.	4.5	40

#	Article	IF	Citations
964	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Frontiers in Endocrinology, 2020, 11, 576027.	1.5	20
965	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 2021, 13, 90.	1.7	21
966	Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 232.	1.8	6
967	ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. International Journal of Molecular Sciences, 2021, 22, 241.	1.8	26
968	A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. Journal of Clinical Medicine, 2020, 9, 4121.	1.0	26
969	Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules, 2021, 26, 4.	1.7	19
970	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals, 2021, 14, 3.	1.7	16
971	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals, 2021, 14, 28.	1.7	17
972	Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Global Health & Medicine, 2020, 2, 282-291.	0.6	14
973	Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Current Oncology, 2020, 27, 173-180.	0.9	5
974	Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. Current Oncology, 2020, 27, 165-172.	0.9	9
975	Lenvatinib as first-line therapy for recurrentÂhepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation, 2020, 10, 297-306.	0.6	8
976	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
977	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine, 2021, 11, 4628-4634.	0.0	0
978	Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. Annals of Translational Medicine, 2021, 9, 1568-1568.	0.7	5
979	Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. National Science Review, 2022, 9, nwab192.	4.6	15
980	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Frontiers in Immunology, 2021, 12, 765101.	2.2	63
981	Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Frontiers in Cell and Developmental Biology, 2021, 9, 700553.	1.8	6

#	Article	IF	Citations
982	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clinical Cancer Research, 2022, 28, 71-83.	3.2	37
983	Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 295-298.	0.6	1
984	Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 211-218.	2.9	18
985	Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. Medicine (United States), 2021, 100, e27576.	0.4	8
986	Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 694409.	1.3	10
987	Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World Journal of Gastrointestinal Oncology, 2021, 13, 1397-1411.	0.8	9
988	Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid, 2022, 32, 153-163.	2.4	13
989	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. Cancers, 2021, 13, 5129.	1.7	2
990	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers, 2021, 13, 5295.	1.7	9
991	Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Medicine, 2021, 13, 166.	3.6	19
992	Firstâ€line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Medicine, 2021, 10, 8530-8541.	1.3	12
993	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 333-350.	4.5	22
994	Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 1136-1148.	0.8	2
995	Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis. Life, 2021, 11, 1066.	1.1	2
996	The Immunology of Hepatocellular Carcinoma. Vaccines, 2021, 9, 1184.	2.1	41
997	Radioembolization in the Setting of Systemic Therapies. Seminars in Interventional Radiology, 2021, 38, 472-478.	0.3	1
998	Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity. Hepatology Research, 2022, 52, 105-119.	1.8	5
999	Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Frontiers in Oncology, 2021, 11, 756672.	1.3	12

#	Article	IF	Citations
1000	Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. Digestive Diseases, 2022, 40, 565-580.	0.8	4
1001	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Journal of Clinical Oncology, 2022, 40, 150-160.	0.8	137
1002	Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety, 2021, , 1-10.	1.0	1
1003	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. Annals of Hepatology, 2021, , 100564.	0.6	1
1004	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology, 2022, 17, 309-323.	0.5	114
1005	Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. OncoTargets and Therapy, 2021, Volume 14, 5019-5026.	1.0	4
1006	The management of post-transplantation recurrence of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 1-16.	4.5	27
1007	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 1025-1035.	3.7	56
1008	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFITY score. Journal of Hepatology, 2022, 76, 353-363.	1.8	132
1009	Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 740790.	2.2	5
1010	A Combinatorial CRISPRâ€“Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment. Cancer Research, 2021, 81, 6219-6232.	0.4	13
1011	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 9-21.	4.2	29
1012	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers, 2021, 13, 5282.	1.7	11
1013	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open, 2021, 5, 1275-1283.	0.7	12
1014	Combining systemic and local therapies for hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 976-978.	3.7	2
1015	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. Acta Hepatologica Japonica, 2021, 62, 656-662.	0.0	0
1016	A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion. Liver Cancer, 2021, 10, 539-544.	4.2	46
1017	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers, 2021, 13, 4962.	1.7	3

#	Article	IF	Citations
1018	Diagnostik und Therapie des hepatozellulÃren Karzinoms. Tumor Diagnostik Und Therapie, 2021, 42, 562-574.	0.1	0
1019	Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1233-1240.	1.8	71
1020	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 2021, 184, 5309-5337.	13.5	588
1021	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer, 2021, 21, 1126.	1.1	29
1022	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	3
1023	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497.	1.3	22
1024	Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Frontiers in Immunology, 2021, 12, 754961.	2.2	16
1025	Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 387-394.	1.4	10
1026	Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Scientific Reports, 2021, 11, 19711.	1.6	9
1027	Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology, 2022, 75, 1139-1153.	3.6	34
1029	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. International Journal of Hyperthermia, 2021, 38, 1519-1528.	1.1	21
1030	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight, 2021, 6, .	2.3	22
1031	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274.	0.7	9
1032	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. International Journal of Molecular Sciences, 2021, 22, 11061.	1.8	49
1033	â€œÎ³Î´T Cell-IL17A-Neutrophilâ€•Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. Frontiers in Immunology, 2021, 12, 699478.	2.2	8
1034	Impact of Nuclear Factor Erythroid 2â€“Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatology Communications, 2022, 6, 665-678.	2.0	10
1035	Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278.	5.0	86
1036	Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Frontiers in Oncology, 2021, 11, 752725.	1.3	28

#	Article	IF	Citations
1037	Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 726008.	1.3	3
1038	Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology, 2021, 28, 4157-4166.	0.9	30
1039	Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment. World Journal of Surgical Oncology, 2021, 19, 313.	0.8	6
1040	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
1041	The impact of hypoxia on immune state in cancer. Life Sciences, 2021, 286, 120057.	2.0	46
1042	Optimizing outcomes in HCC: Comment on â€œoptimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysisâ€•by Jiang etÂal.. Translational Oncology, 2021, 14, 101246.	1.7	0
1043	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncology, 2020, 16, 1659-1664.	1.1	2
1046	Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1281-1295.	1.8	10
1047	Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. Journal of Nanobiotechnology, 2021, 19, 355.	4.2	33
1048	Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. International Journal of Gastrointestinal Intervention, 2021, 10, 183-188.	0.1	1
1049	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. British Journal of Cancer, 2021, , .	2.9	3
1051	Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers, 2021, 13, 5430.	1.7	13
1052	Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus. Journal of Gastrointestinal Surgery, 2022, 26, 822-830.	0.9	7
1053	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clinical Journal of Gastroenterology, 2021, 14, 1718-1724.	0.4	16
1054	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers, 2021, 13, 5475.	1.7	10
1055	Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. Cancers, 2021, 13, 5495.	1.7	15
1056	Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	6
1057	Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?. Frontiers in Immunology, 2021, 12, 731527.	2.2	10

#	Article	IF	Citations
1058	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. International Immunopharmacology, 2021, 101, 108322.	1.7	18
1059	Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer. International Immunopharmacology, 2021, 101, 108302.	1.7	1
1060	Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 423-433.	1.8	4
1061	Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?. Annals of Translational Medicine, 2020, 8, 1701-1701.	0.7	2
1062	Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.2	4
1063	Hepatocellular carcinoma: update on treatment guidelines. Gastrointestinal Nursing, 2020, 18, S18-S26.	0.0	1
1064	Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1557-1557.	0.7	0
1065	Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!. Annals of Translational Medicine, 2020, 8, 1693-1693.	0.7	6
1066	Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints. ChemistrySelect, 2020, 5, 14943-14954.	0.7	2
1067	ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma. Hepatology Communications, 2021, 5, 675-688.	2.0	17
1068	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal Medicine, 2022, 61, 1485-1490.	0.3	3
1069	Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. , 2020, 38, 89-91.		1
1071	Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian Journal of Medical Research, 2020, 152, 468.	0.4	9
1072	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2020, 26, 1.	0.5	13
1074	Identification of Chromatin Organization-Related Gene Signature for Predicting Hepatocellular Carcinoma Prognosis and Immunotherapy Response. SSRN Electronic Journal, 0, , .	0.4	0
1075	External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2022, 12, 28-51.	1.1	92
1076	Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Frontiers in Oncology, 2021, 11, 747950.	1.3	33
1077	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatology Communications, 2022, 6, 633-645.	2.0	4

#	Article	IF	Citations
1078	Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. Cancers, 2021, 13, 5524.	1.7	15
1079	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. JAMA Oncology, 2021, 7, 1843.	3.4	26
1080	Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines, 2021, 9, 1639.	1.4	84
1081	Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2022, 100, 12-21.	0.9	19
1082	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
1083	Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma. Anticancer Research, 2021, 41, 5775-5783.	0.5	5
1084	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clinical Immunology, 2021, 232, 108876.	1.4	4
1085	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. Cancers, 2021, 13, 5586.	1.7	13
1086	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. Breast Cancer Research and Treatment, 2022, 191, 257-267.	1.1	10
1087	Role of Hepatocyteâ€Derived Osteopontin in Liver Carcinogenesis. Hepatology Communications, 2022, 6, 692-709.	2.0	6
1089	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Global Health & Medicine, 2020, 2, 273-281.	0.6	4
1090	Clinical implications of WNT/Î²-catenin signaling for hepatocellular carcinoma. Global Health & Medicine, 2020, 2, 269-272.	0.6	4
1092	Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Liver Cancer, 2020, 20, 177-182.	0.3	1
1094	Advisory Council on combined immunochemotherapy for urothelial cancer. Onkourologiya, 2020, 16, 209-211.	0.1	0
1095	The evolving treatment landscape of hepatocellular carcinoma: more choices, more responsibility. Current Oncology, 2020, 27, S136-S137.	0.9	0
1096	Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. American Journal of Cancer Research, 2020, 10, 4547-4560.	1.4	3
1097	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8
1098	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2319-2330.	1.4	3

#	Article	IF	Citations
1099	Irreversible electroporation enhances immunotherapeutic effect in the off-target tumor in a murine model of orthotopic HCC. American Journal of Cancer Research, 2021, 11, 3304-3319.	1.4	0
1100	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 1745-1745.	0.7	2
1101	Liver diseases fibrosis and cirrhosis. , 2022, , 107-153.		0
1102	HepatozellulÃres Karzinom. , 2022, , 283-290.		0
1103	Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice. Cancer Diagnosis & Prognosis, 2021, 1, 83-88.	0.3	12
1104	New Systemic Treatment Options for Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 633-635.	2.3	0
1105	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1485-1493.	1.8	7
1106	Targeting LRG1 boosts immunotherapy. Med, 2021, 2, 1195-1197.	2.2	0
1107	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
1108	Hypoxia as a driver of resistance to immunotherapy. Drug Resistance Updates, 2021, 59, 100787.	6.5	94
1109	CRISPR/Cas9 in Gastrointestinal Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 727217.	1.8	4
1110	Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 6029.	1.7	2
1111	Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Frontiers in Oncology, 2021, 11, 772195.	1.3	28
1112	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	1.8	35
1113	Liver cell circuits and therapeutic discovery for advanced liver disease and cancer. Comptes Rendus - Biologies, 2021, 344, 233-248.	0.1	0
1114	The role of complement in the clinical course of hepatocellular carcinoma. Immunity, Inflammation and Disease, 2022, 10, .	1.3	8
1115	Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liverâ€related complications. Hepatology Research, 2022, 52, 364-370.	1.8	7
1116	Stereotactic body radiation therapy for primary liver tumors: An effective liverâ€directed therapy in the toolbox. Cancer, 2022, 128, 956-965.	2.0	7

#	Article	IF	Citations
1117	RASSF1A independence and early galectinâ€1 upregulation in PIK3CAâ€induced hepatocarcinogenesis: new therapeutic venues. Molecular Oncology, 2022, 16, 1091-1118.	2.1	8
1118	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver International, 2022, 42, 674-681.	1.9	39
1119	Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver International, 2022, 42, 2055-2066.	1.9	14
1120	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 783236.	2.2	66
1121	Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series. Anticancer Research, 2021, 41, 6225-6230.	0.5	5
1122	Glypican-3â€“Targeted ²²⁷Th Î±-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2022, 63, 1033-1038.	2.8	7
1123	Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology Research, 2022, 52, 269-280.	1.8	28
1124	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 729764.	1.3	28
1125	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	1.7	5
1126	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. Liver Cancer, 2022, 11, 75-84.	4.2	29
1127	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Gaâ€PSMAâ€11 PET Using Cyclotronâ€Produced 68Ga. Hepatology Communications, 2022, 6, 1172-1185.	2.0	15
1128	Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing <scp>nonsurgical</scp> hepatocellular carcinoma therapy. JGH Open, 2021, 5, 1335-1343.	0.7	9
1129	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investigation, 2021, 8, 22-22.	1.3	1
1130	Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opinion on Investigational Drugs, 2022, 31, 379-391.	1.9	5
1131	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022, 76, 681-693.	1.8	1,495
1132	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 12880.	1.8	15
1133	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	3.1	43
1134	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3

#	Article	IF	Citations
1135	Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. Clinical Cancer Research, 2022, 28, 540-551.	3.2	23
1136	Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. Cell Reports Medicine, 2021, 2, 100444.	3.3	4
1138	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. International Immunopharmacology, 2021, 101, 108340.	1.7	23
1139	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. Liver Cancer International, 2022, 3, 34-36.	0.2	7
1140	The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	1
1141	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yesâ€Associated Protein 1 Activation and Transient Expansion of Stemâ€Like Cancer Cells. Hepatology Communications, 2022, 6, 1140-1156.	2.0	6
1142	The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma. Journal of Hepatology, 2021, , .	1.8	2
1143	Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatology Communications, 2022, 6, 1198-1212.	2.0	2
1144	Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Cell Reports, 2021, 37, 109974.	2.9	26
1145	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	12.5	643
1146	Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World Journal of Gastrointestinal Oncology, 2021, 13, 1813-1832.	0.8	11
1147	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers, 2021, 13, 5797.	1.7	13
1148	Estrogen Receptor 1ÂInhibition ofÂWnt/Î²-Catenin SignalingÂContributes toÂSex Differences in Hepatocarcinogenesis. Frontiers in Oncology, 2021, 11, 777834.	1.3	12
1149	Targeting hypoxia and hypoxiaâ€inducible factorâ€1 in the tumor microenvironment for optimal cancer immunotherapy. Journal of Cellular Physiology, 2022, 237, 1285-1298.	2.0	20
1150	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330.	2.0	25
1151	Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2021, 162, 175-184.	0.9	6
1152	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 361-369.	1.9	68
1154	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110638.	0.8	10

#	Article	IF	Citations
1155	Clinical impact of the Model for End Liver Disease (MELD) score on the presence of microvascular invasion and on the postoperative outcome in patients undergoing liver transplantation. Revista Do Colegio Brasileiro De Cirurgioes, 2021, 48, e20212997.	0.3	0
1156	Hepatocellular carcinoma with complete response to the immunotherapy: the oncologistâ€™s dilemma. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	0.7	0
1157	A Status Quo Review of Immunotherapy for Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2021, 11, 5740-5746.	0.0	1
1158	Symptomatic pituitary metastasis from hepatocellular carcinoma: a case report and literature review. International Journal of Transgender Health, 2021, 14, 691-698.	1.1	0
1159	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
1160	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Practice, 2021, 8, 127.	0.2	2
1161	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 259-272.	0.8	3
1162	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110584.	0.3	6
1163	Onkologika. , 2021, , 579-638.		0
1164	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. SSRN Electronic Journal, 0, , .	0.4	0
1165	Multidisciplinary approach to the treatment of advanced hepatocellular carcinoma in the era of new biologic agents. Journal of Nippon Medical School, 2021, , .	0.3	0
1166	A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma. Translational Cancer Research, 2022, 11, 99-112.	0.4	2
1167	A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review. Journal of Gastrointestinal Oncology, 2022, 13, 426-437.	0.6	7
1168	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. SSRN Electronic Journal, 0, , .	0.4	0
1169	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 232.	1.7	6
1170	Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both?. Cancer Research, 2022, 82, 15-17.	0.4	19
1171	Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics, 2021, , 2100141.	1.3	0
1172	OUP accepted manuscript. Oncologist, 2022, 27, e265-e272.	1.9	2

#	Article	IF	Citations
1173	Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. International Journal of Hyperthermia, 2022, 39, 97-107.	1.1	1
1174	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer, 2022, 22, 55.	1.1	14
1175	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 320.	1.7	8
1177	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1. Frontiers in Cell and Developmental Biology, 2021, 9, 790386.	1.8	8
1178	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. Molecular Cancer, 2022, 21, 2.	7.9	14
1179	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers, 2022, 14, 294.	1.7	24
1180	Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib. Malignant Tumours, 2022, 11, 45-52.	0.1	1
1181	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers, 2022, 14, 343.	1.7	19
1182	Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer, 2022, 162, 76-98.	1.3	8
1183	Organoids as research models for hepatocellular carcinoma. Experimental Cell Research, 2022, 411, 112987.	1.2	7
1184	Leberkrebs und TumorheterogenitÃt: Marker fÃ¼r Therapiesteuerung. , 0, , .		0
1185	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2021, 33, e114-e120.	0.8	2
1186	The Evolving Treatment Landscape of Hepatocellular Carcinoma: More Choices, More Responsibility. Current Oncology, 2020, 27, 136-137.	0.9	1
1187	An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies. , 2021, , 3-28.		0
1188	Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 567-576.	2.3	4
1189	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology, 2022, 100, 65-73.	0.9	3
1190	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
1191	Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. BMC Cancer, 2021, 21, 1347.	1.1	3

#	Article	IF	Citations
1192	Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. American Journal of Transplantation, 2022, 22, 1699-1704.	2.6	33
1193	Association of Angiogenesis Gene Expression With Cancer Prognosis and Immunotherapy Efficacy. Frontiers in Cell and Developmental Biology, 2022, 10, 805507.	1.8	3
1194	Genetic Landscape of Multistep Hepatocarcinogenesis. Cancers, 2022, 14, 568.	1.7	7
1195	BMP9-ID1 Signaling Activates HIF-1Î± and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 1475.	1.8	14
1196	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
1197	Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Science Advances, 2022, 8, eabh2635.	4.7	35
1198	Medical Treatment for Hepatocellular Carcinoma in Japan. Journal of Nippon Medical School, 2022, , .	0.3	1
1199	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	1.5	7
1200	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World Journal of Gastroenterology, 2022, 28, 310-331.	1.4	29
1201	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 401-413.	1.9	9
1202	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports, 2022, 42, .	1.1	13
1203	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. International Journal of Molecular Sciences, 2022, 23, 500.	1.8	37
1204	Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy. Cancers, 2022, 14, 226.	1.7	55
1205	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
1206	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621.	1.7	34
1207	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. Cancers, 2022, 14, 454.	1.7	9
1208	A painful mass in the jaw. Cleveland Clinic Journal of Medicine, 2022, 89, 27-35.	0.6	0
1209	Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer. The Lancet Gastroenterology and Hepatology, 2022, 7, 200-201.	3.7	1

#	Article	IF	Citations
1210	Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene, 2022, 41, 1410-1420.	2.6	16
1211	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology, 2022, 18, 1423-1435.	1.1	14
1212	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular Cancer, 2022, 21, 28.	7.9	393
1213	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 208-218.	3.7	105
1214	Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver International, 2022, 42, 2042-2054.	1.9	49
1215	Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. , 2022, 10, e003133.		20
1216	Immunotherapyâ€"another breakthrough in gastrointestinal malignancies. Memo - Magazine of European Medical Oncology, 2022, 15, 20.	0.3	1
1218	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 820.	1.8	15
1219	Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 257-273.	8.2	77
1220	Immuneâ€related lncRNA signature delineates an immuneâ€excluded subtype of liver cancer with unfavorable clinical outcomes. Journal of Clinical Laboratory Analysis, 2022, 36, e24244.	0.9	2
1221	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study. Lancet Oncology, The, 2022, 23, 4-6.	5.1	3
1222	Two distinct stem cellâ€like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications, 2022, 42, 179-183.	3.7	3
1223	Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors. Cancers, 2022, 14, 752.	1.7	0
1224	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815.	4.3	28
1225	Corticosteroids for highâ€grade immune checkpoint inhibitorâ€"mediated hepatitis: Is less more?. Hepatology, 2022, 75, 508-510.	3.6	1
1226	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology, 2023, 77, 109-123.	3.6	31
1227	Patientâ€reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 76, 251-274.	3.6	18
1228	Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World Journal of Gastrointestinal Oncology, 2022, 14, 163-180.	0.8	12

#	Article	IF	Citations
1229	Hepatic Tumor Stiffness Measured by Shear Wave Elastography is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. SSRN Electronic Journal, 0, , .	0.4	0
1230	Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3.	2.8	94
1231	Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.8	12
1232	Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Frontiers in Oncology, 2021, 11, 835889.	1.3	32
1233	Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences, 2021, 8, 800679.	1.6	2
1234	Is There an Impact of Locoregional Therapy on Immune Response Modulation in HCC?. Radiology, 2022, 303, 226-228.	3.6	2
1235	A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment. Hpb, 2022, 24, 1280-1290.	0.1	4
1236	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	3.7	79
1237	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
1238	Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 657512.	1.3	16
1239	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. Frontiers in Pharmacology, 2021, 12, 786174.	1.6	8
1240	Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. Liver Cancer, 2022, 11, 219-232.	4.2	20
1241	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66.		1
1242	Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	6
1243	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare (Switzerland), 2022, 10, 218.	1.0	1
1244	Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Liver Transplantation, 2022, 28, 895-896.	1.3	9
1245	A hepatocellularis carcinoma komplex kezelÃ©se.. Orvosi Hetilap, 2022, 162, 2-31.	0.1	1
1246	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526

#	Article	IF	Citations
1247	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Frontiers in Oncology, 2022, 12, 822507.	1.3	5
1248	Tumors resurrect an embryonic vascular program to escape immunity. Science Immunology, 2022, 7, eabm6388.	5.6	27
1249	Hepatocellular Carcinoma with Extensive Macrovascular Invasion. Journal of General Internal Medicine, 2022, , 1.	1.3	0
1250	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology, 2022, 76, 630-645.	3.6	13
1251	Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging, 2022, 22, 1.	1.2	11
1252	Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers, 2022, 14, 504.	1.7	14
1254	Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?. Journal of Hepatology, 2022, 76, 975-980.	1.8	24
1255	Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 245-253.	3.7	34
1256	Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database. Frontiers in Pharmacology, 2021, 12, 760013.	1.6	3
1258	Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Current Oncology Reports, 2022, 24, 187-193.	1.8	10
1260	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149.	1.1	14
1262	Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases. Anticancer Research, 2022, 42, 1161-1167.	0.5	3
1263	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastaticÂcastration-resistant prostate cancer. Future Oncology, 2022, 18, 1185-1198.	1.1	10
1264	Cadinane-Type Sesquiterpenoids with Cytotoxic Activity from the Infected Stems of the Semi-mangrove Hibiscus tiliaceus. Journal of Natural Products, 2022, 85, 127-135.	1.5	7
1265	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology, 2022, 303, 455-464.	3.6	53
1266	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. Future Oncology, 2022, , .	1.1	4
1267	Regional differences: clinical practice guidelines on the management of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 161-163.	0.7	0
1268	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of New Systemic Agents. Radiology, 2022, , 212826.	3.6	0

#	Article	IF	Citations
1269	The Role of Macroautophagy and Chaperone-Mediated Autophagy in the Pathogenesis and Management of Hepatocellular Carcinoma. Cancers, 2022, 14, 760.	1.7	11
1270	Inflammation in Hepatocellular Carcinoma Patients Undergoing Hepatectomy: An Important Target for Ongoing Study. Annals of Surgical Oncology, 2022, 29, 2148-2149.	0.7	0
1271	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. Cancers, 2022, 14, 768.	1.7	1
1273	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596.	2.0	76
1274	Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment. Journal of Translational Medicine, 2022, 20, 62.	1.8	7
1275	Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research, 2022, 412, 113042.	1.2	4
1276	Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Hepatoma Research, 0, , .	0.6	3
1277	Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 827.	1.7	18
1278	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Seminars in Cancer Biology, 2022, 86, 981-996.	4.3	15
1279	Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers, 2022, 14, 883.	1.7	38
1280	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. Journal of Hepatology, 2022, 77, 116-127.	1.8	40
1281	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs, 2022, 36, 137-151.	2.2	6
1282	Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.4	5
1283	Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response. Clinical Cancer Research, 2022, 28, 1479-1481.	3.2	4
1284	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 203-214.	2.3	1
1285	Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers. Journal of Gastrointestinal Cancer, 2022, , 1.	0.6	2
1286	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. CardioVascular and Interventional Radiology, 2022, 45, 1599-1607.	0.9	21
1287	Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy. Pathology Research and Practice, 2022, 232, 153808.	1.0	5

#	Article	IF	Citations
1288	Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib. Medicine (United States), 2022, 101, e28680.	0.4	12
1289	A step toward a better understanding of hepatocellular progression after transarterial embolization. Diagnostic and Interventional Imaging, 2022, 103, 125-126.	1.8	8
1290	miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Molecular Therapy - Nucleic Acids, 2022, 27, 1191-1224.	2.3	40
1291	Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. International Journal of Hyperthermia, 2022, 39, 278-286.	1.1	19
1292	Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. ESMO Open, 2022, 7, 100396.	2.0	9
1294	Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Journal of Clinical Oncology, 2022, 40, 468-480.	0.8	98
1295	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver International, 2022, 42, 1229-1240.	1.9	17
1296	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell International, 2022, 22, 73.	1.8	21
1297	Development of antigenâ€prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Science, 2022, , .	1.7	4
1298	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460.	0.4	38
1299	Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nature Communications, 2022, 13, 758.	5.8	94
1300	Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology, 2022, 13, 778505.	1.6	11
1301	Inhibition of the VEGF signaling pathway attenuates tumorâ€associated macrophage activity in liver cancer. Oncology Reports, 2022, 47, .	1.2	23
1302	Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. Journal of Hepatology, 2022, 77, 219-236.	1.8	16
1303	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	0.9	31
1304	Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 134-144.	0.6	19
1305	Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 2022, 11, 571-591.	1.3	29
1306	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 862-873.	1.8	568

#	Article	IF	Citations
1307	Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 883-895.	1.8	32
1308	Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 337-346.	1.9	6
1309	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances, 2022, 6, 1152-1161.	2.5	13
1310	Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 780798.	1.3	1
1311	The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Frontiers in Oncology, 2021, 11, 783480.	1.3	42
1312	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Frontiers in Oncology, 2021, 11, 801379.	1.3	21
1313	The past, present and future of conversion therapy for liver cancer. American Journal of Cancer Research, 2021, 11, 4711-4724.	1.4	2
1314	Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids. Journal of Gastrointestinal Oncology, 2021, 13, 0-0.	0.6	2
1315	Telomerase in hepatocellular carcinoma. , 2022, , 181-197.		0
1316	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. International Journal of Biological Sciences, 2022, 18, 2775-2794.	2.6	27
1317	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. Advances in Cancer Research, 2022, , 367-413.	1.9	6
1318	Implications of genetic heterogeneity in hepatocellular cancer. Advances in Cancer Research, 2022, , 103-135.	1.9	5
1319	Updates on the staging and treatment of hepatocellular carcinoma. , 2022, , 307-319.		0
1320	Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research, 2022, , 319-341.	1.9	2
1321	Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial. SSRN Electronic Journal, 0, , .	0.4	0
1322	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210802.	1.4	43
1323	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.5	3
1325	Neurological complications of GI cancers. , 2022, , 365-386.		0

#	Article	IF	Citations
1326	Nuclear Medicine Therapy in primary liver cancers. , 2022, , .		0
1327	Role of transcription factors in hepatocellular carcinoma. , 2022, , 149-163.		0
1329	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv, 2022, 94, 216-253.	0.2	19
1330	Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer. Current Cancer Drug Targets, 2022, 22, 639-650.	0.8	2
1331	A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell International, 2022, 22, 95.	1.8	8
1332	Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers. Oncogene, 2022, 41, 2039-2053.	2.6	7
1333	Two cases of rapid progression of esophageal varices after atezolizumabâ€“bevacizumab treatment for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 451-459.	0.4	8
1334	A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. ELife, 2022, 11, .	2.8	47
1335	Inflammatory Scores: Correlation with Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing Transarterial Radioembolization. CardioVascular and Interventional Radiology, 2022, 45, 461-475.	0.9	4
1336	SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 83-98.	1.8	4
1337	Î²-Catenin signaling in hepatocellular carcinoma. Journal of Clinical Investigation, 2022, 132, .	3.9	80
1338	Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 566-567.	1.8	7
1339	Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?. Future Oncology, 2022, , .	1.1	4
1340	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. Future Oncology, 2022, 18, 1691-1703.	1.1	4
1341	Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidenceâ€based treatment recommendation with multidisciplinary clinical decisionâ€making. Liver International, 2022, 42, 488-491.	1.9	8
1342	Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. Anticancer Research, 2022, 42, 1403-1412.	0.5	7
1343	What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. Current Oncology Reports, 2022, 24, 451-461.	1.8	1
1344	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16

#	Article	IF	Citations
1345	Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of Oncology, 2022, 2022, 1-12.	0.6	2
1346	Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?. World Journal of Gastroenterology, 2022, 28, 704-714.	1.4	2
1347	Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Review of Anticancer Therapy, 2022, 22, 297-306.	1.1	3
1348	Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 383-396.	1.8	36
1349	Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Frontiers in Oncology, 2022, 12, 809709.	1.3	13
1350	Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 810269.	1.3	14
1351	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. Nature Communications, 2022, 13, 954.	5.8	38
1352	Neutrophilâ€“lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 698-706.	0.8	27
1353	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 425-435.	1.9	3
1354	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
1355	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	6.1	90
1356	Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 792676.	1.8	18
1357	Use of chemotherapy to treat hepatocellular carcinoma. BioScience Trends, 2022, 16, 31-45.	1.1	35
1358	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. International Journal of Molecular Sciences, 2022, 23, 2022.	1.8	13
1359	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. JAMA Network Open, 2022, 5, e2149040.	2.8	48
1360	Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 87-93.	4.2	20
1361	VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Current Oncology Reports, 2022, 24, 463-474.	1.8	28
1362	Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy. Liver Cancer, 2022, 11, 383-396.	4.2	19

#	Article	IF	Citations
1363	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 2707.	1.8	9
1364	Ferroptosis in Cancer Immunotherapyâ€"Implications for Hepatocellular Carcinoma. Immuno, 2022, 2, 185-217.	0.6	3
1365	Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research, 2022, 28, 3499-3508.	3.2	32
1366	Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma. BMC Cancer, 2022, 22, 229.	1.1	11
1367	System analysis based on the cancerâ€"immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma. , 2022, 10, e004414.		10
1368	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 233-263.	1.8	27
1369	Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nature Communications, 2022, 13, 1372.	5.8	44
1370	Lenvatinib plus pembrolizumab for systemic therapy-naÃ¯ve and -experienced unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 2631-2643.	2.0	23
1371	Small Moleculeâ€Induced Differentiation As a Potential Therapy for Liver Cancer. Advanced Science, 2022, 9, e2103619.	5.6	8
1372	Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 732-740.	1.4	24
1373	Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer, 2022, 22, 335.	1.1	12
1375	Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion. Updates in Surgery, 2022, 74, 927-936.	0.9	6
1376	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer, 2022, 22, 293.	1.1	18
1377	Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma. Anticancer Research, 2022, 42, 1905-1910.	0.5	7
1378	Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Annals of Medicine, 2022, 54, 803-811.	1.5	9
1380	Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 814120.	1.3	3
1381	Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. International Journal of Molecular Sciences, 2022, 23, 3778.	1.8	45
1382	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery, 2022, 21, 440-462.	21.5	58

#	Article	IF	Citations
1383	Atezolizumab and bevacizumab for <scp>HCC</scp> in the real world. Liver International, 2022, 42, 727-728.	1.9	1
1384	Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review. Frontiers in Oncology, 2022, 12, 803454.	1.3	3
1385	Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?. Seminars in Liver Disease, 2022, , .	1.8	3
1386	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760.	1.7	20
1387	Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. Journal of Clinical Medicine, 2022, 11, 1444.	1.0	12
1388	Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology, 2022, 29, 2422-2434.	0.9	2
1389	The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 141-155.	1.8	10
1390	Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. Journal of Liver Cancer, 2022, 22, 69-74.	0.3	4
1391	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 2022, 164, 95-104.	1.3	0
1392	Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study. Liver Cancer, 2022, 11, 368-382.	4.2	10
1393	Pretreatment Positron Emission Tomography with ¹⁸F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma. Oncology, 2022, 100, 320-330.	0.9	5
1394	Immunotherapy and Transarterial therapy of <scp>HCC</scp>: What the interventional radiologist needs to know about the changing landscape of <scp>HCC</scp> treatment?. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 478-482.	0.9	10
1395	Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Frontiers in Oncology, 2022, 12, 764923.	1.3	4
1396	Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 2801.	1.8	13
1397	Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver Cancer, 2022, 11, 315-328.	4.2	31
1398	Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediateâ€Stage Hepatocellular Carcinoma, What Else Can We Do?. Frontiers in Oncology, 2022, 12, 824799.	1.3	3
1399	Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma. Oncology Letters, 2022, 23, 146.	0.8	8
1400	Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Frontiers in Immunology, 2022, 13, 848387.	2.2	66

#	Article	IF	Citations
1401	ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, 842351.	1.1	8
1402	Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2022, 114, 1301-1305.	3.0	22
1403	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2022, 22, 253-264.	1.5	20
1404	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. JTO Clinical and Research Reports, 2022, 3, 100312.	0.6	7
1405	Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101854.	0.7	3
1406	Tumor endothelial cellâ€induced CD8⁺ Tâ€cell exhaustion via GPNMB in hepatocellular carcinoma. Cancer Science, 2022, 113, 1625-1638.	1.7	18
1407	AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology, 2022, 162, 937-951.	0.6	5
1408	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 40-50.	0.3	0
1409	Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 487-497.	1.1	3
1410	Transarterial Radioembolization Versus Atezolizumabâ€“Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Advances in Therapy, 2022, , 1.	1.3	6
1411	Lightâ€activatable multifunctional paclitaxel nanoprodrug for synergistic chemoâ€photodynamic therapy in liver cancer. BioFactors, 2022, 48, 918-925.	2.6	2
1412	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open, 2022, 5, e222265.	2.8	26
1413	Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Reports, 2022, 5, e1613.	0.6	4
1414	Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. , 2022, 1, 49-54.		1
1415	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers, 2022, 14, 1722.	1.7	26
1416	Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 2022, 40, 252-254.	7.7	9
1417	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers, 2022, 14, 1526.	1.7	7
1418	A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Oncology, 2022, 2022, 1-10.	0.6	2

#	Article	IF	Citations
1419	Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2022, 31, 483-494.	1.9	2
1420	Bioinformatics Analysis Combined With Experiments Predicts PUDP as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Through Its Interaction With Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 830174.	1.3	4
1421	AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology, 2022, 162, 920-934.	0.6	81
1422	Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy. Frontiers in Immunology, 2022, 13, 815598.	2.2	3
1423	Component with abundant immuneâ€related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Cancer Science, 2022, , .	1.7	3
1425	A clinical and pathological update on hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 14-22.	0.3	11
1426	Prognostic significance of ‹scp›albuminâ€“bilirubin‹/scp› score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 662-670.	0.9	5
1427	Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study. Nutrition and Cancer, 2022, 74, 3118-3127.	0.9	1
1428	Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study. Cancers, 2022, 14, 1568.	1.7	9
1429	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903.	1.3	2
1430	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
1431	Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 127-140.	1.8	5
1432	Mutational signatures and processes in hepatobiliary cancers. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 367-382.	8.2	2
1433	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 2022, 14, 1747.	1.7	36
1434	The Treatment Landscape of Advanced Hepatocellular Carcinoma. Current Oncology Reports, 2022, 24, 917-927.	1.8	21
1435	Tumor-immune Co-evolution in Hepatocellular Carcinoma and Its Implication for Immunotherapy Resistance. , 2022, , .		1
1436	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. PLoS ONE, 2022, 17, e0265235.	1.1	4
1437	Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 265-272.	1.8	18

#	Article	IF	Citations
1438	Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. Hpb, 2022, 24, 1482-1491.	0.1	11
1439	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitorâ€"Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. Journal of Clinical Oncology, 2022, 40, 1929-1938.	0.8	33
1440	Hypoxiaâ€driven immunosuppression by Treg and typeâ€2 conventional dendritic cells in HCC. Hepatology, 2022, 76, 1329-1344.	3.6	71
1441	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. Cancers, 2022, 14, 1800.	1.7	7
1442	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460.	3.2	39
1443	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	0.7	55
1444	Care of the Hepatology Patient in the COVID-19 Era. Current Hepatology Reports, 2022, , 1-12.	0.4	2
1445	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 397-409.	1.8	59
1446	A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumabâ€"bevacizumab to avoid graft rejection?. Liver Transplantation, 2022, 28, 1262-1263.	1.3	0
1447	Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996â€"2030). Gastroenterology, 2022, 162, 1098-1110.e2.	0.6	5
1448	CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway. Science China Life Sciences, 2022, 65, 1998-2016.	2.3	9
1450	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology, 2022, 77, 748-760.	1.8	57
1451	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling, 2022, 20, 44.	2.7	109
1452	Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Frontiers in Oncology, 2022, 12, 807102.	1.3	18
1453	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€Pugh A and B cirrhosis: A realâ€world study. Hepatology, 2022, 76, 1000-1012.	3.6	114
1454	Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 2022, 20, 1752-1763.	1.9	3
1455	A Potential Prognostic Marker for Recognizing VEGF-Positive Hepatocellular Carcinoma Based on Magnetic Resonance Radiomics Signature. Frontiers in Oncology, 2022, 12, 857715.	1.3	6
1456	Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomarkers in Medicine, 2022, 16, 435-448.	0.6	0

#	Article	IF	Citations
1457	The Immune Response: A New Frontier in Interventional Oncology. Radiology, 2022, 303, 229-230.	3.6	0
1458	Immunotherapy for hepatocellular carcinoma: a â€œCRAFITYâ€•approach to patient stratification. Hepatobiliary Surgery and Nutrition, 2022, 11, 327-329.	0.7	1
1459	Reply to: â€œPrognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?â€• Journal of Hepatology, 2022, 76, 988-989.	1.8	0
1460	Poloâ€like kinase 4 inhibitor CFIâ€400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. Hepatology, 2023, 77, 729-744.	3.6	16
1461	Immune checkpoint inhibitors for hepatocellular carcinoma â€“ A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	0.8	3
1462	Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells. Frontiers in Oncology, 2022, 12, 854096.	1.3	13
1463	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open, 2022, 12, e059779.	0.8	1
1464	Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy, 2022, 14, 489-503.	1.0	1
1465	Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles. Chemistry of Materials, 2022, 34, 3694-3704.	3.2	4
1466	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. JAMA Oncology, 2022, 8, 904.	3.4	13
1467	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open, 2022, 7, 100417.	2.0	3
1468	Changing epidemiology of hepatocellular carcinoma in Asia. Liver International, 2022, 42, 2029-2041.	1.9	105
1469	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	3.6	97
1470	Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction. Bioorganic and Medicinal Chemistry Letters, 2022, 63, 128647.	1.0	4
1471	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
1472	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer, 2022, 167, 42-53.	1.3	2
1473	Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188720.	3.3	26
1474	Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review. Translational Oncology, 2022, 20, 101414.	1.7	3

#	Article	IF	Citations
1475	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology, 2022, 42, 101748.	0.8	2
1476	A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer. Cancer Biology and Medicine, 2022, 19, 136-139.	1.4	1
1477	Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering, 2022, 10, 57-64.	3.2	4
1478	Systematic Investigation of Biocompatible Cationic Polymeric Nucleic Acid Carriers for Immunotherapy of Hepatocellular Carcinoma. Cancers, 2022, 14, 85.	1.7	1
1479	Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report. BMC Gastroenterology, 2021, 21, 470.	0.8	3
1480	Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story. Journal of Gastrointestinal Cancer, 2021, 52, 1217-1222.	0.6	3
1481	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	1.7	44
1482	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatology Research, 2022, 52, 298-307.	1.8	31
1483	Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. Life, 2021, 11, 1400.	1.1	1
1484	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 48-60.	4.2	25
1485	Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases. OncoTargets and Therapy, 2021, Volume 14, 5447-5453.	1.0	2
1486	Radiologic Response as a Prognostic Factor in Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion after Transarterial Chemoembolization and Radiotherapy. Liver Cancer, 2022, 11, 152-161.	4.2	2
1487	FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opinion on Investigational Drugs, 2022, 31, 393-400.	1.9	4
1488	Systemic treatment of hepatocellular carcinoma: the times they are a-changinâ€™. Hepatobiliary Surgery and Nutrition, 2021, 10, 893-895.	0.7	2
1489	Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development, 2022, 7, 1-3.	0.4	1
1490	Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with isoâ€‘high intensity in theÂhepatobiliary phase of Gdâ€‘EOBâ€‘DTPAâ€‘MRI. Molecular and Clinical Oncology, 2021, 16, 53.	0.4	5
1491	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. Gastrointestinal Tumors, 2022, 9, 19-26.	0.3	4
1492	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980.	1.0	11

#	Article	IF	Citations
1493	Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. Academic Radiology, 2022, 29, 1378-1386.	1.3	3
1494	Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 798832.	1.3	16
1495	Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. International Journal of Molecular Sciences, 2021, 22, 13073.	1.8	10
1496	First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Frontiers in Oncology, 2021, 11, 771045.	1.3	20
1497	Phase Ib Study of Atezolizumab Plus Interferon-Î± with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology, 2021, 28, 5466-5479.	0.9	2
1498	An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 766609.	1.6	9
1499	Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study. Frontiers in Immunology, 2021, 12, 756872.	2.2	29
1500	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133.	1.3	83
1501	Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. Anticancer Research, 2022, 42, 35-44.	0.5	8
1502	Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. Cancers, 2022, 14, 48.	1.7	30
1503	Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 6307.	1.7	17
1504	Immunomodulation for hepatocellular carcinoma therapy: current challenges. Current Opinion in Oncology, 2022, 34, 155-160.	1.1	8
1505	Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma?. World Journal of Gastrointestinal Surgery, 2021, 13, 1523-1535.	0.8	4
1506	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers, 2021, 13, 6337.	1.7	3
1507	Comparative study between sorafenib and lenvatinib as the firstâ€line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a realâ€world setting. JGH Open, 2022, 6, 29-35.	0.7	6
1508	Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma. EClinicalMedicine, 2021, 42, 101201.	3.2	14
1509	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 141-153.	1.1	5
1510	A targetable LIFRâ^'NF-Î¹Bâ^'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117

#	Article	IF	Citations
1511	Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2136128.	2.8	29
1512	HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances, 2022, 2, .	1.2	3
1513	Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Frontiers in Immunology, 2021, 12, 792781.	2.2	39
1514	Novel Molecular Targets for Hepatocellular Carcinoma. Cancers, 2022, 14, 140.	1.7	8
1515	Low Inorganic Phosphate Stress Inhibits Liver Cancer Progression: from In Vivo to In Vitro. Advanced Therapeutics, 2022, 5, .	1.6	10
1516	Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. OncoTargets and Therapy, 2021, Volume 14, 5521-5532.	1.0	6
1517	Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 180-181.	4.2	3
1518	Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. World Journal of Gastrointestinal Oncology, 2021, 13, 1896-1918.	0.8	5
1519	Body Composition as a Novel Prognostic Biomarker for the Patients with Advanced Hepatocellular Carcinoma. Yamaguchi Medical Journal, 2021, 70, 157-164.	0.1	0
1520	Differentiation of malignant from non-malignant portal vein thrombosis in liver cirrhosis: the challenging dilemma. Egyptian Liver Journal, 2021, 11, .	0.3	3
1521	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 2076-2087.	0.8	4
1522	Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers, 2021, 13, 6310.	1.7	6
1523	Antiâ€'VEGF antibody triggers the effect of antiâ€'PDâ€'L1 antibody in PDâ€'L1^{low}and immune desertâ€'like mouse tumors. Oncology Reports, 2021, 47, .	1.2	10
1524	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. Clinical Cancer Research, 2022, 28, 3443-3451.	3.2	19
1525	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 2038-2049.	0.8	3
1526	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria â€" Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
1527	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 2022, 14, 41.	2.0	27
1528	CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. GastroenterologÃa Y HepatologÃa, 2022, 45, 742-752.	0.2	6

#	Article	IF	Citations
1529	Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 10483-10493.	0.8	9
1530	Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.	1.4	0
1531	Neoadjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 1550-1566.	0.8	9
1533	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine, 2022, 11, 602-617.	1.3	1
1534	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. Journal of Nuclear Medicine, 2022, 63, 57-58.	2.8	1
1535	Prior Knowledge-Aware Fusion Network for Prediction of Macrovascular Invasion in Hepatocellular Carcinoma. IEEE Transactions on Medical Imaging, 2022, 41, 2644-2657.	5.4	6
1536	Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature. Internal Medicine, 2022, , .	0.3	0
1537	Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. Cancer Control, 2022, 29, 107327482210929.	0.7	4
1538	Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210861.	1.4	13
1539	OUP accepted manuscript. Gastroenterology Report, 2022, 10, goac016.	0.6	2
1540	Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends, 2022, 16, 130-141.	1.1	14
1541	The Use of Transcatheter Arterial Embolization and Systemic Therapyfor the Treatment of Hepatocellular Carcinoma. Journal of the Nihon University Medical Association, 2022, 81, 11-17.	0.0	0
1542	Electrolyte Abnormalities Associated With The Use of Atezolizumab â€“ A Systematic Review. Journal of Community Hospital Internal Medicine Perspectives, 2022, 12, 35-44.	0.4	1
1543	Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)â€“Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study. CardioVascular and Interventional Radiology, 2022, , 1.	0.9	2
1544	Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab. Frontiers in Oncology, 2022, 12, 848129.	1.3	3
1545	Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study. International Journal of General Medicine, 2022, Volume 15, 3977-3989.	0.8	4
1546	Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncology, 2022, 18, 2269-2288.	1.1	12
1547	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology, 2022, 76, 1649-1659.	3.6	18

#	Article	IF	Citations
1548	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	3.2	31
1550	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 3537-3545.	3.2	52
1551	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical Cancer Research, 2022, 28, 2547-2554.	3.2	32
1552	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056.	1.7	24
1553	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 683-694.	1.8	45
1554	Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatology Research, 2022, 52, 630-640.	1.8	25
1555	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 333-339.	1.4	65
1556	Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 315-325.	1.8	5
1557	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. Journal of Thoracic Oncology, 2022, 17, 900-908.	0.5	23
1559	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Frontiers in Immunology, 2022, 13, 862084.	2.2	18
1560	Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model. Nanomaterials, 2022, 12, 1364.	1.9	3
1561	Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan. Scientific Reports, 2022, 12, 6479.	1.6	8
1562	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 1901.	1.7	15
1563	Resina Draconis extract exerts <scp>antiâ€HCC</scp> effects through <scp>METTL3â€m6Aâ€Survivin</scp> axis. Phytotherapy Research, 2022, 36, 2542-2557.	2.8	2
1564	Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Frontiers in Public Health, 2022, 10, 869960.	1.3	12
1565	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305.	3.2	8
1566	Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Biomaterials, 2022, 284, 121527.	5.7	30
1567	Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma. Gene, 2022, , 146519.	1.0	0

#	Article	IF	Citations
1568	Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/Î²-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers, 2022, 14, 2066.	1.7	8
1569	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018.	1.7	15
1570	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
1571	Progress in Radiotherapy for Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, 868034.	1.3	18
1572	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. JGH Open, 2022, 6, 301-308.	0.7	7
1573	Systemic Therapy in Metastatic Hepatocellular Carcinoma. Current Gastroenterology Reports, 2022, 24, 65-71.	1.1	4
1574	Efficacy and safety of <scp>PD</scp>â€1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Medicine, 2022, 11, 3612-3622.	1.3	13
1575	Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Frontiers in Oncology, 2022, 12, 874473.	1.3	22
1576	Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy. Materials and Design, 2022, 217, 110656.	3.3	15
1577	Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbeck's Archives of Surgery, 2022, 407, 2373-2380.	0.8	2
1578	Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open, 2022, 7, 100465.	2.0	17
1592	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunology, Immunotherapy, 2022, 71, 2837-2848.	2.0	5
1593	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Archives of Pharmacal Research, 2022, 45, 263-279.	2.7	11
1594	Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene, 2022, 41, 3011-3023.	2.6	14
1595	COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterology, 2022, 9, e000794.	1.1	19
1596	Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial. BMJ Open, 2022, 12, e049992.	0.8	3
1597	Alternatively Spliced Form of Angiopoietin-2 as a New Vascular Rheostat. Cancer Research, 2021, 81, 35-37.	0.4	3
1599	AÂmultidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes. Clinical and Experimental Hepatology, 2022, 8, 42-48.	0.6	3

#	Article	IF	Citations
1600	Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.. Journal of Clinical and Translational Research, 2021, 7, 811-833.	0.3	1
1601	Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.. American Journal of Cancer Research, 2021, 11, 6107-6118.	1.4	0
1602	Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.. American Journal of Cancer Research, 2021, 11, 6173-6187.	1.4	0
1603	Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273.		0
1604	Recent advances in medical treatment of hepatocellular cancer. , 2022, , 365-375.		0
1605	Immunotherapy for hepatocellular cancer: a review of current status. , 2022, , 245-258.		0
1606	A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Internal Medicine, 2022, , .	0.3	4
1607	Immune checkpoint inhibitors for hepatocellular carcinoma. , 2022, , 215-223.		0
1608	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2022, 12, 3079-3086.	0.0	0
1609	The Somatic Mutational Landscape and Role of ARID1A Gene in Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
1610	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. Liver Cancer, 2022, 11, 329-340.	4.2	5
1611	Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. Clinical Epidemiology, 2022, Volume 14, 581-590.	1.5	3
1612	Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	0.2	0
1613	CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 2022, 71, 2093-2106.	6.1	66
1614	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. Clinical Colorectal Cancer, 2022, , .	1.0	0
1615	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. JGH Open, 2022, 6, 309-316.	0.7	6
1616	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Investigational New Drugs, 2022, 40, 789-797.	1.2	14
1617	Surgical Indications for Huge Hepatocellular Carcinoma. Anticancer Research, 2022, 42, 2573-2581.	0.5	1

#	Article	IF	Citations
1618	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics, 2022, 14, 507-517.	1.0	4
1619	Advanced hepatocellular carcinoma: Impact of systemic treatments on healthâ€related quality of life and patientâ€reported outcomes. Liver Cancer International, 0, , .	0.2	1
1620	PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2190.	1.7	4
1621	Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. Disease Markers, 2022, 2022, 1-10.	0.6	2
1622	Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, 867627.	1.1	12
1623	An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life, 2022, 12, 665.	1.1	11
1624	Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis. Frontiers in Oncology, 2022, 12, 882272.	1.3	0
1625	Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology, 2023, 77, 65-76.	3.6	10
1626	Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC. Hepatology, 2022, 76, E78-E79.	3.6	2
1627	Childâ€“Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. Journal of Clinical Medicine, 2022, 11, 2550.	1.0	3
1628	Ketogenic Diets and Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, .	1.3	3
1629	Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses, 2022, 14, 986.	1.5	37
1630	From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade. Frontiers in Oncology, 2022, 12, .	1.3	0
1631	Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-6.	0.8	4
1632	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation, 2022, 132, .	3.9	44
1633	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers, 2022, 14, 2396.	1.7	8
1634	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. International Journal of Clinical Oncology, 2022, 27, 1110-1119.	1.0	19
1635	Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers, 2022, 14, 2357.	1.7	18

#	Article	IF	Citations
1636	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 533-546.	1.0	6
1637	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opinion on Investigational Drugs, 2022, 31, 681-691.	1.9	7
1638	ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal. Frontiers in Oncology, 2022, 12, .	1.3	2
1639	Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers, 2022, 14, 2381.	1.7	4
1640	Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the Î³-Glutamyl Transpeptidase-to-Albumin Ratio. Journal of Gastrointestinal Surgery, 2022, 26, 1619-1627.	0.9	2
1641	Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment. Liver Cancer, 2022, 11, 407-425.	4.2	9
1642	A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer, 2022, 22, 517.	1.1	7
1643	Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology, 2022, 29, 3259-3271.	0.9	2
1644	Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. Frontiers in Oncology, 2022, 12, .	1.3	6
1645	Reply. Hepatology, 2022, 76, E82-E83.	3.6	0
1646	Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1179-1190.	1.4	7
1647	Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study. Cancer Management and Research, 2022, Volume 14, 1715-1727.	0.9	1
1648	Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. Journal of Viral Hepatitis, 2022, 29, 543-550.	1.0	3
1649	Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies. Annals of Surgical Oncology, 2022, , 1.	0.7	3
1650	The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. Annals of Surgery Open, 2022, 3, e163.	0.7	5
1651	Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Frontiers in Oncology, 2022, 12, .	1.3	1
1652	Versican Secreted by Cancer-Associated Fibroblasts is a Poor Prognostic Factor in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 7135-7146.	0.7	11
1653	Non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1513-1519.	1.2	3

#	Article	IF	Citations
1654	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomedicine and Pharmacotherapy, 2022, 150, 113064.	2.5	14
1655	Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. Pharmacological Research Modern Chinese Medicine, 2022, 3, 100108.	0.5	2
1656	Hepatocellular carcinoma as the Rose of Jericho: from the desert of sorafenib, to the blossoming of immunotherapy. Hepatobiliary Surgery and Nutrition, 2021, .	0.7	0
1657	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	5.7	126
1658	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications, 2022, 6, 1776-1785.	2.0	7
1659	Treatment of patients with cancer using PDâ€1/PDâ€L1 antibodies: Adverse effects and management strategies (Review). International Journal of Oncology, 2022, 60, .	1.4	9
1660	Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity. JHEP Reports, 2022, 4, 100498.	2.6	18
1661	The roles of TGF-Î² and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
1662	Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology, 2023, 77, 77-91.	3.6	50
1664	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 50-57.	0.4	1
1665	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1197-1206.	1.4	13
1666	Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers, 2022, 14, 2469.	1.7	8
1667	The Efficacy and Safety of Transarterial Chemoembolization Plus Iodine 125 Seed Implantation in the Treatment of Hepatocellular Carcinoma With Oligometastases: A Case Series Reports. Frontiers in Oncology, 2022, 12, .	1.3	0
1668	Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Frontiers in Pharmacology, 2022, 13, .	1.6	4
1669	MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF. Cancer Cell International, 2022, 22, 192.	1.8	4
1670	Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and <scp>antiâ€PD</scp>â€1 based immunotherapy in hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 1321-1334.	2.3	12
1671	Human liver single nucleus and singleÂcell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Medicine, 2022, 14, 50.	3.6	27
1672	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1348-1361.	1.8	75

#	Article	IF	Citations
1673	A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumabâ€“bevacizumab treatment. Clinical Journal of Gastroenterology, 2022, 15, 776-783.	0.4	10
1674	NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance. Journal of Controlled Release, 2022, 347, 389-399.	4.8	14
1675	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
1676	Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Expert Opinion on Investigational Drugs, 2022, 31, 693-706.	1.9	2
1677	Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma. Medicine (United States), 2022, 101, e29289.	0.4	1
1678	Role of radiomics in predicting immunotherapy response. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 575-591.	0.9	10
1679	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naÃ¯ve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
1680	Safety and Efficacy of¹⁶⁶Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. Journal of Nuclear Medicine, 2022, 63, 1891-1898.	2.8	11
1681	Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1899-1911.	1.4	0
1682	Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1606-1620.	1.4	0
1683	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210979.	1.4	7
1684	Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience. Journal of Cancer, 2022, 13, 2656-2661.	1.2	6
1685	Survival impact of immune cells infiltrating peritumoral area of hepatocellular carcinoma. Cancer Science, 2022, 113, 4048-4058.	1.7	8
1686	An International Retrospective Observational Study of Liver Functional Deterioration after Repeat Liver Resection for Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 2598.	1.7	4
1687	Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma. Hepatology, 2022, 76, 1660-1672.	3.6	11
1688	Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/Î²â€‘catenin signal activation. Oncology Letters, 2022, 24, .	0.8	8
1689	Significance of postâ€progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open, 0, , .	0.7	3
1690	Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon, 2022, 8, e09538.	1.4	13

#	Article	IF	Citations
1692	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. Journal of Clinical and Translational Hepatology, 2022, 10, 955-964.	0.7	9
1693	The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Frontiers in Immunology, 2022, 13, .	2.2	17
1694	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers, 2022, 14, 2549.	1.7	10
1699	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127.	1.2	20
1700	An exploratory clinical trial of apatinib combined with intensityâ€modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Medicine, 0, , .	1.3	5
1701	A novel DNA methylationâ€driver gene signature for longâ€term survival prediction of hepatitisâ€positive hepatocellular carcinoma patients. Cancer Medicine, 0, , .	1.3	2
1702	Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Frontiers in Immunology, 0, 13, .	2.2	7
1703	The Î±-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. Frontiers in Oncology, 0, 12, .	1.3	2
1704	Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 263-274.	0.7	1
1705	Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world. Hepatology, 2022, 76, E84-E85.	3.6	0
1706	Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Frontiers in Oncology, 0, 12, .	1.3	22
1707	Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. Advances in Therapy, 2022, 39, 3334-3346.	1.3	7
1708	Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	7
1709	Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response. American Journal of Physiology - Cell Physiology, 2022, 323, C95-C103.	2.1	8
1710	Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Medicine, 2022, 11, 4880-4888.	1.3	9
1711	Classification of <scp>PDâ€L1</scp> expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Science, 2022, 113, 3255-3266.	1.7	8
1712	Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 1-5.	2.3	0
1713	Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	2

#	Article	IF	Citations
1714	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34
1715	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€”Lung-MAP S1800A. Journal of Clinical Oncology, 2022, 40, 2295-2307.	0.8	84
1716	Hepatocellular Carcinoma: Pick the Winnerâ€”Tyrosine Kinase Inhibitor Versus Immuno-oncology Agentâ€“Based Combinations. Journal of Clinical Oncology, 2022, 40, 2763-2773.	0.8	18
1717	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean Journal of Transplantation, 2022, 36, 82-98.	0.0	9
1718	Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 517-536.	1.8	0
1719	Durable complete response is achieved by balloonâ€occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications, 2022, 6, 2594-2604.	2.0	3
1720	Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 141-149.	1.0	4
1721	Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Childâ€Pugh B cirrhosis. Cancer Medicine, 2023, 12, 189-199.	1.3	11
1722	First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, 10, 1304.	1.4	9
1723	Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Frontiers in Oncology, 0, 12, .	1.3	5
1724	InÂVivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma. , 2022, 1, 905-908.		3
1725	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of Clinical Oncology, 2022, 40, 2285-2287.	0.8	1
1726	NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	1.9	4
1727	Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	6
1728	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	17
1729	Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data. Frontiers in Immunology, 2022, 13, .	2.2	1
1730	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€”Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
1731	Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. BMC Gastroenterology, 2022, 22, .	0.8	1

#	Article	IF	Citations
1732	Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers, 2022, 14, 2798.	1.7	87
1733	Hypertension and renal disease during anti-cancer therapies. , 2023, , 185-199.		0
1735	Interventional oncology update. European Journal of Radiology Open, 2022, 9, 100430.	0.7	2
1736	Comparative Efficacy of Novel Combination Strategies for Unresectable Hepatocellular Carcinoma (HCC): A Network Metanalysis of Phase III Trials. SSRN Electronic Journal, 0, , .	0.4	0
1737	Immunotherapy in hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	1
1739	Durable benefit and change in TCR clonality with nivolumab in a Lynch syndromeâ€“associated glioma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211008.	1.4	1
1740	A Case of Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. Internal Medicine, 2022, , .	0.3	5
1741	Advances in the surgical treatment of liver cancer. BioScience Trends, 2022, 16, 178-188.	1.1	24
1742	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	1.8	6
1743	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
1744	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Frontiers in Oncology, 0, 12, .	1.3	8
1745	Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open, 2022, 6, 477-486.	0.7	13
1746	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. Liver Cancer, 2022, 11, 426-439.	4.2	11
1747	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Science Advances, 2022, 8, .	4.7	15
1748	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.	1.7	5
1749	Hepatotropic Peptides Grafted onto Maleimide-Decorated Nanoparticles: Preparation, Characterization and In Vitro Uptake by Human HepaRG Hepatoma Cells. Polymers, 2022, 14, 2447.	2.0	0
1750	Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Meditsinskiy Sovet, 2022, , 31-39.	0.1	2
1751	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26

#	Article	IF	Citations
1752	Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature. Frontiers in Immunology, 0, 13, .	2.2	5
1753	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatology International, 2022, 16, 1150-1160.	1.9	35
1754	The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3
1755	Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?. Liver Cancer, 2022, 11, 283-289.	4.2	4
1756	Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells, 2022, 11, 1857.	1.8	10
1757	Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers, 2022, 14, 2959.	1.7	8
1758	Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatology International, 2022, 16, 858-867.	1.9	15
1759	Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology, 2023, 77, 6-9.	3.6	1
1760	Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. World Journal of Gastrointestinal Oncology, 2022, 14, 1103-1114.	0.8	8
1761	Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 1637-1646.	0.9	3
1762	Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. Liver Cancer, 2022, 11, 440-450.	4.2	22
1764	Proton Therapy in the Management of Hepatocellular Carcinoma. Cancers, 2022, 14, 2900.	1.7	4
1765	Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. Canadian Liver Journal, 0, , .	0.3	0
1766	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. International Journal of Clinical Oncology, 0, , .	1.0	1
1767	Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Frontiers in Immunology, 0, 13, .	2.2	2
1768	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, .	1.3	19
1769	Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 2561-2568.	1.4	5
1770	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMBÂand PD-L1. Immunotherapy, 0, , .	1.0	8

#	Article	IF	Citations
1771	Idarubicinâ€Loaded <scp>DEBâ€TACE</scp> plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity scoreâ€matching analysis. Cancer Medicine, 2023, 12, 61-72.	1.3	8
1772	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Frontiers in Oncology, 0, 12, .	1.3	15
1773	Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer, 2022, 11, 460-473.	4.2	13
1774	Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitorâ€“treated unresectable hepatocellular carcinoma. , 2022, 10, e004779.		47
1775	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World Journal of Clinical Oncology, 2022, 13, 448-472.	0.9	6
1776	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611.	15.2	185
1777	High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
1778	Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OncoTargets and Therapy, 0, Volume 15, 629-636.	1.0	2
1779	MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers, 2022, 14, 2880.	1.7	7
1780	Safety and feasibility of contrast-enhanced computed tomography with a nanoparticle contrast agent for evaluation of diethylnitrosamine-induced liver tumors in a rat model. Academic Radiology, 2022, , .	1.3	0
1781	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	18
1782	Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European Journal of Cancer, 2022, 171, 193-202.	1.3	11
1784	Evaluation of cancer stem cells markers expression in HCC trough real-time polymerase chain reaction. Methods in Cell Biology, 2022, , .	0.5	0
1785	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	10
1786	Potential Candidates for Liver Resection in Liver-Confined Advanced HCC: A Chinese Multicenter Observational Study. SSRN Electronic Journal, 0, , .	0.4	0
1787	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. Advances in Clinical Medicine, 2022, 12, 5913-5936.	0.0	0
1788	Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 592-596.	0.7	42
1789	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18

#	Article	IF	Citations
1790	Cerebral hemorrhage during systemic chemotherapy with atezolizumab and bevacizumab for hepatocellular carcinoma. Acta Hepatologica Japonica, 2022, 63, 297-300.	0.0	1
1791	TKIs beyond immunotherapy predict improved survival in advanced HCC. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
1792	Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with antiâ€VEGF/TKI and immunotherapy. Hepatology, 2022, 76, 1203-1218.	3.6	22
1793	Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses. International Journal of Radiation Biology, 2023, 99, 419-430.	1.0	2
1794	Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Radiation Oncology, 2022, 17, .	1.2	5
1795	Emerging insights on immunotherapy in liver cancer. Antioxidants and Redox Signaling, 0, , .	2.5	4
1796	Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clinical Cancer Research, 2022, 28, 3890-3901.	3.2	14
1797	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. Frontiers in Immunology, 0, 13, .	2.2	16
1799	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 857-864.	0.8	3
1800	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 969-978.	1.2	9
1801	Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report. Clinical Journal of Gastroenterology, 0, , .	0.4	0
1802	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
1803	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , .	0.1	0
1804	Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. OncoTargets and Therapy, 0, Volume 15, 703-716.	1.0	2
1805	Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterology, 2023, 14, 45-51.	0.9	1
1806	The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity. Cancers, 2022, 14, 3150.	1.7	14
1807	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
1808	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 571-581.	1.8	10

#	Article	IF	Citations
1809	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. Cancers, 2022, 14, 3213.	1.7	10
1810	Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy. Lancet Oncology, The, 2022, 23, 962-963.	5.1	2
1811	Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC â€“ A Substudy From the SORAMIC Trial. , 0, 1, .		0
1812	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer. Cancer Immunology Research, 2022, 10, 1111-1126.	1.6	10
1813	Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Frontiers in Oncology, 0, 12, .	1.3	2
1814	Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1873-1882.	1.2	2
1815	A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. Clinical Journal of Gastroenterology, 0, , .	0.4	1
1816	Pretreatment Modified Albuminâ€“Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology, 2022, 29, 4799-4810.	0.9	8
1817	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers, 2022, 14, 3332.	1.7	11
1818	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer, 2022, 11, 558-571.	4.2	6
1819	Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World Journal of Surgical Oncology, 2022, 20, .	0.8	8
1820	Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer, 2022, 11, 527-539.	4.2	16
1821	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Review of Anticancer Therapy, 2022, 22, 1009-1015.	1.1	2
1822	Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	129
1823	Ficolin-3 may act as a tumour suppressor by recognising O-GlcNAcylation site in hepatocellular carcinoma. Medical Hypotheses, 2022, , 110899.	0.8	0
1824	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology, 2022, 2022, 1-27.	0.6	5
1825	Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1826	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 995-1008.	5.1	237

#	Article	IF	Citations
1827	Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immunoâ€oncology: A network metaâ€analysis of randomized sorafenibâ€controlled trials. Hepatology Communications, 2022, 6, 2886-2900.	2.0	2
1828	Editorial: â€™All you need is immunotherapyâ€™: a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?. Current Opinion in Oncology, 2022, 34, 379-381.	1.1	0
1829	ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1830	Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Frontiers in Oncology, 0, 12, .	1.3	10
1831	Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs. Clinical Cancer Research, 2022, 28, 3405-3407.	3.2	2
1832	Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Communications Medicine, 2022, 2, .	1.9	5
1833	Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies. Radiology Imaging Cancer, 2022, 4, .	0.7	3
1834	Mechanisms of resistance to immune checkpoint inhibitors. Cancer Science, 2022, 113, 3303-3312.	1.7	12
1835	<scp>SMARCA4</scp>â€deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report. Thoracic Cancer, 2022, 13, 2264-2266.	0.8	10
1836	Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. Diagnostics, 2022, 12, 1635.	1.3	2
1837	The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody. Frontiers in Immunology, 0, 13, .	2.2	4
1838	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology, 2022, 57, 587-597.	2.3	5
1839	Immune thrombocytopenic purpura caused by combination therapy of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A case presentation. Acta Hepatologica Japonica, 2022, 63, 335-341.	0.0	1
1840	Dosing, efficacy and safety of lenvatinb in the realâ€world treatment of hepatocellular carcinoma: Results from a Canadian database. Liver Cancer International, 2022, 3, 119-127.	0.2	1
1841	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 0, 13, .	2.2	10
1842	<scp>Realâ€world</scp> effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in <scp>US</scp> clinical practice. Cancer Reports, 0, , .	0.6	2
1843	Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers, 2022, 14, 3367.	1.7	24
1844	Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology and Hepatology, 2022, 7, 1049-1060.	3.7	3

#	Article	IF	Citations
1845	Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Frontiers in Immunology, 0, 13, .	2.2	9
1846	Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. Journal of Hepatocellular Carcinoma, 0, Volume 9, 595-607.	1.8	1
1847	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. Biomolecules, 2022, 12, 930.	1.8	2
1848	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	15
1849	Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses. Annals of Surgical Oncology, 2022, 29, 6815-6826.	0.7	2
1850	Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infectious Diseases, 2022, 22, .	1.3	4
1851	GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metabolism, 2022, 34, 1151-1167.e7.	7.2	40
1852	Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers, 2022, 14, 3373.	1.7	17
1853	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. Journal of Hematology and Oncology, 2022, 15, .	6.9	58
1854	The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. Journal of Immunotherapy, 0, Publish Ahead of Print, .	1.2	3
1855	Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study. Surgery, 2022, 172, 1147-1155.	1.0	4
1856	Response to immunotherapy plus antiâ€angiogenic agent combination challenges hepatocellular carcinoma prognostic scores. Hepatology Communications, 2022, 6, 3595-3596.	2.0	0
1857	Hepatocellular carcinoma treatments: A new hope, but a headache for clinicians and researchers. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101927.	0.7	0
1858	Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. International Immunopharmacology, 2022, 109, 108866.	1.7	8
1859	Iron chelator deferasirox inhibits NF-ÎºB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomedicine and Pharmacotherapy, 2022, 153, 113363.	2.5	14
1860	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. International Immunopharmacology, 2022, 110, 108968.	1.7	2
1861	Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Annals of Hepatology, 2022, 27, 100740.	0.6	1
1862	Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. Cancers, 2022, 14, 3574.	1.7	4

#	Article	IF	Citations
1863	Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). Liver Cancer, 2022, 11, 511-526.	4.2	11
1864	Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge. Journal of Hepatocellular Carcinoma, 0, Volume 9, 661-670.	1.8	7
1865	Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 430-439.	0.6	6
1866	Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma. JAMA Network Open, 2022, 5, e2222721.	2.8	8
1867	Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Digestive and Liver Disease, 2022, 54, 1563-1572.	0.4	11
1868	Two Milestone Studies in Liver Cancer Immunotherapy. , 2022, 1, .		1
1869	Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Frontiers in Oncology, 0, 12, .	1.3	5
1870	Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3065-3073.	1.2	6
1871	Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 3551.	1.7	14
1872	A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clinical Case Reports (discontinued), 2022, 10, .	0.2	3
1873	Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 399-406.	4.2	31
1874	Case report: Urgent liver pathologies: All in one. Frontiers in Surgery, 0, 9, .	0.6	2
1875	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Hormone and Metabolic Research, 2022, 54, 795-812.	0.7	1
1876	Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?. Cancers, 2022, 14, 3615.	1.7	0
1877	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3568.	1.7	2
1878	Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. British Journal of Radiology, 2022, 95, .	1.0	8
1879	Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	1.4	8
1880	Characteristics and outcomes of hepatocellular carcinoma patients with macrovascular invasion following surgical resection: a meta-analysis of 40 studies and 8,218 patients. Hepatobiliary Surgery and Nutrition, 2022, 11, 848-860.	0.7	4

#	Article	IF	Citations
1881	Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. International Journal of Biological Sciences, 2022, 18, 5369-5390.	2.6	14
1882	Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib. Future Oncology, 0, , .	1.1	2
1884	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Cytokine and Growth Factor Reviews, 2022, 67, 1-10.	3.2	4
1885	Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?. World Journal of Gastroenterology, 2022, 28, 3595-3607.	1.4	1
1886	Therapeutic targeting of VEGF and/or TGF-Î² to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. Frontiers in Oncology, 0, 12, .	1.3	4
1887	Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World Journal of Gastroenterology, 2022, 28, 3573-3585.	1.4	4
1888	Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy. BMJ Case Reports, 2022, 15, e250662.	0.2	3
1889	Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2022, 12, 139-150.	0.1	2
1891	Elevated Liver Enzymes in a Patient With Hepatocellular Carcinoma on Immune Checkpoint Inhibitor Therapy: A Diagnostic and Therapeutic Challenge. ACG Case Reports Journal, 2022, 9, e00834.	0.2	1
1892	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1893	CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. Frontiers in Oncology, 0, 12, .	1.3	8
1894	Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 8112.	1.8	6
1895	Critical Analysis of the Updated Barcelona Clinic Liver Cancer (BCLC) Group Guidelines. Annals of Surgical Oncology, 2022, 29, 7231-7234.	0.7	14
1896	Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
1897	A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <scp>BilT</scp>â€01. Cancer, 2022, 128, 3523-3530.	2.0	22
1899	Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 371-384.	2.0	7
1900	Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
1901	Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data. Scientific Reports, 2022, 12, .	1.6	3

#	Article	IF	Citations
1902	The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	2.2	15
1903	Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. BMJ Case Reports, 2022, 15, e250009.	0.2	1
1904	Itâ€™s time to propose a uniform criteria for determining â€œclinical complete responseâ€•in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 620-622.	0.7	1
1905	Reply to: â€œChallenges and issues in bivariate endpoints in study designs of translational medicineâ€• Journal of Hepatology, 2022, , .	1.8	0
1906	Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	14
1907	The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. Journal of Clinical Medicine, 2022, 11, 4874.	1.0	5
1908	Proton therapy in the treatment of hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1909	Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib. Journal of Gastrointestinal Cancer, 0, , .	0.6	0
1910	Heat-shock protein 90Î± is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study. Hepatology International, 2022, 16, 1208-1219.	1.9	18
1911	Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers, 2022, 14, 3938.	1.7	8
1912	CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	17
1913	New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterology Journal, 2022, 10, 765-774.	1.6	33
1914	Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World Journal of Gastrointestinal Oncology, 2022, 14, 1510-1527.	0.8	3
1915	Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Frontiers in Immunology, 0, 13, .	2.2	12
1916	Immune-based combination therapy to convert immunologically cold tumors into hotÂtumors: an update and new insights. Acta Pharmacologica Sinica, 2023, 44, 288-307.	2.8	14
1917	Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. Cancers, 2022, 14, 3892.	1.7	1
1918	TranscatheterÂarterial chemoembolizationÂplus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial. Future Oncology, 2022, 18, 3367-3375.	1.1	5
1919	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clinical Cancer Research, 2023, 29, 30-39.	3.2	53

#	Article	IF	Citations
1920	Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. Liver Cancer, 2023, 12, 44-56.	4.2	1
1921	Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. , 2022, 10, e004006.		14
1922	SIRT in 2025. CardioVascular and Interventional Radiology, 2022, 45, 1622-1633.	0.9	6
1923	Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. OncoImmunology, 2022, 11, .	2.1	1
1924	Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Cancer Medicine, 2023, 12, 2646-2657.	1.3	9
1925	Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Medicine, 2023, 12, 2731-2738.	1.3	15
1927	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	90
1928	Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 717-728.	1.8	6
1929	Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials. JAMA Network Open, 2022, 5, e2226252.	2.8	10
1930	Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomesâ€"A Preliminary Study. Nanomaterials, 2022, 12, 2833.	1.9	3
1931	Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1932	Lenvatinib for the treatment of hepatocellular carcinomaâ€"a real-world multicenter Australian cohort study. Hepatology International, 2022, 16, 1170-1178.	1.9	7
1933	Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. Clinical Gastroenterology and Hepatology, 2023, 21, 2421-2423.e2.	2.4	4
1934	Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World Journal of Gastroenterology, 2022, 28, 3981-3993.	1.4	3
1935	Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
1936	Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. Liver International, 2022, 42, 2538-2547.	1.9	15
1937	Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. Anticancer Research, 2022, 42, 4461-4470.	0.5	0
1938	Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus, 2022, , .	0.2	6

#	Article	IF	Citations
1939	Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 579-590.	1.9	6
1940	Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4716-4726.	3.3	2
1941	Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells. Non-coding RNA, 2022, 8, 61.	1.3	0
1942	What is the status of immunotherapy in thyroid neoplasms?. Frontiers in Endocrinology, 0, 13, .	1.5	12
1943	Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World Journal of Gastrointestinal Oncology, 2022, 14, 1446-1455.	0.8	3
1944	Does HCC Etiology Impact the Efficacy of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma? An Asian Liver Radiation Therapy Group Study. Journal of Hepatocellular Carcinoma, 0, Volume 9, 707-715.	1.8	0
1945	Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy. Journal of Oncology, 2022, 2022, 1-9.	0.6	4
1946	Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. Journal of Hepatocellular Carcinoma, 0, Volume 9, 823-837.	1.8	8
1947	Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. International Journal of Clinical Oncology, 2022, 27, 1725-1732.	1.0	5
1948	Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	8
1949	Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers, 2022, 14, 4028.	1.7	25
1950	Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering, 2022, 9, 406.	1.6	2
1951	Lycorine inhibits angiogenesis by docking to PDGFRÎ±. BMC Cancer, 2022, 22, .	1.1	3
1952	Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. Journal of Hepatology, 2022, 77, 1586-1597.	1.8	12
1953	Current status of liver transplantation for <scp>nonâ€Β nonâ€Ć</scp> liver cirrhosis and hepatocellular carcinoma. Annals of Gastroenterological Surgery, 0, , .	1.2	1
1954	Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Scientific Reports, 2022, 12, .	1.6	6
1955	First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer, 2023, 12, 7-18.	4.2	7
1956	Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Medicinal Chemistry, 0, , .	1.1	1

#	Article	IF	Citations
1957	Interventional radiology meets immuno-oncology for hepatocellular carcinoma. Journal of Hepatology, 2022, , .	1.8	5
1958	Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. Pharmaceutics, 2022, 14, 1768.	2.0	2
1959	Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade. Journal of Pancreatology, 2022, 5, 58-68.	0.3	1
1960	Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma. , 2023, 2, 83-95.		6
1961	Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Frontiers in Immunology, 0, 13, .	2.2	4
1962	Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers, 2022, 14, 3971.	1.7	5
1963	Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 2023, 13, 632-647.	5.7	6
1964	Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. Journal of Hepatocellular Carcinoma, 0, Volume 9, 855-867.	1.8	5
1965	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Frontiers in Immunology, 0, 13, .	2.2	6
1966	Validation of the easyâ€toâ€use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatology Research, 2022, 52, 1050-1059.	1.8	6
1967	Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. Hepatology International, 2022, 16, 1179-1187.	1.9	6
1968	Oncofetal reprogramming in tumour development and progression. Nature Reviews Cancer, 2022, 22, 593-602.	12.8	22
1969	Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 420-429.	0.6	9
1970	Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	1
1971	The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77, 1773-1796.	3.6	101
1972	Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatology International, 2022, 16, 1199-1207.	1.9	17
1973	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0
1974	Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Medicine, 2023, 12, 2572-2579.	1.3	5

#	Article	IF	Citations
1975	Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma. World Journal of Surgical Oncology, 2022, 20, .	0.8	2
1976	Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Current Oncology, 2022, 29, 5489-5507.	0.9	19
1977	Re: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial. European Journal of Cancer, 2022, , .	1.3	0
1978	Realâ€world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80Âyears old. Hepatology Research, 0, , .	1.8	2
1979	Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open, 2022, 7, 100562.	2.0	11
1980	Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer, 2022, 174, 68-77.	1.3	45
1981	Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. European Journal of Cancer, 2022, 174, 57-67.	1.3	21
1982	Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies. Digestive and Liver Disease, 2022, , .	0.4	0
1983	What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Reports, 2022, 4, 100578.	2.6	9
1984	Atezolizumab plus bevacizumab versus nivolumab as firstâ€line treatment for advanced or unresectable hepatocellular carcinoma: A costâ€effectiveness analysis. Cancer, 2022, 128, 3995-4003.	2.0	9
1985	Immunotherapy for hepatobiliary malignancies: Progress and prospective. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 409-412.	0.6	6
1986	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Frontiers in Oncology, 0, 12, .	1.3	13
1987	Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences, 2022, 23, 10038.	1.8	4
1988	Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	13
1989	Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers, 2022, 14, 4284.	1.7	9
1990	Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Frontiers in Oncology, 0, 12, .	1.3	7
1991	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1011-1027.	1.8	3
1992	The economics of advanced and unresectable hepatocellular carcinoma. Cancer, 0, , .	2.0	0

#	Article	IF	Citations
1993	Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 72-88.e18.	0.6	48
1994	Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biology, 2022, 56, 102463.	3.9	60
1995	Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open, 2022, 7, 100576.	2.0	4
1996	Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. European Journal of Cancer, 2022, 175, 204-213.	1.3	41
1997	Inducing vascular normalization: A promising strategy for immunotherapy. International Immunopharmacology, 2022, 112, 109167.	1.7	2
1998	Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief, 2022, 45, 108558.	0.5	1
1999	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
2000	Molecular and Genetic Profiling for the Diagnosis and Therapy of Hepatobiliary and Pancreatic Malignancies. , 2022, , 747-759.		0
2001	Prognostication algorithm for non-cirrhotic non-B non-C hepatocellular carcinomaâ€"a multicenter study under the aegis of the French Association of Hepato-Biliary Surgery and liver Transplantation. Hepatobiliary Surgery and Nutrition, 2023, 12, 192-204.	0.7	1
2002	Polypharmacology in Clinical Applicationsâ€"Anticancer Polypharmacology. , 2022, , 73-132.		0
2003	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211001.	1.4	5
2004	Immune checkpoint inhibitor therapy for hepatocellular carcinoma. Annals of Gastroenterology, 2022, , .	0.4	0
2005	Beyond management to conquer life-threatening tumor thrombosis in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, .	0.7	0
2006	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal, 0, , .	0.4	0
2007	Available Immunotherapy Drugs in Oncology. Current Clinical Pathology, 2022, , 5-23.	0.0	0
2008	Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study. SSRN Electronic Journal, 0, , .	0.4	0
2009	Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776.		0
2010	Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma. Internal Medicine, 2023, 62, 1467-1472.	0.3	1

#	Article	IF	Citations
2011	Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer, 2022, 128, 3470-3478.	2.0	8
2012	PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes, 2022, 13, 1535.	1.0	0
2013	Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study. Journal of Gastrointestinal Cancer, 0, , .	0.6	2
2015	Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	1
2016	The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. Cancers, 2022, 14, 4255.	1.7	3
2017	The Effect of Race on Outcomes in Veterans With Hepatocellular Carcinoma at a Single Center. , 2022, , .		0
2018	CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2
2019	Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer, 2023, 22, 34-44.	1.0	1
2020	National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clinical Gastroenterology and Hepatology, 2023, 21, 1581-1589.	2.4	5
2021	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer, 2023, 12, 116-128.	4.2	5
2022	Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 1942-1958.	0.6	5
2023	miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Cells, 2022, 11, 2673.	1.8	9
2024	Neoadjuvant Therapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 929-946.	1.8	15
2025	Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules, 2022, 27, 5537.	1.7	9
2026	The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma, 0, Volume 9, 913-927.	1.8	3
2027	Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
2028	Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	3
2029	Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	2

#	Article	IF	Citations
2030	Tumor vessel co-option: The past & the future. Frontiers in Oncology, 0, 12, .	1.3	17
2031	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 4209.	1.7	9
2032	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers, 2022, 14, 4201.	1.7	1
2033	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell, 2022, 40, 1027-1043.e9.	7.7	34
2034	PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Frontiers in Oncology, 0, 12, .	1.3	2
2035	The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers, 2022, 14, 4383.	1.7	15
2036	Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
2037	Personalized neoantigen vaccine combined with PD-1 blockade increases CD8⁺ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. , 2022, 10, e004389.		12
2038	Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma. Cancers, 2022, 14, 4553.	1.7	1
2039	SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 11092.	1.8	17
2040	Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography. Journal of Medical Ultrasonics (2001), 2023, 50, 57-62.	0.6	2
2042	Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study. Clinical Cancer Research, 2022, 28, 4642-4648.	3.2	12
2043	Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A biâ€institutional propensityâ€matched cohort study. Journal of Hepato-Biliary-Pancreatic Sciences, 0, , .	1.4	1
2044	Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Frontiers in Oncology, 0, 12, .	1.3	0
2045	Proton Beam Therapy for Treatment-NaÃ¯ve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade. Cancers, 2022, 14, 4445.	1.7	7
2046	A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 1101-1107.	0.4	2
2047	Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Frontiers in Genetics, 0, 13, .	1.1	4
2048	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Molecular Cancer, 2022, 21, .	7.9	5

#	Article	IF	Citations
2049	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology, 2022, 13, .	0.8	6
2050	Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology, 0, 12, .	1.3	9
2051	miR-aculous new avenues for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
2052	Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surgical Oncology, 2022, 44, 101844.	0.8	7
2053	The NF-Î²B Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines, 2022, 10, 2233.	1.4	7
2054	Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. Gut, 2023, 72, 996-1006.	6.1	4
2055	Oncogenic Î²-catenin stimulation of AKT2â€“CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	9
2056	Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis. International Journal of Surgery Oncology, 2022, 7, 58.	0.2	0
2058	Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. Journal of Pharmacology and Experimental Therapeutics, 2022, 383, 208-216.	1.3	4
2059	PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. Frontiers in Immunology, 0, 13, .	2.2	24
2060	Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience. Frontiers in Oncology, 0, 12, .	1.3	12
2061	The immune landscape of hepatocellular carcinomaâ€‘where we are? (Review). Oncology Letters, 2022, 24, .	0.8	6
2062	Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International, 2023, 43, 8-17.	1.9	6
2063	Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma. Cancers, 2022, 14, 4715.	1.7	15
2064	Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	8
2065	The Role of Immunotherapy in Pancreatic Cancer. Current Oncology, 2022, 29, 6864-6892.	0.9	18
2066	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
2069	Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International, 2022, 42, 2607-2619.	1.9	8

#	Article	IF	Citations
2070	The hepatocellular carcinoma modified Gustave Roussy Immune score (<scp>HCCâ€GRIm score</scp>) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis. Cancer Medicine, 2023, 12, 4259-4269.	1.3	8
2071	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462.	0.9	6
2072	Surgical Resection of a Recurrent Hepatocellular Carcinoma with Portal Vein Thrombosis: Is It a Good Treatment Option? A Case Report and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 5287.	1.0	5
2073	Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, , .	0.6	1
2074	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nature Reviews Cancer, 2022, 22, 640-656.	12.8	38
2076	Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 4929-4942.	1.4	5
2077	Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Frontiers in Oncology, 0, 12, .	1.3	6
2078	Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 973-985.	1.8	1
2079	Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	2
2080	câ€Relâ€“dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis. Hepatology, 2023, 78, 1050-1063.	3.6	2
2081	HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	11
2082	Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatology Communications, 2022, 6, 3223-3233.	2.0	7
2083	Lung metastases after liver cancer resection cured by immunotherapy: case report and literature review. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	2
2084	Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology, 2023, 77, 1943-1957.	3.6	5
2085	Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety. Journal of the Formosan Medical Association, 2022, 121, 2430-2437.	0.8	3
2086	Immunotherapy and Hepatocellular Cancer: Where Are We Now?. Cancers, 2022, 14, 4523.	1.7	7
2087	Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Investigational New Drugs, 2022, 40, 1290-1297.	1.2	6
2088	Development and validation of a modified albuminâ€“bilirubin grade and Î±-fetoprotein score (mALF) Tj ETQq1 1 0.784314 rgBT /Ove International, 2023, 17, 86-96.	1.9	7

#	Article	IF	Citations
2089	Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, .	1.2	5
2090	Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2023, 115, 202-213.	0.4	25
2091	Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers, 2022, 14, 4387.	1.7	5
2092	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	2
2093	Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study. Journal of Hepatocellular Carcinoma, 0, Volume 9, 999-1010.	1.8	10
2094	Obesity and cancerâ€"extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases. Cancer and Metastasis Reviews, 2022, 41, 517-547.	2.7	9
2095	The beneficial impact of metabolic dysfunctionâ€associated fatty liver disease on lenvatinib treatment in patients with nonâ€viral hepatocellular carcinoma. Hepatology Research, 2023, 53, 104-115.	1.8	12
2096	Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. Cancers, 2022, 14, 4601.	1.7	13
2097	Perspective: Advances in liver transplantation for hepatocellular carcinoma â€“ A prototype for transplant oncology. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 4-6.	0.6	5
2098	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	5
2099	Comprehensive multiomics analysis of cuproptosis-related gene characteristics in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	10
2100	Selective internal radiation therapy for hepatocellular carcinoma: A 15â€year multicenter Australian cohort study. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 2173-2181.	1.4	1
2101	Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. JGH Open, 2022, 6, 754-762.	0.7	1
2103	LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers, 2022, 14, 4584.	1.7	1
2104	Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma. JAMA Oncology, 0, , .	3.4	0
2105	Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. Frontiers in Immunology, 0, 13, .	2.2	2
2106	Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization. World Journal of Gastroenterology, 0, 28, 5324-5337.	1.4	8
2107	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology, 2022, 11, .	2.1	28

#	Article	IF	Citations
2108	NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clinical Cancer Research, 2023, 29, 513-520.	3.2	30
2109	Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report. Medicine (United States), 2022, 101, e30486.	0.4	2
2110	Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment. Journal of Hepatocellular Carcinoma, 0, Volume 9, 947-957.	1.8	12
2111	The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study. Frontiers in Oncology, 0, 12, .	1.3	2
2112	Emerging Trends in Immunotherapy for Cancer. Diseases (Basel, Switzerland), 2022, 10, 60.	1.0	17
2113	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology, 0, 13, .	2.2	6
2114	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 4616.	1.7	18
2115	Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 11363.	1.8	6
2116	Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. Nature Communications, 2022, 13, .	5.8	2
2117	Current landscape of personalized clinical treatments for triple-negative breast cancer. Frontiers in Pharmacology, 0, 13, .	1.6	11
2118	Evolution of precision oncologyâ€guided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	1.5	5
2119	The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy. Cancer Imaging, 2022, 22, .	1.2	1
2120	Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma. Annals of Surgical Oncology, 2023, 30, 2782-2790.	0.7	22
2121	Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. Frontiers in Oncology, 0, 12, .	1.3	6
2122	Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Nonâ€“Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist, 2022, 27, e938-e948.	1.9	8
2123	Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. OncoImmunology, 2022, 11, .	2.1	1
2124	Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	9
2125	Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects. Liver Cancer, 2022, 11, 487-496.	4.2	5

#	Article	IF	Citations
2127	Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Global Oncology, 2022, , .	0.8	4
2128	Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of postâ€progression systemic therapy. Liver Cancer International, 0, , .	0.2	0
2129	Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	4
2130	Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors. Anticancer Research, 2022, 42, 4795-4804.	0.5	4
2131	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomaterials Science and Engineering, 2022, 8, 4819-4826.	2.6	2
2132	DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC. Scientific Reports, 2022, 12, .	1.6	2
2133	Enhancement of dendritic cellÂimmunotherapy by recalling antigens for hepatocellular carcinoma in mice. Immunotherapy, 2022, 14, 1225-1236.	1.0	1
2134	Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer. Frontiers in Genetics, 0, 13, .	1.1	1
2136	Overview of Ongoing Clinical Trials on Radioembolization. CardioVascular and Interventional Radiology, 2022, 45, 1659-1662.	0.9	3
2137	Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine, 2022, 54, 101679.	3.2	3
2138	DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model. Cancer Letters, 2022, 550, 215930.	3.2	3
2139	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. Cancer Epidemiology, 2022, 81, 102265.	0.8	2
2140	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open, 2022, 7, 100591.	2.0	47
2141	Hypoxia features as potential indicators in prognosis, immunotherapy and drug screening in Hepatocellular carcinoma patients. Translational Cancer Research, 2021, .	0.4	1
2142	Long-term Survival of a Patient of Hepatocellular Carcinoma after Resection of Bilateral Multiple Pulmonary Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2021, 46, 599-604.	0.0	0
2143	Research Progress of Systematic Therapy for Advanced Primary Liver Cancer. Advances in Clinical Medicine, 2022, 12, 9622-9627.	0.0	0
2144	Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 876-878.	0.7	1
2145	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. Cancer Control, 2022, 29, 107327482211305.	0.7	4

#	Article	IF	Citations
2146	Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances, 2022, 12, 31068-31082.	1.7	8
2147	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. , 2022, , 125-200.		0
2148	Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211336.	0.8	4
2149	First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Current Oncology, 2022, 29, 7305-7326.	0.9	2
2150	Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Frontiers in Oncology, 0, 12, .	1.3	2
2151	Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Advances, 2023, 7, 1488-1495.	2.5	7
2152	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World Journal of Hepatology, 0, 14, 1862-1874.	0.8	5
2153	Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses, 2022, 14, 2355.	1.5	3
2154	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125.	1.8	11
2155	Analysis of Lenvatinibâ€™s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 5066.	1.7	3
2156	Immunotherapy and Hepatocellular Carcinoma. , 0, , .		0
2157	Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2023, 384, 331-342.	1.3	3
2158	Optimizing Treatment Strategies with Preoperative Assessment for Microvascular Invasion in Hepatocellular Carcinoma. Annals of Surgical Oncology, 0, , .	0.7	0
2159	Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk. BMC Medical Imaging, 2022, 22, .	1.4	0
2160	One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Medicine, 2022, 20, .	2.3	4
2161	Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nature Communications, 2022, 13, .	5.8	5
2162	Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Frontiers in Oncology, 0, 12, .	1.3	3
2163	Single-cell transcriptomics reveals the role of Macrophage-NaÃ¯ve CD4â€‰+â€‰T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. Journal of Translational Medicine, 2022, 20, .	1.8	9

#	Article	IF	Citations
2164	Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy, 2022, 14, 1341-1351.	1.0	9
2165	Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study. Frontiers in Immunology, 0, 13, .	2.2	7
2166	Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Reports, 2023, 5, 100620.	2.6	13
2167	Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of Personalized Medicine, 2022, 12, 1788.	1.1	9
2168	Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment. Journal of Personalized Medicine, 2022, 12, 1726.	1.1	0
2169	Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. Cancers, 2022, 14, 5154.	1.7	1
2171	Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	0
2172	A history of variceal bleeding is associated with furtherÂbleeding under atezolizumabâ€“bevacizumab in patients with <scp>HCC</scp>. Liver International, 2022, 42, 2843-2854.	1.9	8
2173	Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. Cancers, 2022, 14, 4896.	1.7	4
2174	Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and nonâ€viral infection: A Japanese multicenter observational study. Cancer Medicine, 2023, 12, 5293-5303.	1.3	9
2175	Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression. Liver Cancer, 2023, 12, 180-183.	4.2	3
2176	Cross-Reactive T Cell Response Exists in Chronic Lymphocytic Choriomeningitis Virus Infection upon Pichinde Virus Challenge. Viruses, 2022, 14, 2293.	1.5	1
2177	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
2178	A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Management and Research, 0, Volume 14, 3037-3046.	0.9	2
2179	The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea. Clinical and Molecular Hepatology, 2023, 29, 99-101.	4.5	4
2181	Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1065-1079.	1.8	5
2182	Immunotherapy for GI Malignancies, Ready for Prime Time?. Annals of Surgical Oncology, 2023, 30, 1787-1793.	0.7	1
2183	Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. Frontiers in Molecular Biosciences, 0, 9, .	1.6	6

#	Article	IF	Citations
2184	Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. Journal of Cellular Biochemistry, 2022, 123, 1663-1673.	1.2	2
2185	Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Cancers, 2022, 14, 5013.	1.7	12
2186	CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
2187	Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma. JAMA Oncology, 2022, 8, 1825.	3.4	27
2188	Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 37-49.	8.2	94
2190	Genomeâ€Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. Advanced Science, 2022, 9, .	5.6	7
2191	A case of <scp>HCC</scp> successfully treated with infliximabâ€steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. Cancer Reports, 2022, 5, .	0.6	4
2192	Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. Scientific Reports, 2022, 12, .	1.6	5
2193	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Frontiers in Oncology, 0, 12, .	1.3	1
2194	Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	3
2195	An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma. BMC Medical Genomics, 2022, 15, .	0.7	5
2197	Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer, 2022, 22, .	1.1	3
2198	Potential of VEGFR2 expression as a predictive marker of PDâ€‘1 blockade in patients with advanced NSCLC. Oncology Reports, 2022, 48, .	1.2	4
2199	Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers, 2022, 14, 5173.	1.7	6
2200	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochemical Journal, 2022, 479, 2219-2260.	1.7	6
2202	Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment. Medicine (United States), 2022, 101, e31200.	0.4	1
2203	Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using realâ€world data. Hepatology Research, 2023, 53, 116-126.	1.8	6
2204	Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 7-13.	0.6	8

#	Article	IF	Citations
2205	Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Targeted Oncology, 2022, 17, 643-653.	1.7	16
2206	Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. Journal of Hepatology, 2023, 78, 343-355.	1.8	10
2207	Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatology Research, 2023, 53, 172-178.	1.8	5
2208	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	1.8	6
2209	STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment. Cancer Cell International, 2022, 22, .	1.8	5
2210	Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. International Journal of Cancer, 2023, 152, 480-495.	2.3	11
2211	Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. Journal of Drug Delivery Science and Technology, 2022, 77, 103905.	1.4	5
2212	Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clinical and Experimental Metastasis, 2023, 40, 5-32.	1.7	5
2213	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
2214	Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology, 2022, 12, 1575-1576.	0.4	6
2215	Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. Internal Medicine, 2022, 61, 3157-3164.	0.3	1
2216	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1149-1169.	1.8	3
2217	An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2023, 32, 101-117.	0.6	4
2218	<scp>ALBI</scp> grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	0
2219	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
2220	Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression. Cancer Letters, 2022, 551, 215960.	3.2	9
2221	Contrast-enhanced ultrasonography for the diagnosis of spontaneous necrosis of hepatocellular carcinoma: A report of 2 cases. Radiology Case Reports, 2023, 18, 173-181.	0.2	2
2222	A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research, 2023, 281, 289-298.	0.8	3

#	Article	IF	Citations
2223	Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma: A Case Report. Internal Medicine, 2023, , .	0.3	1
2225	Diagnosis and Management of Hepatocellular Carcinoma. In Clinical Practice, 2022, , 327-354.	0.1	0
2226	Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?. Hepatobiliary Surgery and Nutrition, 2022, 11, 927-930.	0.7	4
2227	Advanced nonmetastatic hepatocellular carcinoma: curative surgery may be an option. Hepatobiliary Surgery and Nutrition, 2022, .	0.7	0
2228	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211348.	0.6	2
2229	Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. Anticancer Research, 2022, 42, 5479-5486.	0.5	2
2230	Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research, 2022, 42, 5465-5473.	0.5	2
2231	Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment. Anticancer Research, 2022, 42, 5205-5215.	0.5	1
2232	Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Frontiers in Oncology, 0, 12, .	1.3	1
2233	Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers. Hpb, 2022, , .	0.1	1
2234	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences, 2022, 23, 13961.	1.8	10
2235	A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment. International Cancer Conference Journal, 0, , .	0.2	1
2236	Wnt/Î²-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers, 2022, 14, 5468.	1.7	8
2237	Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus. Transplantation, 0, Publish Ahead of Print, .	0.5	0
2238	Editorial: Identification of novel biomarkers for pancreatic and hepatocellular cancers. Frontiers in Oncology, 0, 12, .	1.3	0
2239	Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 203-222.	8.2	113
2240	Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World Journal of Transplantation, 0, 12, 331-346.	0.6	2
2242	Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets, 2022, 26, 767-780.	1.5	1

#	Article	IF	Citations
2243	Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. Frontiers in Surgery, 0, 9, .	0.6	1
2244	Transthyretin Cardiac Amyloidosis Mimicking Immune Checkpoint-Induced Myocarditis in a Patient Treated with Atezolizumab and Bevacizumab for Advanced Hepatocellular Carcinoma: A Case Report. Case Reports in Oncology, 0, , 967-973.	0.3	0
2245	A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-23.	0.9	2
2246	Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Frontiers in Immunology, 0, 13, .	2.2	9
2247	Have We Found the â€œHoly Grailâ€•That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?. Gastroenterology, 2023, 164, 15-18.	0.6	0
2248	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Aheadâ€”A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117.	1.8	7
2249	Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, .	1.2	1
2250	Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals. Journal of Oncology, 2022, 2022, 1-17.	0.6	1
2251	Cell membrane-coated human hair nanoparticles for precise disease therapies. Journal of Nanobiotechnology, 2022, 20, .	4.2	4
2252	Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-32.	0.9	2
2253	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
2254	The regulation and functions of <scp>ACSL3</scp> and <scp>ACSL4</scp> in the liver and hepatocellular carcinoma. Liver Cancer International, 2023, 4, 28-41.	0.2	1
2255	Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	5
2256	Differential regulation of TNFÎ± and IL-6 expression contributes to immune evasion in prostate cancer. Journal of Translational Medicine, 2022, 20, .	1.8	5
2257	Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International, 2023, 4, 13-27.	0.2	0
2258	Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (United States), 2022, 101, e31479.	0.4	2
2259	Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Science Translational Medicine, 2022, 14, .	5.8	57
2260	Emerging evidence of immunotherapy for colorectal cancer. Annals of Gastroenterological Surgery, 2023, 7, 216-224.	1.2	4

#	Article	IF	Citations
2261	Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma. BMC Bioinformatics, 2022, 23, .	1.2	1
2262	Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 13834.	1.8	9
2263	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. Biomedicines, 2022, 10, 2827.	1.4	4
2264	Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature, 2022, 612, 141-147.	13.7	177
2265	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, .	0.8	1
2266	Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. PLoS ONE, 2022, 17, e0277407.	1.1	2
2267	Challenges in neoantigen-directed therapeutics. Cancer Cell, 2023, 41, 15-40.	7.7	27
2268	Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World Journal of Gastroenterology, 0, 28, 6034-6044.	1.4	6
2269	Rapid progression of hepatocellular carcinoma in a pregnant woman: A case report. Clinical Case Reports (discontinued), 2022, 10, .	0.2	0
2271	Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Advances in Therapy, 0, , .	1.3	1
2272	Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C). BMC Gastroenterology, 2022, 22, .	0.8	3
2273	Atezolizumab plus tivozanib for immunologically cold tumor types: theÂIMMCO-1 trial. Future Oncology, 0, , .	1.1	0
2274	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology, 2022, 18, 3769-3782.	1.1	11
2275	Exosomal delivery of TRAIL and miRâ€‘335 for theÂtreatment of hepatocellular carcinoma (Review). International Journal of Molecular Medicine, 2022, 51, .	1.8	3
2276	Approach to systemic therapy in advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 931-934.	0.7	1
2277	Evolution of systemic therapy for advanced-stage hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 899-902.	0.7	1
2278	Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma. Materials and Design, 2023, 225, 111457.	3.3	2
2279	Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. Journal of Gastrointestinal Oncology, 2022, .	0.6	1

#	Article	IF	Citations
2280	Congenital cardiac liver cirrhosis with combined hepatocellular- cholangiocarcinomaâ€"a case report. Journal of Gastrointestinal Oncology, 2022, .	0.6	1
2281	The efficacy of sorafenib after progression on atezolizumab and bevacizumab combination therapy in a patient with advanced hepatocellular carcinoma. Journal of Cancer Research and Practice, 2022, 9, 149.	0.2	0
2282	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
2283	A powerful antitumor â€œtridentâ€: the combination of radio-, immuno- and anti-angiogenesis therapy based on mesoporous silica single coated gold nanoparticles. Journal of Materials Chemistry B, 2023, 11, 879-889.	2.9	2
2284	Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine, 2023, 87, 104397.	2.7	3
2285	Detecting liver cirrhosis in computed tomography scans using clinically-inspired and radiomic features. Computers in Biology and Medicine, 2023, 152, 106378.	3.9	6
2286	Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188841.	3.3	0
2287	Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188848.	3.3	3
2288	Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Letters, 2023, 555, 216038.	3.2	23
2289	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European Journal of Cancer, 2023, 180, 9-20.	1.3	38
2290	Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation. Translational Oncology, 2023, 28, 101603.	1.7	0
2291	Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. JHEP Reports, 2023, 5, 100633.	2.6	8
2292	An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET+ hepatocellular carcinoma. Biochemistry and Biophysics Reports, 2023, 33, 101412.	0.7	3
2293	Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial. Journal of Investigative Medicine High Impact Case Reports, 2022, 10, 232470962211294.	0.3	1
2294	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Technology in Cancer Research and Treatment, 2022, 21, 153303382211173.	0.8	2
2295	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
2296	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
2297	Interdisciplinary Approach in Hepatobiliary Cancers. , 2022, , 1-40.		0

#	Article	IF	Citations
2298	First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211406.	1.4	5
2299	Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1217-1228.	1.8	7
2300	Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology, 0, 12, .	1.3	3
2301	Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma. Strahlentherapie Und Onkologie, 0, , .	1.0	0
2302	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
2303	Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study. JCO Global Oncology, 2022, , .	0.8	3
2304	Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety, 2023, 22, 323-329.	1.0	0
2305	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. , 2022, 10, e005457.		19
2306	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers, 2022, 14, 5834.	1.7	24
2307	Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?. Liver International, 2022, 42, 2597-2598.	1.9	0
2308	Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma. , 2022, 45, .		0
2309	Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of Hepatology, 2023, 78, 376-389.	1.8	13
2310	Treatment of portal hypertension in patients with HCC in the era of Baveno VII. Journal of Hepatology, 2023, 78, 658-662.	1.8	9
2311	Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	0
2312	Therapeutic Antibodies in Cancer Treatment in the UK. International Journal of Molecular Sciences, 2022, 23, 14589.	1.8	1
2313	Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients. Medicine (United States), 2022, 101, e31665.	0.4	1
2314	Outcomes of malignancy in adults with congenital heart disease: a single center experience. Cardio-Oncology, 2022, 8, .	0.8	1
2315	New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. Cancers, 2022, 14, 5868.	1.7	5

#	Article	IF	Citations
2316	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167.	1.9	3
2317	Bridging and downstaging with <scp>TACE</scp> in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant. Annals of Gastroenterological Surgery, 0, , .	1.2	1
2318	Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese realâ€world practice. Cancer, 2023, 129, 590-599.	2.0	8
2319	Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis. Oncotarget, 2022, 13, 1286-1298.	0.8	5
2320	Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Review of Molecular Diagnostics, 2022, 22, 1009-1035.	1.5	1
2321	Hepatocellular cancer of non-viral etiology: more questions than answers?. Medical Alphabet, 2022, , 7-12.	0.0	0
2322	Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. Cancer Immunology, Immunotherapy, 2023, 72, 1395-1403.	2.0	1
2323	Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1187-1200.	1.8	2
2324	Ferritin Nanocaged Doxorubicin Potentiates Chemoâ€Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. Small Methods, 2023, 7, .	4.6	10
2325	Highlighting novel targets in immunotherapy for liver cancer. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1029-1041.	1.4	3
2326	ACR Appropriateness CriteriaÂ® Management of Liver Cancer: 2022 Update. Journal of the American College of Radiology, 2022, 19, S390-S408.	0.9	1
2327	Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?. Expert Review of Anticancer Therapy, 0, , 1-9.	1.1	1
2328	Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Gut and Liver, 2023, 17, 24-33.	1.4	4
2329	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2023, 41, 1434-1443.	0.8	50
2330	A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. Journal of Inflammation Research, 0, Volume 15, 6729-6743.	1.6	6
2331	Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the firstâ€line treatment for unresectable hepatocellular carcinoma. Cancer Medicine, 2023, 12, 7077-7089.	1.3	10
2332	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 1-120.	0.3	24
2333	Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	0

#	Article	IF	Citations
2334	The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology, 2022, 18, 4119-4136.	1.1	4
2335	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis, 2023, 26, 279-293.	3.7	12
2336	Baseline <scp>ALBI</scp> score and early variation of serum <scp>AFP</scp> predicts outcomes in patients with <scp>HCC</scp> treated by atezolizumabâ€“bevacizumab. Liver International, 2023, 43, 708-717.	1.9	18
2337	Associating Immunotherapy and Targeted Therapies: Facts and Hopes. Clinical Cancer Research, 2023, 29, 1183-1193.	3.2	3
2338	Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers, 2022, 14, 6139.	1.7	0
2339	Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers, 2022, 14, 5966.	1.7	11
2340	Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2023, 29, 754-763.	3.2	10
2341	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
2342	Immune Checkpoint Inhibitor Therapy inÂOncology. JACC: CardioOncology, 2022, 4, 579-597.	1.7	25
2343	Whole-exome sequencing identifies a set of genes as markers of hepatocellular carcinomaÂearly recurrence. Hepatology International, 2023, 17, 393-405.	1.9	3
2344	Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	4
2345	Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	21.5	69
2346	Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2347	Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget, 2022, 13, 1314-1321.	0.8	4
2348	Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. Cancers, 2022, 14, 6245.	1.7	0
2349	Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Current Pharmaceutical Design, 2023, 29, 2-14.	0.9	2
2350	Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery. Anticancer Research, 2022, 42, 6127-6134.	0.5	1
2351	New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Medicine, 2023, 12, 6980-6993.	1.3	8

#	Article	IF	Citations
2352	Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study. Anticancer Research, 2022, 42, 6007-6018.	0.5	1
2353	Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumabâ€“bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clinical Journal of Gastroenterology, 2023, 16, 224-228.	0.4	5
2354	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer With High Tumor Mutation Burden. JAMA Oncology, 2023, 9, 344.	3.4	13
2355	Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomaterialia, 2023, 157, 337-351.	4.1	3
2356	Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2022, 14, 6089.	1.7	6
2357	In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer. Scientific Reports, 2022, 12, .	1.6	2
2358	An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends, 2022, 16, 405-425.	1.1	7
2359	The Role of Radiomics and AI Technologies in the Segmentation, Detection, and Management of Hepatocellular Carcinoma. Cancers, 2022, 14, 6123.	1.7	5
2360	Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 0, , 107815522211454.	0.5	0
2362	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clinical and Molecular Hepatology, 2023, 29, 206-216.	4.5	19
2363	The prospect of tumor microenvironment-modulating therapeutical strategies. Frontiers in Oncology, 0, 12, .	1.3	7
2364	Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. Journal of Clinical Oncology, 2023, 41, 1898-1908.	0.8	22
2365	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2366	Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/Î²â€cateninâ€activated hepatocellular carcinoma. Hepatology Research, 2023, 53, 344-356.	1.8	1
2367	Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology, 2023, 32, 240-249.	1.4	5
2368	Pathogenesis to management of hepatocellular carcinoma. Genes and Cancer, 2022, 13, 72-87.	0.6	2
2369	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1247-1261.	1.8	7
2370	Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1263-1278.	1.8	2

#	Article	IF	Citations
2371	The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers, 2022, 14, 6151.	1.7	3
2372	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers, 2023, 15, 23.	1.7	21
2373	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
2374	Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2023, 8, 169-178.	3.7	24
2375	Mitochondrial Role in Intrinsic Apoptosis Induced by a New Synthesized Chalcone in Hepatocellular Carcinoma Cells. Biomedicines, 2022, 10, 3120.	1.4	4
2376	Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open, 2022, 12, e064688.	0.8	3
2377	Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine, 2023, 12, 7772-7783.	1.3	8
2378	p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma. Molecular Pharmaceutics, 2023, 20, 331-340.	2.3	3
2379	CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. GastroenterologÃa Y HepatologÃa (English Edition), 2022, 45, 742-752.	0.0	0
2380	Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCCâ€"A Proof-of-Concept Study. Cancers, 2022, 14, 6036.	1.7	1
2381	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	36
2382	Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology, 0, , .	0.8	21
2383	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers, 2023, 15, 50.	1.7	5
2384	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 2022, 10, 3202.	1.4	26
2385	Immunotherapy in hepatocellular carcinoma: how does underlying liver disease influence therapeutic strategy and outcomes ?. Liver International, 0, , .	1.9	6
2386	Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. Current Oncology, 2022, 29, 9813-9825.	0.9	7
2387	Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	3
2388	Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1353-1368.	1.8	11

#	Article	IF	Citations
2389	Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	2
2390	Yttrium-90 Radioembolization: Current Indications and Outcomes. Journal of Gastrointestinal Surgery, 2023, 27, 604-614.	0.9	4
2392	Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma. Cells, 2023, 12, 202.	1.8	0
2393	Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity. Liver Cancer, 2023, 12, 1-6.	4.2	6
2395	Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nature Metabolism, 2023, 5, 61-79.	5.1	77
2397	Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211424.	1.4	4
2398	Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211406.	0.8	4
2399	Atezolizumab plus bevacizumab in patients with childâ€“Pugh B advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211485.	1.4	6
2400	Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery, 0, 15, 19-31.	0.8	4
2401	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology, Immunotherapy, 2023, 72, 1365-1379.	2.0	93
2402	Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5975-5987.	1.2	2
2403	TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication. Cancer Gene Therapy, 2023, 30, 738-751.	2.2	2
2404	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
2405	Liver Transplantation after Successful Downstaging of a Locally Advanced Hepatocellular Carcinoma with Systemic Therapy. Digestive Diseases, 2023, 41, 641-644.	0.8	5
2406	Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. Medical Review, 2023, .	0.3	0
2407	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology, 0, 13, .	1.6	13
2408	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers, 2023, 15, 348.	1.7	3
2409	Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors. Current Oncology, 2023, 30, 786-802.	0.9	0

#	Article	IF	Citations
2410	Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver International, 2023, 43, 695-707.	1.9	11
2411	Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram. Journal of Hepatocellular Carcinoma, 0, Volume 10, 69-79.	1.8	19
2412	Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. Digestive and Liver Disease, 2023, 55, 833-847.	0.4	6
2413	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Frontiers in Oncology, 0, 12, .	1.3	1
2414	A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. Cell Discovery, 2023, 9, .	3.1	8
2415	Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	1
2417	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Frontiers in Immunology, 0, 13, .	2.2	9
2418	Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut, 2023, 72, 1196-1210.	6.1	16
2419	Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death and Disease, 2023, 14, .	2.7	6
2421	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase 2 study. Hepatology Research, 0, , .	1.8	2
2422	Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology and Oncology, 2023, 12, .	2.0	17
2423	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	3
2424	High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Reports, 2023, 5, 100672.	2.6	17
2425	Atezolizumab induced new-onset type 1 diabetes mellitus. Journal of Oncology Pharmacy Practice, 0, , 107815522311516.	0.5	1
2426	Clinical Significance of Signal Regulatory Protein Alpha (SIRPÎ±) Expression in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2023, 30, 3378-3389.	0.7	1
2427	Growing need of adjuvant therapy and expanded access for liver transplant in hepatocellular carcinoma. Annals of Translational Medicine, 2023, .	0.7	0
2428	A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumabâ€“bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen. Clinical Journal of Gastroenterology, 0, , .	0.4	1
2430	Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current Oncology, 2023, 30, 749-757.	0.9	4

#	Article	IF	Citations
2431	Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology, 2023, 77, 1139-1149.	3.6	7
2432	Bevacizumab biosimilar candidate TAB008 compared to AvastinÂ® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5907-5914.	1.2	1
2433	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology Research, 2023, 53, 450-459.	1.8	2
2434	In Silico Reâ€Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposureâ€“Response Simulation. Journal of Clinical Pharmacology, 2023, 63, 672-680.	1.0	3
2435	Cancer statistics, 2023. Ca-A Cancer Journal for Clinicians, 2023, 73, 17-48.	157.7	4,445
2436	Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biology and Medicine, 2023, 20, 25-43.	1.4	15
2437	Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. Hepatology, 2024, 79, 213-223.	3.6	3
2438	Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial. In Vivo, 2023, 37, 454-460.	0.6	10
2439	Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-20.	0.8	0
2441	MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut, 2023, 72, 1942-1958.	6.1	16
2442	Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Frontiers in Immunology, 0, 13, .	2.2	1
2443	Revealing Prognostic and Immunotherapy-Sensitive Characteristics of a Novel Cuproptosis-Related LncRNA Model in Hepatocellular Carcinoma Patients by Genomic Analysis. Cancers, 2023, 15, 544.	1.7	0
2444	Clinical Analysis of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation Combined with Targeted Therapy and Immunotherapy in the Treatment of Large Hepatocellular Carcinoma. Journal of Biosciences and Medicines, 2023, 11, 18-25.	0.1	0
2446	Microbiota and Liver Cancer. , 2023, , 67-90.		1
2447	A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 1681.	1.8	1
2448	Target Trial Emulation: A Design Tool for Cancer Clinical Trials. JCO Clinical Cancer Informatics, 2023, , .	1.0	1
2449	Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey. Clinics and Research in Hepatology and Gastroenterology, 2023, 47, 102059.	0.7	2
2450	PI3K Î´ inhibitor PI-3065 induces apoptosis in hepatocellular carcinoma cells by targeting survivin. Chemico-Biological Interactions, 2023, 371, 110343.	1.7	0

#	Article	IF	Citations
2451	Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma. Gene, 2023, 855, 147133.	1.0	2
2452	Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management. Journal of the American College of Surgeons, 2023, 236, 399-410.	0.2	3
2453	Development of PD-1 / PD-L1 in the treatment of liver cancer. , 2022, 1, 57-59.		0
2454	A case of response to combination treatment with autologous immunotherapy and bevacizumab in advanced non-small cell lung cancer. Respiratory Medicine Case Reports, 2023, 42, 101804.	0.2	1
2455	Clinical Significance of Glycolytic Metabolic Activity in Hepatocellular Carcinoma. Cancers, 2023, 15, 186.	1.7	1
2456	Prinzipien der nicht-chirurgischen lokoregionÃren Therapie. Springer Reference Medizin, 2023, , 1-10.	0.0	0
2457	Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Review of Gastroenterology and Hepatology, 2023, 17, 31-43.	1.4	4
2458	Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers. Translational Research, 2023, 256, 14-29.	2.2	1
2459	Microbiome and Metabolomics in Liver Cancer: Scientific Technology. International Journal of Molecular Sciences, 2023, 24, 537.	1.8	13
2460	Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. European Journal of Internal Medicine, 2023, 111, 37-46.	1.0	3
2461	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clinics and Practice, 2023, 13, 22-40.	0.6	14
2462	Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease. Journal of Oncology, 2022, 2022, 1-14.	0.6	4
2463	Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers, 2023, 15, 257.	1.7	11
2464	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. Npj Breast Cancer, 2022, 8, .	2.3	8
2465	Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. Cancers, 2023, 15, 236.	1.7	0
2466	Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!. Cancers, 2023, 15, 232.	1.7	1
2467	Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses, 2023, 15, 126.	1.5	3
2468	Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. Cancers, 2023, 15, 260.	1.7	1

#	Article	IF	Citations
2469	Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clinical and Molecular Hepatology, 2023, 29, 217-229.	4.5	8
2470	Very late local recurrences of hepatocellular carcinoma with macrovascular invasion treated with stereotactic body radiotherapy: Report of two cases. Liver Cancer International, 0, , .	0.2	0
2471	Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment. Liver Cancer International, 0, , .	0.2	0
2472	Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Frontiers in Oncology, 0, 12, .	1.3	4
2474	Fibrosis and Immunotherapy in Hepatocellular Carcinoma. , 2023, , 255-281.		1
2475	Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in Immunology, 0, 14, .	2.2	1
2476	Mechanisms of drug resistance in HCC. Hepatology, 2024, 79, 926-940.	3.6	23
2477	Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 654.	1.7	7
2478	Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. International Journal of Molecular Sciences, 2023, 24, 2358.	1.8	5
2479	Top advances of the year: Hepatobiliary cancers. Cancer, 2023, 129, 1149-1155.	2.0	1
2480	Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy. Anticancer Research, 2023, 43, 875-882.	0.5	1
2481	The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	4
2482	A DNA/DMXAA/Metalâ€“Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity. Advanced Materials, 0, , 2210440.	11.1	16
2483	Tumor immunology. , 2023, , 245-452.		0
2484	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. Clinical and Molecular Hepatology, 2023, 29, 230-241.	4.5	8
2485	Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. Diagnostic and Interventional Imaging, 2023, 104, 192-199.	1.8	3
2486	Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 854.	1.7	2
2487	Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib. Anticancer Research, 2023, 43, 911-918.	0.5	0

#	Article	IF	Citations
2488	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
2489	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology, Immunotherapy, 2023, 72, 1381-1394.	2.0	3
2490	Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon. Hepatology, 2023, 77, 1074-1077.	3.6	0
2491	eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2055.	1.8	1
2492	LenvatinibVersusSorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis. Anticancer Research, 2023, 43, 755-763.	0.5	2
2493	Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 593.	1.7	4
2494	Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer. Anticancer Research, 2023, 43, 613-620.	0.5	1
2495	Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Scientific Reports, 2023, 13, .	1.6	2
2496	Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Current Oncology, 2023, 30, 1708-1719.	0.9	2
2497	Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Frontiers in Oncology, 0, 12, .	1.3	1
2498	Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	5
2499	Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). Oncology Reports, 2023, 49, .	1.2	5
2500	Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 719.	1.7	2
2501	Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Antiâ€“PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. Cancer Discovery, 2023, 13, 858-879.	7.7	4
2502	Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLoS ONE, 2023, 18, e0280442.	1.1	3
2503	PD-L1: expression regulation. Blood Science, 2023, 5, 77-91.	0.4	5
2504	Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of Hepatology, 2023, 78, 770-782.	1.8	96
2505	Complete Metabolic Response by 18F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2023, 48, 417-419.	0.7	1

#	Article	IF	Citations
2506	FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?. International Journal of Molecular Sciences, 2023, 24, 2685.	1.8	6
2507	Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 600.	1.7	3
2508	Immunotherapies in rare cancers. Molecular Cancer, 2023, 22, .	7.9	15
2509	Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma. BMC Cancer, 2023, 23, .	1.1	3
2510	Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2023, 41, 2571-2582.	0.8	17
2511	Practice-Changing Evidence in Surgical Oncology 2021: Hepatobiliary Articles. Annals of Surgical Oncology, 2023, 30, 1960-1965.	0.7	2
2512	A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncology, 2022, 18, 4465-4471.	1.1	1
2513	Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma. Magnetic Resonance in Medical Sciences, 2023, 22, 209-220.	1.1	2
2514	Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Clinical Journal of Gastroenterology, 2023, 16, 407-415.	0.4	2
2515	ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3155.	1.8	3
2516	Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells, 2023, 12, 612.	1.8	3
2517	TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2023, 23, 279-291.	1.1	29
2518	Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2345-2354.	1.2	2
2519	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis after interval hepatectomy for ruptured hepatocellular carcinoma. Acta Hepatologica Japonica, 2023, 64, 132-140.	0.0	0
2520	Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
2521	Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 4885.	1.8	5
2522	Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumorâ€Initiating Stemâ€Like Cells. Advanced Science, 2023, 10, .	5.6	4
2523	Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. World Journal of Surgical Oncology, 2023, 21, .	0.8	2

#	Article	IF	Citations
2524	Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Academic Radiology, 2023, 30, S53-S60.	1.3	2
2525	A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab. Journal of Liver Cancer, 2023, 23, 213-218.	0.3	1
2526	Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2023, 15, 2070.	1.7	2
2527	Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment. Cancer Biomarkers, 2023, 36, 231-250.	0.8	0
2528	Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer. Pharmaceutics, 2023, 15, 1207.	2.0	2
2529	Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. World Journal of Gastrointestinal Oncology, 0, 15, 617-631.	0.8	3
2530	Postprogression treatment of lenvatinib plus PDâ€1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Cancer, 2023, 129, 2235-2244.	2.0	3
2531	Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy. Cancer Communications, 0, , .	3.7	0
2532	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2023, 29, 2291-2298.	3.2	3
2533	What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?. Clinical and Molecular Hepatology, 2023, 29, 332-334.	4.5	0
2534	Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. Pharmaceutics, 2023, 15, 1143.	2.0	13
2535	Favorable Prognostic Factors for Survival Outcomes of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis After Hepatectomy. Annals of Surgical Oncology, 2023, 30, 4279-4289.	0.7	2
2536	The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2023, 12, 256-260.	0.7	1
2537	Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188866.	3.3	10
2538	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer, 2023, 184, 62-72.	1.3	9
2539	Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. JHEP Reports, 2023, 5, 100702.	2.6	14
2540	Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America, 2023, 107, 623-640.	1.1	0
2541	CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinoma. Experimental Cell Research, 2023, 426, 113513.	1.2	1

#	Article	IF	Citations
2542	Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma. Computers in Biology and Medicine, 2023, 158, 106872.	3.9	2
2543	Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on FAERS databases. European Journal of Pharmacology, 2023, 946, 175561.	1.7	3
2544	A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma. Journal of Pharmacological Sciences, 2023, 152, 69-75.	1.1	1
2545	Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology, 2023, 70, 102362.	1.7	1
2546	Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. Current Opinion in Pharmacology, 2023, 70, 102365.	1.7	2
2547	Magnetic Resonance Imaging Predictors of Hepatocellular Carcinoma Progression and Dropout in Patients in Liver Transplantation Waiting List. Transplantation Direct, 2022, 8, e1365.	0.8	0
2548	Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Frontiers in Oncology, 0, 13, .	1.3	1
2549	Organoids as an Enabler of Precision Immuno-Oncology. Cells, 2023, 12, 1165.	1.8	2
2550	Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 2261-2271.	1.4	1
2554	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters, 2023, 556, 216063.	3.2	2
2555	Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. EClinicalMedicine, 2023, 56, 101816.	3.2	2
2556	Gold Nanorodâ€“mesoporous silica core shell nanocomposites for NIR-II photothermal ablation and dual PD-L1/VEGF blockade therapy in hepatocellular carcinoma. Chemical Engineering Journal, 2023, 459, 141426.	6.6	11
2557	Immunotherapy prototype Mark 3.0 model in primary liver cancer: adding locoregional stereotactic therapy and prognostic factors classification management. Medical Review, 2023, 2, 547-552.	0.3	0
2559	DKK1â€CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Science, 2023, 114, 2063-2077.	1.7	2
2560	The neutrophilâ€toâ€lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis. Hepatology Research, 2023, 53, 511-521.	1.8	4
2561	Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma. Cancers, 2023, 15, 931.	1.7	3
2562	Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. World Journal of Meta-analysis, 0, 11, 47-54.	0.1	0
2563	The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2805.	1.8	6

#	Article	IF	Citations
2564	HÃmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
2565	Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report. Surgical Case Reports, 2023, 9, .	0.2	0
2566	Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	2
2567	Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. Oncology Research, 2022, 30, 243-258.	0.6	0
2568	Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma. Asian Journal of Surgery, 2023, 46, 4251-4260.	0.2	0
2569	A case of hepatocellular carcinoma with â€œpseudoprogressionâ€•followed by complete response to atezolizumab plus bevacizumab. Clinical Journal of Gastroenterology, 2023, 16, 392-396.	0.4	1
2570	Evansâ€™ syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 0, , .	0.4	2
2572	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines, 2023, 11, 468.	1.4	13
2573	Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma. Cancers, 2023, 15, 988.	1.7	1
2575	Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Cureus, 2023, , .	0.2	1
2576	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. International Journal of Molecular Sciences, 2023, 24, 3226.	1.8	3
2577	Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLoS ONE, 2023, 18, e0281459.	1.1	6
2578	Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. International Journal of Molecular Sciences, 2023, 24, 3217.	1.8	2
2579	Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma. Liver Transplantation, 2023, 29, 559-563.	1.3	4
2580	Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study. Liver Cancer, 2023, 12, 321-338.	4.2	9
2581	Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatology International, 2023, 17, 709-719.	1.9	17
2582	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	44
2583	Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediateâ€stage hepatocellular carcinoma. Hepatology Research, 2023, 53, 531-539.	1.8	1

#	Article	IF	Citations
2584	Non-alcoholic fatty liver disease-related hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 127-142.	0.3	5
2585	Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3441.	1.8	13
2586	Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
2587	Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Liver Cancer, 2023, 12, 467-478.	4.2	0
2588	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	19
2589	Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. Journal of Clinical and Experimental Hepatology, 2023, 13, 618-623.	0.4	16
2590	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World Journal of Gastroenterology, 0, 29, 1054-1075.	1.4	18
2592	An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Frontiers in Genetics, 0, 14, .	1.1	3
2593	The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancerâ€"Challenges and opportunities. Frontiers in Molecular Biosciences, 0, 10, .	1.6	4
2594	A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival. Gastroenterology Insights, 2023, 14, 38-44.	0.7	2
2595	Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clinical and Experimental Medicine, 2023, 23, 1901-1916.	1.9	11
2596	Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, 125I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus. Journal of Hepatocellular Carcinoma, 0, Volume 10, 231-240.	1.8	0
2597	Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3625.	1.8	1
2599	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clinical and Molecular Hepatology, 2023, 29, 593-604.	4.5	6
2600	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
2601	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2023, 12, 309-320.	4.2	5
2602	Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Frontiers in Oncology, 0, 13, .	1.3	1
2603	Identification of Drug Targets and Agents Associated with Hepatocellular Carcinoma through Integrated Bioinformatics Analysis. Current Cancer Drug Targets, 2023, 23, 547-563.	0.8	2

#	Article	IF	Citations
2604	Effectiveness and safety of lenvatinib plus antiâ€programmed deathâ€1 antibodies in patients with hepatocellular carcinoma: A <scp>realâ€world</scp> cohort study. Cancer Medicine, 2023, 12, 9202-9212.	1.3	3
2605	Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut and Liver, 2023, 17, 339-340.	1.4	0
2606	MicroRNA-223: a key regulator of liver tumour microenvironment. Gut, 2023, 72, 1811-1812.	6.1	0
2607	Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2023, 184, 103940.	2.0	1
2608	Management of Hepatocellular Carcinoma. JAMA Surgery, 2023, 158, 410.	2.2	72
2609	Updates on Organoid Model for the Study of Liver Cancer. Technology in Cancer Research and Treatment, 2023, 22, 153303382311540.	0.8	0
2610	Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy. Drug Design, Development and Therapy, 0, Volume 17, 507-518.	2.0	1
2611	Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3941.	1.8	14
2612	Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Digestive and Liver Disease, 2023, 55, 464-470.	0.4	7
2613	Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study. Frontiers in Immunology, 0, 14, .	2.2	6
2614	Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study. Frontiers in Oncology, 0, 13, .	1.3	2
2615	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, 0, Volume 10, 267-279.	1.8	1
2616	Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Frontiers in Immunology, 0, 14, .	2.2	3
2617	Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment. Journal of Hepatocellular Carcinoma, 0, Volume 10, 281-290.	1.8	1
2618	Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma. World Journal of Surgical Oncology, 2023, 21, .	0.8	0
2619	Atezolizumabe mais Bevacizumabe como Ponte para Transplante HepÃ¡tico no Carcinoma Hepatocelular. Brazilian Journal of Transplantation, 2023, 26, .	0.1	0
2620	Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma. Brazilian Journal of Transplantation, 2023, 26, .	0.1	0
2621	Breakthroughs in Hepatocellular Carcinoma Therapies. Clinical Gastroenterology and Hepatology, 2023, 21, 2135-2149.	2.4	20

#	Article	IF	Citations
2622	The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma. Liver International, 2023, 43, 528-530.	1.9	2
2623	Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers, 2023, 15, 1308.	1.7	3
2624	Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. Current Oncology, 2023, 30, 2493-2500.	0.9	7
2625	Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers, 2023, 15, 1310.	1.7	4
2626	Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by threeâ€dimensional reconstruction volumetry. Cancer Medicine, 0, , .	1.3	1
2627	Emerging treatment strategies in hepatobiliary cancer. Expert Review of Anticancer Therapy, 2023, 23, 243-256.	1.1	1
2628	Relationship between Being Overweight and Clinical Outcomes of Ablation Therapy for Hepatocellular Carcinoma under Ultrasound Guidance: A Retrospective Analysis. Cancers, 2023, 15, 1289.	1.7	0
2629	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers, 2023, 15, 1324.	1.7	1
2630	Systemic therapy in advanced hepatocellular carcinoma. Clinical and Molecular Hepatology, 2023, 29, 516-519.	4.5	3
2631	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer, 2023, 22, .	7.9	29
2632	Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment. Molecular and Clinical Oncology, 2023, 18, .	0.4	1
2633	Ferroptosis-Related Gene SLC1A5 Is a Novel Prognostic Biomarker and Correlates with Immune Microenvironment in HBV-Related HCC. Journal of Clinical Medicine, 2023, 12, 1715.	1.0	2
2634	Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology, 2023, 78, 1402-1417.	3.6	4
2635	Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma. Cancer Investigation, 2023, 41, 405-421.	0.6	1
2637	Three cases of immune-related hypopituitarism after atezolizumabâ€“bevacizumab treatment for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2023, 16, 422-431.	0.4	2
2638	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Frontiers in Oncology, 0, 13, .	1.3	1
2639	Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity. International Journal of Molecular Sciences, 2023, 24, 4422.	1.8	3
2640	Network meta-analysis: A map to navigate the maze of treatment for advanced hepatocellular carcinoma. European Journal of Internal Medicine, 2023, 111, 32-34.	1.0	0

#	Article	IF	Citations
2641	Tumorâ€derived insulinâ€like growth factorâ€binding proteinâ€1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Communications, 2023, 43, 415-434.	3.7	2
2642	Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSHâ€HCC Guidelines). Hepatology Research, 2023, 53, 383-390.	1.8	39
2643	Nomogram for tumour response based on prospective cohorts of hepatocellular carcinoma patients receiving immunotherapy combined with targeted therapy: development and validation. Annals of Translational Medicine, 2023, 11, 199-199.	0.7	3
2644	Degradation of helicase-like transcription factor (HLTF) by Î²-TrCP promotes hepatocarcinogenesis via activation of the p62/mTOR axis. Journal of Molecular Cell Biology, 2023, 15, .	1.5	2
2645	The development and prospects of liver surgery. , 2023, 2, 100009.		0
2646	Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. American Heart Journal Plus, 2023, 27, 100283.	0.3	0
2647	Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatology Research, 0, , .	1.8	0
2648	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2649	Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Hepatology, 2023, 77, E82-E83.	3.6	0
2650	Polyunsaturated Fatty Acidâ€“Bound Î±-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism. Cancer Research, 2023, 83, 1543-1557.	0.4	6
2651	Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk. Digestive Surgery, 2023, 40, 84-89.	0.6	2
2652	Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond. Seminars in Immunology, 2023, 66, 101736.	2.7	2
2653	Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment. Cancers, 2023, 15, 1470.	1.7	1
2654	Identification of Prognosis-Related Oxidative Stress Model with Immunosuppression in HCC. Biomedicines, 2023, 11, 695.	1.4	0
2655	Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research, 2023, 43, 1377-1384.	0.5	1
2657	Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 1523.	1.7	2
2658	Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. , 2023, 2, 36-51.		1
2659	A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments. Clinical Journal of Gastroenterology, 0, , .	0.4	1

#	Article	IF	Citations
2660	Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene, 2023, 42, 1051-1057.	2.6	4
2661	Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clinical and Translational Medicine, 2023, 13, .	1.7	2
2662	The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2023, 22, 153303382311597.	0.8	3
2663	Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treatment Reviews, 2023, 115, 102526.	3.4	1
2664	Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
2665	Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 1568.	1.7	2
2666	A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2023, 12, 216-228.	0.7	15
2667	Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Reports, 2023, 42, 112162.	2.9	8
2668	Immune Strategies for Gastrointestinal Cancer: HCC. , 2023, , 163-176.		0
2669	Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study. Journal of Liver Cancer, 2023, 23, 166-176.	0.3	0
2670	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences, 2023, 24, 5002.	1.8	6
2671	Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer, 2023, 12, 479-493.	4.2	3
2672	Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150. Gastroenterology, 2023, 165, 286-288.e4.	0.6	17
2673	Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Hpb, 2023, 25, 775-787.	0.1	1
2674	Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma. Briefings in Bioinformatics, 2023, 24, .	3.2	1
2675	A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: Integrated analysis of bulk and single-cell RNA sequencing. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
2676	Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. Journal of Hepatology, 2023, 79, 538-551.	1.8	27
2677	A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 2023, 164, 1279-1292.	0.6	8

#	Article	IF	Citations
2678	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports, 2023, 5, 100719.	2.6	10
2680	Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study. Cancer Immunology, Immunotherapy, 0, , .	2.0	2
2681	Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German realâ€world cohort. Alimentary Pharmacology and Therapeutics, 2023, 57, 1313-1325.	1.9	14
2683	Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumabâ€“Bevacizumab in Hepatocellular Carcinoma. Cancers, 2023, 15, 1661.	1.7	4
2684	The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review. Frontiers in Oncology, 0, 13, .	1.3	1
2685	Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. Vaccines, 2023, 11, 614.	2.1	4
2686	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. European Journal of Pharmacology, 2023, 949, 175586.	1.7	27
2687	Disruption of SLFN11 Deficiencyâ€“Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Antiâ€“PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 1261-1278.	0.6	17
2688	Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	0.2	0
2689	Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update. Liver Cancer, 2023, 12, 95-102.	4.2	7
2691	Histoneâ€lysine Nâ€methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Mycâ€driven liver cancer. Molecular Oncology, 2023, 17, 2275-2294.	2.1	4
2692	Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers, 2023, 15, 1680.	1.7	8
2693	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1407-1424.	1.4	0
2694	FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Journal of Hepatology, 2023, 79, 109-125.	1.8	20
2695	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 1311-1324.	2.3	13
2696	B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell, 2023, 41, 466-489.	7.7	16
2697	Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clinical and Molecular Hepatology, 2023, 29, 252-262.	4.5	7
2698	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers, 2023, 3, 121-160.	0.8	2

#	Article	IF	Citations
2699	Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis. BMC Cancer, 2023, 23, .	1.1	3
2700	Immunotherapy for advanced or recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 405-424.	0.8	0
2701	Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
2702	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics, 2023, 13, 1520-1544.	4.6	19
2703	SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Science Signaling, 2023, 16, .	1.6	3
2704	Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma. Cancers, 2023, 15, 1748.	1.7	2
2705	Immunotherapy for HCC: limitations in patients with NASH. Annals of Hepatology, 2023, 28, 100886.	0.6	1
2706	Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1551-1568.	1.4	5
2707	Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma. Clinical Immunology, 2023, 249, 109290.	1.4	0
2708	Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?. Targeted Oncology, 2023, 18, 221-233.	1.7	9
2709	Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clinical and Translational Gastroenterology, 2023, 14, e00581.	1.3	2
2711	CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Frontiers in Immunology, 0, 14, .	2.2	2
2712	A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nature Medicine, 2023, 29, 859-868.	15.2	30
2713	Combination immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2023, 79, 506-515.	1.8	46
2714	Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab. Journal of Liver Cancer, 2023, 23, 225-229.	0.3	2
2715	Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers, 2023, 15, 1798.	1.7	9
2716	Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. World Journal of Gastroenterology, 0, 29, 1669-1684.	1.4	0
2717	Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. , 2023, , .		0

#	Article	IF	Citations
2718	PhaseÂI study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial. Hepatology Research, 2023, 53, 649-660.	1.8	4
2719	Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials. Cancers, 2023, 15, 1808.	1.7	6
2720	Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Frontiers in Oncology, 0, 13, .	1.3	1
2721	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 487-503.	8.2	55
2722	IMbrave 151 missed primary endpoint in advanced BTC. , 0, , .		0
2723	Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. International Immunopharmacology, 2023, 118, 110019.	1.7	15
2724	Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis. BMJ Open, 2023, 13, e059457.	0.8	1
2725	Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma. Clinical and Molecular Hepatology, 2023, 29, 335-338.	4.5	0
2726	Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology, 0, 14, .	1.5	3
2727	Discovery of Core-Fucosylated Glycopeptides as Diagnostic Biomarkers for Early HCC in Patients with NASH Cirrhosis Using LC-HCD-PRM-MS/MS. ACS Omega, 2023, 8, 12467-12480.	1.6	6
2728	Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	4
2729	ICEGAN: inverse covariance estimating generative adversarial network. Machine Learning: Science and Technology, 2023, 4, 025008.	2.4	6
2730	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
2731	Main factors influencing long-term outcomes of liver transplantation in 2022. World Journal of Hepatology, 0, 15, 321-352.	0.8	2
2732	A New Frontier of Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Advances in Clinical Medicine, 2023, 13, 4382-4388.	0.0	0
2733	Establishment and validation of a cuproptosis-related lncRNA signature that predicts prognosis and potential targeted therapy in hepatocellular carcinoma. Biotechnology and Genetic Engineering Reviews, 0, , 1-26.	2.4	2
2734	TOPAZ-1: a new standard of care for advanced biliary tract cancers?. Immunotherapy, 0, , .	1.0	0
2735	Correlation and efficacy of <scp>TACE</scp> combined with lenvatinib plus <scp>PD</scp>â€1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Medicine, 2023, 12, 11315-11333.	1.3	5

#	Article	IF	Citations
2736	Progress in the Study of Hepatocellular Carcinoma Microenvironment and Its Clinical Significance. Advances in Clinical Medicine, 2023, 13, 4415-4420.	0.0	0
2737	How to optimize the treatment strategy for advanced-stage hepatocellular carcinoma with macrovascular invasion. Journal of Liver Cancer, 2023, 23, 121-123.	0.3	0
2738	Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2023, 91, 337-344.	1.1	1
2739	Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. Journal of Liver Cancer, 2023, 23, 177-188.	0.3	1
2740	The predictive value of <scp>PDâ€Ł1</scp> expression in patients with advanced hepatocellular carcinoma treated with <scp>PD</scp>â€ł/<scp>PDâ€Ł1</scp> inhibitors: A systematic review and metaâ€ anal ysis. Cancer Medicine, 2023, 12, 9282-9292.	1.3	8
2741	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. Liver Cancer International, 2023, 4, 58-72.	0.2	0
2742	Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. Journal of Gastroenterology, 2023, 58, 413-424.	2.3	10
2743	Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. BMC Gastroenterology, 2023, 23, .	0.8	0
2744	ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma. Cancer Cell International, 2023, 23, .	1.8	0
2745	Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discovery, 2023, 9, .	2.0	7
2746	Management of hepatocellular carcinomaÂfrom diagnosis in routine clinical practice. Hepatic Oncology, 2022, 9, .	4.2	0
2747	Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment. Frontiers in Oncology, 0, 13, .	1.3	1
2748	Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellularâ€“cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2749	Drug-Eluting Microspheres and Hepatocellular Carcinoma: Improving Outcomes Related to Drug or Better Practice?. CardioVascular and Interventional Radiology, 2023, 46, 447-448.	0.9	0
2750	Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. Hepatology Communications, 2023, 7, .	2.0	0
2751	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines, 2023, 11, 1020.	1.4	6
2752	Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482311606.	1.4	4
2753	Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2023, 12, 248-251.	0.7	0

#	Article	IF	Citations
2754	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
2755	Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7565-7577.	1.2	5
2756	The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report. Journal of Liver Cancer, 2023, 23, 230-234.	0.3	0
2757	Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy. Hepatology, 2023, 78, 1009-1011.	3.6	1
2758	Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. Cancers, 2023, 15, 2001.	1.7	5
2759	The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer. International Journal of Molecular Sciences, 2023, 24, 6314.	1.8	0
2760	Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials. Liver Cancer, 2023, 12, 445-456.	4.2	1
2761	Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. , 2023, 11, e006680.		6
2762	Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series. SAGE Open Medical Case Reports, 2023, 11, 2050313X2311644.	0.2	2
2763	Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer. Scandinavian Journal of Gastroenterology, 2023, 58, 1009-1020.	0.6	4
2764	Radioembolization for Treatment of Hepatocellular Carcinoma: Current Evidence and Patterns of Utilization. Journal of Vascular and Interventional Radiology, 2023, 34, 1200-1213.	0.2	1
2765	A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients. Journal of Ovarian Research, 2023, 16, .	1.3	1
2766	Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. International Immunopharmacology, 2023, 118, 110068.	1.7	1
2767	Identification of TIAM1 as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6387.	1.8	1
2768	Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. Investigational New Drugs, 2023, 41, 340-349.	1.2	4
2769	Bevacizumab plus AtezolizumabImprove the Immune Microenvironment and Achieve High Quality Survival of Advanced in HCC. Advances in Clinical Medicine, 2023, 13, 4867-4873.	0.0	0
2770	The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes. Biomedicines, 2023, 11, 1062.	1.4	2
2771	Elevated Alfa-Fetoprotein and Des-Gamma-Carboxy Prothrombin Levels Predict Poor Outcomes After Liver Transplantation for Hepatocellular Carcinoma Beyond the Japan Criteria. Transplantation Proceedings, 2023, 55, 606-612.	0.3	2

#	Article	IF	Citations
2772	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC Gastroenterology, 2023, 23, .	0.8	0
2773	Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Hepatology International, 2023, 17, 915-926.	1.9	2
2774	Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatology International, 2023, 17, 904-914.	1.9	10
2775	In silico trials of combination immuno-radiation for unresectable hepatocellular carcinoma. Translational Cancer Research, 2023, .	0.4	0
2776	The participation of tumor residing pericytes in oral squamous cell carcinoma. Scientific Reports, 2023, 13, .	1.6	1
2777	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Therapeutics and Clinical Risk Management, 0, Volume 19, 329-339.	0.9	2
2778	Immune checkpoint inhibitors in liver transplant: a case series. Journal of Gastrointestinal Oncology, 2023, 14, 1141-1148.	0.6	7
2779	Ferroptosis in hepatocellular carcinoma: from bench to bedside. Hepatology, 0, Publish Ahead of Print, .	3.6	14
2780	Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation, 2023, 21, .	0.6	3
2781	Crosstalk between Gut Microbiota and Hepatocellular Carcinoma. Gastrointestinal Disorders, 2023, 5, 127-143.	0.4	1
2782	The future of hepatology. Hepatology, 2023, 78, 637-648.	3.6	1
2783	Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer, 2023, 12, 405-444.	4.2	11
2784	Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut, 2023, 72, 1758-1773.	6.1	14
2785	Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Oncologist, 2023, 28, e526-e533.	1.9	6
2786	Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis. Hepatology Research, 0, , .	1.8	2
2787	TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. International Journal of Surgery, 2023, 109, 1222-1230.	1.1	6
2788	Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series. Internal Medicine, 2023, 62, 3341-3346.	0.3	2
2789	Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents. Journal of Hepatocellular Carcinoma, 0, Volume 10, 587-598.	1.8	1

#	Article	IF	Citations
2790	Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras. JHEP Reports, 2023, 5, 100759.	2.6	1
2792	Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. Nature Communications, 2023, 14, .	5.8	6
2793	Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway. Clinical Medicine Insights: Oncology, 2023, 17, 117955492311612.	0.6	1
2794	What is the Effect of Bevacizumab on Cartilage and Synovium in a Rabbit Model of Hemophilic Arthropathy?. Clinical Orthopaedics and Related Research, 2023, Publish Ahead of Print, .	0.7	1
2795	Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Reports Medicine, 2023, 4, 101009.	3.3	1
2796	Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatology International, 2023, 17, 753-764.	1.9	11
2798	Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models. Journal of Clinical Investigation, 2023, 133, .	3.9	1
2800	Targeting angiogenesis in oncology, ophthalmology and beyond. Nature Reviews Drug Discovery, 2023, 22, 476-495.	21.5	43
2801	Irradiation stent with 125I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial. International Journal of Surgery, 2023, 109, 1188-1198.	1.1	5
2803	First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PLoS ONE, 2023, 18, e0279786.	1.1	2
2804	Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacologica Sinica, 2023, 44, 1879-1889.	2.8	15
2805	Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein. Cancers, 2023, 15, 2304.	1.7	4
2806	IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. Frontiers in Immunology, 0, 14, .	2.2	3
2807	The impact of curative conversion therapy aimed at a cancerâ€free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine, 2023, 12, 12325-12335.	1.3	6
2808	Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. Molecular Therapy, 2023, 31, 2077-2088.	3.7	4
2809	Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of Oncology, 2023, 2023, 1-8.	0.6	3
2810	Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis, 2023, 26, 313-347.	3.7	50
2811	TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial. Frontiers in Oncology, 0, 13, .	1.3	3

#	Article	IF	Citations
2812	HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct Features. Liver Cancer, 2024, 13, 41-55.	4.2	0
2813	Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2023, 16, 567-571.	0.4	1
2814	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. , 2023, 34, 311-321.		0
2815	Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. , 2023, 11, e006334.		0
2816	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473.	1.0	1
2817	Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , .		0
2818	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathology Research and Practice, 2023, 246, 154470.	1.0	0
2819	Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 7640.	1.8	5
2820	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. International Journal of Molecular Sciences, 2023, 24, 7592.	1.8	1
2821	Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma. , 2023, , 387-402.		0
2823	Targeted therapy. , 2023, , 413-458.		0
2824	Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. Journal of Inflammation Research, 0, Volume 16, 1783-1804.	1.6	0
2825	The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis. Medicine (United States), 2023, 102, e32591.	0.4	0
2826	Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease. Journal of Hepatology, 2023, 79, e73-e76.	1.8	14
2827	FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	3
2828	Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Letters, 2023, 563, 216192.	3.2	4
2854	Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis. Frontiers in Immunology, 0, 14, .	2.2	1
2864	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0

#	Article	IF	Citations
2889	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2907	Emerging evidence for adapting radiotherapy to immunotherapy. Nature Reviews Clinical Oncology, 2023, 20, 543-557.	12.5	36
2974	ESMO update: upper gastrointestinal cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 105-107.	0.3	1
2989	Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma. Hepatology International, 2023, 17, 827-829.	1.9	1
3016	Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy. Frontiers in Immunology, 0, 14, .	2.2	4
3037	New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. Drugs, 2023, 83, 1091-1109.	4.9	2
3048	Immunotherapy of Biliary Tract Cancer. , 2023, , .		0
3059	Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. European Radiology, 2023, 33, 9167-9181.	2.3	1
3063	Advanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm. , 2023, 40, .		1
3074	Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective. Journal of Gastrointestinal Surgery, 2023, 27, 2245-2259.	0.9	0
3077	MAFLD: an optimal framework for understanding liver cancer phenotypes. Journal of Gastroenterology, 2023, 58, 947-964.	2.3	3
3088	Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
3099	Biology and therapeutic targeting of vascular endothelial growth factor A. Nature Reviews Molecular Cell Biology, 2023, 24, 816-834.	16.1	28
3156	Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
3205	Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798.	12.5	5
3214	Checkpoint inhibitors and anti-angiogenic agents: a winning combination. British Journal of Cancer, 0, , .	2.9	2
3228	Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	1
3236	Unexpected anti-tumor effect of immune checkpoint inhibitors followed by transcatheter arterial chemoembolization for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 0, , .	0.4	0

#	Article	IF	Citations
3245	Hepatobiliary-phase gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-to-date review. European Radiology, 2023, 33, 8764-8775.	2.3	0
3247	Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology, 2023, 20, 864-884.	12.5	14
3265	Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 16191-16201.	1.2	2
3276	Hepatitis Viruses: Hepatocellular Carcinoma. , 2023, , 1-36.		0
3323	New Frontiers in Transarterial Chemoembolization: Combination with Systemic Therapies. , 2023, , 107-117.		0
3343	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	2.0	4
3385	Targeting ferroptosis in hepatocellular carcinoma. Hepatology International, 2024, 18, 32-49.	1.9	0
3496	Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review. Clinical Journal of Gastroenterology, 0, , .	0.4	0
3514	Molecular Pathology of Liver Tumors. , 2023, , 201-230.		0
3527	Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Drugs, 0, , .	4.9	0
3569	Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab. Frontiers in Oncology, 0, 13, .	1.3	1
3599	Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management. Pharmaceutical Medicine, 2024, 38, 25-38.	1.0	0
3655	A patient alive without disease 32Âmonths after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report. Clinical Journal of Gastroenterology, 2024, 17, 311-318.	0.4	0
3703	Treatment of hepatocellular carcinoma with a portal vein tumor thrombus and pulmonary metastases of rectal cancer with microsatellite stability using atezolizumab plus bevacizumab. Clinical Journal of Gastroenterology, 2024, 17, 286-291.	0.4	0
3739	HÃmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
3758	Liver Cancer Surgery. , 2023, , 263-267.		0
3827	Chronobiologically Targeted Anticancer Strategy: Synergistic Inhibition of CD39 and CD73 with Adenosine Receptor Agonists. , 2024, , .		0